---
document_datetime: 2023-09-21 20:17:35
document_pages: 80
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/fycompa-h-c-2434-ii-0047-epar-assessment-report-variation_en.pdf
document_name: fycompa-h-c-2434-ii-0047-epar-assessment-report-variation_en.pdf
version: success
processing_time: 112.8800482
conversion_datetime: 2025-12-20 10:34:01.924315
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
17 September 2020 EMA/695418/2020

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Fycompa

International non-proprietary name: perampanel

Procedure No. EMEA/H/C/002434/II/0047

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................6                                  |                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6  |                                                                                                           |
| 1.2. Steps taken for the assessment of the product.........................................................6                |                                                                                                           |
| 2. Scientific discussion                                                                                                    | ................................................................................7                         |
| 2.1. Introduction.........................................................................................................7 |                                                                                                           |
| 2.1.1. The development programme/compliance with CHMP guidance/scientific advice                                            | ........8                                                                                                 |
| 2.2. Non-clinical aspects                                                                                                   | ..............................................................................................9           |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | ...........................................................9                                              |
| 2.2.2. Discussion on non-clinical aspects......................................................................11           |                                                                                                           |
| 2.2.3. Conclusion on the non-clinical aspects................................................................11             |                                                                                                           |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................12      |
| 2.3.1. Introduction....................................................................................................12   |                                                                                                           |
| 2.3.2. Pharmacokinetics.............................................................................................12      |                                                                                                           |
| 2.3.3. Discussion on clinical pharmacology...................................................................28             |                                                                                                           |
| 2.3.4. Conclusions on clinical pharmacology.................................................................28              |                                                                                                           |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................29      |
| 2.4.1. Main studies                                                                                                         | ...................................................................................................29     |
| 2.4.2. Discussion on clinical efficacy............................................................................45        |                                                                                                           |
| 2.4.3. Conclusions on the clinical efficacy.....................................................................46          |                                                                                                           |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................47    |
| 2.5.1. Discussion on clinical safety                                                                                        | ..............................................................................68                          |
| 2.5.2. Conclusions on clinical safety                                                                                       | ............................................................................69                            |
| 2.5.3. PSUR cycle                                                                                                           | .....................................................................................................69   |
| 2.6. Risk management plan........................................................................................69         |                                                                                                           |
| 2.7. Update of the Product information                                                                                      | ........................................................................72                                |
| 2.7.1. User consultation.............................................................................................72     |                                                                                                           |
| 3. Benefit-Risk Balance..............................................................................73                     |                                                                                                           |
| 3.1. Therapeutic Context                                                                                                    | ...........................................................................................73             |
| 3.1.1. Disease or condition.........................................................................................73      |                                                                                                           |
| 3.1.2. Available therapies and unmet medical need.......................................................74                  |                                                                                                           |
| 3.1.3. Main clinical studies                                                                                                | .........................................................................................74               |
| 3.2. Favourable effects                                                                                                     | ..............................................................................................74          |
| 3.3. Uncertainties and limitations about favourable effects.............................................75                  |                                                                                                           |
| 3.4. Unfavourable effects...........................................................................................76      |                                                                                                           |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | .........................................77                                                               |
| 3.6. Benefit-risk assessment and discussion.................................................................77              |                                                                                                           |
| 3.6.1. Importance of favourable and unfavourable effects..............................................77                    |                                                                                                           |
| 3.6.2. Balance of benefits and risks.............................................................................78         |                                                                                                           |
| 3.7. Conclusions                                                                                                            | .......................................................................................................79 |
| 4. Recommendations.................................................................................79                       |                                                                                                           |
| 5. EPAR changes........................................................................................80                   |                                                                                                           |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ABNAS

Aldenkamp-Baker Neuropsychological Assessment Schedule

AE

Adverse Event

AED

antiepileptic drug

ADR

adverse drug reaction

ALAG1

Lag time

ALT

alanine aminotransferase

AMPA

α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

ASF

Average Seizure Frequency

ATC

Anatomical Therapeutic Chemical

AUCss

Area under the Curve, at steady-state

BMI

Body Mass Index

BP

Blood Pressure

BPR

Blood Plasma Ratio

BSV

Between subject variability

Cav,ss

Concentration average, at steady-state

CBCL

Child Behavior Check List

CBZ

Carbamazepine

CGI

Clinical Global Impression

CGIC

Clinical Global Impression of Change

CHMP

Committee for Medicinal Products for Human Use

CL/F

Apparent Clearance

Cmaxss

Concentration maximal, at steady-state

CNS

Central Nervous System

C-SSRS

Columbia-Suicide Severity Rating Scale

CWRES

Conditional weighted residual

DBS

Dried Blood Spot

EAP

Extended Access Program

EEG

electroencephalogram

EIAED

Enzyme-Inducing Antiepileptic Drug

EMA

European Medicines Agency

EOT

end of treatment

ERA

Environmental Risk Assessment

FAS

Full Analysis Set

GGT

Gamma Glutamyl Transferase

GLP

Good Laboratory Practice

GOF

Goodness Of Fit

IGE

Idiopathic Generalized Epilepsy

<div style=\"page-break-after: always\"></div>

| IGF      | Insulin-like Growth Factor                                |
|----------|-----------------------------------------------------------|
| IIV      | Inter-Individual Variability                              |
| ILAE     | International League Against Epilepsy                     |
| IOV      | Inter-Occasion Variability                                |
| ISO      | International Standardization Organisation                |
| ISR      | Incurred Samples Reanalysis                               |
| Ka       | Absorption constant                                       |
| LC-MS/MS | Liquid Chromatography coupled to tandem mass spectrometry |
| LGPT     | Lafayette Grooved Pegboard Test                           |
| LLOQ     | Lower Limit of Quantification                             |
| LOCF     | Last Observation Carried Forward                          |
| LTPB     | Log-transformed percentage change from baseline           |
| MedDRA   | Medical Dictionary for Regulatory Activities              |
| MOA      | Mechanism of Action                                       |
| OECD     | Organization for Economic Co-operation and Development    |
| OFV      | Objective Function                                        |
| OXC      | Oxcarbazepine                                             |
| PcVPC    | Predicted corrected Visual Predictive Check               |
| PD       | Pharmacodynamic(s)                                        |
| PGTC     | Primary Generalized Tonic-Clonic                          |
| PGTCS    | Primary Generalized Tonic-Clonic Seizures                 |
| PK       | pharmacokinetic                                           |
| PopPKPD  | Population PK/PD                                          |
| POS      | Partial-Onset Seizures                                    |
| PRED     | Population Prediction                                     |
| PT       | Preferred Term                                            |
| QC       | Quality control                                           |
| QD       | once daily                                                |
| Q/F      | Apparent inter-compartmental clearance                    |
| QTc      | QT interval corrected for heart rate                      |
| RSE      | Relative Standard Error                                   |
| RUV      | Residual unexplained Variability                          |
| SAE      | Serious Adverse Event                                     |
| SAWP     | Scientific Advice Working Party                           |
| SD       | Standard Deviation                                        |
| SF       | Seizure Frequency                                         |
| SGTC     | Secondarily Generalized Tonic-Clonic                      |
| SMQ      | Standardized MedDRA Query                                 |
| SOC      | System Organ Class                                        |

<div style=\"page-break-after: always\"></div>

| TAD   | Time After Dose                            |
|-------|--------------------------------------------|
| TEAE  | Treatment-Emergent Adverse Event           |
| TOP   | Topiramate                                 |
| ULOQ  | Upper Limit of Quantification              |
| V2/F  | Apparent central Volume of distribution    |
| V3/F  | Apparent peripheral Volume of distribution |
| VAS   | Visual Analog Scale                        |
| VNS   | Vagal Nerve Stimulator                     |
| VPC   | Visual Predictive Check                    |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Eisai GmbH submitted to the European Medicines Agency on 28 August 2019 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, IIIA and IIIB   |

Extension of Indication to include the paediatric patients from 2 to 11 years of age for the adjunctive treatment of Partial-Onset Seizures with or without secondary generalisation and Primary Generalised Tonic-Clonic Seizures with idiopathic generalised epilepsy for Fycompa.

As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 4.3 has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included (an) EMA Decision(s) P/0217/2019 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP EMEA-000467-PIP01-08 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH received Scientific Advice from the CHMP on 25 January 2018

(EMEA/H/SA/608/10/2017/PED/II). The Scientific Advice pertained to clinical aspects and in relation to paediatric development of the dossier.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Alexandre Moreau

Co-Rapporteur:

N/A

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 28 August 2019    |
| Start of procedure:                                  | 14 September 2019 |
| CHMP Rapporteur Assessment Report                    | 14 November 2019  |
| PRAC Rapporteur Assessment Report                    | 19 November 2019  |
| PRAC Outcome                                         | 28 November 2019  |
| CHMP members comments                                | 4 December 2019   |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 6 December 2019   |
| Request for supplementary information (RSI)          | 12 December 2019  |
| CHMP Rapporteur Assessment Report                    | 31 March 2020     |
| PRAC Rapporteur Assessment Report                    | 31 March 2020     |
| PRAC members comments                                | 8 April 2020      |
| Updated PRAC Rapporteur Assessment Report            | 14 April 2020     |
| PRAC Outcome                                         | 17 April 2020     |
| CHMP members comments                                | 23 April 2020     |
| Updated CHMP Rapporteur Assessment Report            | 24 April 2020     |
| Request for supplementary information (RSI)          | 30 April 2020     |
| Responses to RSI by                                  | 10 July 2020      |
| CHMP Rapporteur Assessment Report                    | 19 August 2020    |
| PRAC Rapporteur Assessment Report                    | 19 August 2020    |
| PRAC members comments                                | n/a               |
| Updated PRAC Rapporteur Assessment Report            | n/a               |
| PRAC Outcome                                         | 3 September 2020  |
| CHMP members comments                                | 7 September 2020  |
| Updated CHMP Rapporteur Assessment Report            | 11 September 2020 |
| Opinion                                              | 17 September 2020 |

## 2. Scientific discussion

## 2.1. Introduction

Fycompa includes the active substance perampanel, a potent, non-competitive, and highly selective antagonist of the α -amino-3-hydroxy-5-methyl-4-isoxzaoleproprionic acid (AMPA) glutamate receptor. It was approved in the European Union (EU) through the centralised procedure in July 2012 as adjunctive therapy for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older, and as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures (PGTCS) in adult and adolescent patients aged 12 years and older with idiopathic generalized epilepsy (IGE) in Jun 2015. The precise mechanism by which perampanel exerts its antiepileptic effect has not yet been fully elucidated.

<div style=\"page-break-after: always\"></div>

Fycompa is available as film-coated tablets (2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg) and 0.5 mg/mL oral suspension. Treatment should be initiated by titrating the dose from 2mg/day to a maintenance dose of 4 to 8 mg/day, which may be further increased to a maximum dose of 12 mg/day. Fycompa should be given once daily at bedtime.

In the current submission, the MAH proposes to extend the approved indications to children aged 2 years and older. The proposed changes are supported through extrapolation of adult and adolescent efficacy and paediatric pharmacokinetic (PK) data derived from 2 open-label studies: an exploratory Phase 2 study (Study E2007-G000-232 or Study 232) which included data from subjects from patients with epilepsy from 2 to &lt;12 years of age and a pivotal long-term open-label Phase 3 study (Study E2007-G000-311 or Study 311) in paediatric patients aged 4 to &lt; 12 years old with inadequately controlled POS and PGTC seizures.

## 2.1.1. The development programme/compliance with CHMP guidance/scientific advice

The MAH received scientific advice from the CHMP on 25 January 2018

(MEA/H/SA/608/10/2017/PED/II). The scientific advice pertained to clinical aspects in relation to the paediatric development of the dossier.

The main points addressed during the CHMP scientific are summarized hereafter:

- -The  CHMP  considers  that  there  is  no  sound  evidentiary  basis  to  establish  the  proposed extrapolation  concept  (that  matching  PK,  PK/PD  in  children  and  adults  can  predict  efficacy  in children).

That said, it is recognized that only limited efficacy data will be available across relevant strata of the target population and so work in this direction is encouraged. PK and PD data in paediatric patients with PGTCS of IGE across age groups are needed in sufficient numbers to support PK/PD modelling.

In addition, the proposed PK model needs to be further substantiated, with early samples in paediatric patients across the age classes that will be included in any indication. The latter may be obtained from children with POS. It is not precluded that an improved extrapolation exercise together with clinical data from study 311 might suffice for assessment of efficacy and riskbenefit in children.

- -The lower limit of age in study 311 is 4 years. No children aged &lt;2 years were included in the metaanalysis.  Before  2  years  of  age,  the  hyperexcitability  of  the  immature  brain  have  significant consequences on the PK and PD resulting in greater variability. Between 2- 4 years, the variability in PD response may still remain. Thus, no efficacy data was gained in the claimed indication of PGTCS  of  IGE  in  the  2-4  age  group,  consequently,  there  appears  to  be  no  robust  basis  to extrapolate down to 2 years of age. Nevertheless, this is ultimately an assessment issue.
- -The youngest population is considered the most difficult population to support adequately for extrapolation. PK and PD need to be specifically assessed in the youngest children. A ratio of a total sample size is a poor basis from a scientific perspective on which to discuss the adequacy of the proposed sample size. The CHMP emphasizes that a sufficient number of children aged 4-7 need  to  be  included  to  provide  information  on  PK  and  PD  in  that  age  range  so  that  robust conclusions can be drawn. It is appreciated that feasibility is also an issue for consideration at PDCO.

During the scientific advice, the following points were discussed:

- -Efficacy:  the  similarity  of  therapeutic  response  cannot  be  ensured,  especially  in  the  youngest children,  as  the  brain  is  maturing  until  7  years  of  age  with  different  hyper  or  hypoexcitability

<div style=\"page-break-after: always\"></div>

thresholds depending on the area considered. In addition, the youngest children may also have differences in PK. Consequently, the similarity of the exposure/response relationships between adults  and  the  different  paediatric  age  class  considered  (2-4,  4-7  and  7-11)  needs  to  be demonstrated by the relevant data.

- -Safety: The most common IGE in children is Childhood Absence Epilepsia (CAE), in which the most common seizure types  are  absences,  followed  by  myoclonia,  however  PGTCS  can  also,  albeit rarely,  be  encountered  in  CAE.  Isolated  PGTCS  are  very  rare  in  children  as  opposed  to  being common in adults.
- -In children PGTCS appears within more complex syndromes associating different seizure types, the effect  of  perampanel  on  these  other  seizure  types  should  be  assessed  within  the  safety assessment, at least to rule out a detrimental effect (or quantify it to integrate it into the overall benefit/risk assessment). The effect of perampanel on neuropsychological aspects in a developing brain and  on  growth  should  also  be  specifically assessed  in the paediatric population. Consequently, safety cannot be extrapolated.

In  addition,  the  guideline  on  clinical  investigation  of  medicinal  products  in  the  treatment  of epileptic disorders highlights (CHMP/EWP/566/98 Rev.2/Corr) is taken in consideration for the assessment of the paediatric extension of indication, with in particular:

- -Focal epilepsies especially cryptogenic and symptomatic, and idiopathic generalized epilepsies, with  absences,  myoclonic  and/or  generalized  convulsive  seizures,  where  the  efficacy  of  AEDs seems to be comparable in childhood and adulthood. Focal epilepsies in children older than 4 years  old  have  a  similar  clinical  expression  to  focal  epilepsies  in  adolescents  and  adults.  In refractory focal epilepsies, the results of efficacy trials performed in adults could to some extent be extrapolated to children provided the dose is established.
- -From the  safety  view  point,  a  minimum  of  100  children  treated  by  the  study  drug  should  be followed for at least one year. Moreover short term and long-term studies should be designed to detect possible impact on brain development, learning, intelligence, growth, endocrine functions and puberty. Some of these studies may require continuation in the post marketing period. (See Guideline on clinical investigation of medicinal products in children (CPMP/EWP/462/95).

## 2.2. Non-clinical aspects

No new non-clinical data other than an updated environmental risk assessment (ERA), have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

The Environmental Risk Assessment was updated, including a Phase II estimation of exposure:

## Summary of environmental risk assesment

| Substance (INN/Invented Name): perampanel                                                                  |
|------------------------------------------------------------------------------------------------------------|
| Chemical name (IUPAC): 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile hydrate (4:3) |
| CAS-number: 380917-97-5                                                                                    |
| Molecular/structural formula & stability :                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                                     |                                                             | The stability of perampanel drug substance in solutions (pH 2 - 12) was investigated after storage at 25 °C (light shielded and light irradiated at 1000 lux) and 60 °C (light shielded) for 2 weeks. The residual percentage of perampanel drug substance did not change in solutions stored at 25 °C and 60 °C under light shielded conditions. In contrast, when exposed to light, degradation of perampanel drug substance was observed in solutions of various pH values.   | The stability of perampanel drug substance in solutions (pH 2 - 12) was investigated after storage at 25 °C (light shielded and light irradiated at 1000 lux) and 60 °C (light shielded) for 2 weeks. The residual percentage of perampanel drug substance did not change in solutions stored at 25 °C and 60 °C under light shielded conditions. In contrast, when exposed to light, degradation of perampanel drug substance was observed in solutions of various pH values.   | The stability of perampanel drug substance in solutions (pH 2 - 12) was investigated after storage at 25 °C (light shielded and light irradiated at 1000 lux) and 60 °C (light shielded) for 2 weeks. The residual percentage of perampanel drug substance did not change in solutions stored at 25 °C and 60 °C under light shielded conditions. In contrast, when exposed to light, degradation of perampanel drug substance was observed in solutions of various pH values.   | The stability of perampanel drug substance in solutions (pH 2 - 12) was investigated after storage at 25 °C (light shielded and light irradiated at 1000 lux) and 60 °C (light shielded) for 2 weeks. The residual percentage of perampanel drug substance did not change in solutions stored at 25 °C and 60 °C under light shielded conditions. In contrast, when exposed to light, degradation of perampanel drug substance was observed in solutions of various pH values.   | The stability of perampanel drug substance in solutions (pH 2 - 12) was investigated after storage at 25 °C (light shielded and light irradiated at 1000 lux) and 60 °C (light shielded) for 2 weeks. The residual percentage of perampanel drug substance did not change in solutions stored at 25 °C and 60 °C under light shielded conditions. In contrast, when exposed to light, degradation of perampanel drug substance was observed in solutions of various pH values.   |
|---------------------------------------------------------------------|-------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PBT screening                                                       |                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Result                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Conclusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Bioaccumulation potential- log K ow                                 | OECD107                                                     | OECD107                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 2.86                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 2.86                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | No potential for PBT                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PBT-assessment                                                      |                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Parameter                                                           | Result relevant for conclusion                              | Result relevant for conclusion                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Conclusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Bioaccumulation                                                     | log K ow                                                    | log K ow                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 2.86                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 2.86                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | No potential for PBT                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                     | BCF                                                         | BCF                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Persistence                                                         | DT50 or ready biodegradability                              | DT50 or ready biodegradability                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Toxicity                                                            | NOEC or CMR                                                 | NOEC or CMR                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PBT-statement :                                                     | The compound is not considered as                           | The compound is not considered as                                                                                                                                                                                                                                                                                                                                                                                                                                                | The compound is not considered as                                                                                                                                                                                                                                                                                                                                                                                                                                                | The compound is not considered as                                                                                                                                                                                                                                                                                                                                                                                                                                                | The compound is not considered as                                                                                                                                                                                                                                                                                                                                                                                                                                                | The compound is not considered as                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Phase I                                                             | Phase I                                                     | Phase I                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Phase I                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Phase I                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Phase I                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Phase I                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Calculation                                                         | Value                                                       | Value                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Unit                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Unit                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Conclusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0.00096                                                     | 0.00096                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | μg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | μg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | >0.01 threshold (N)                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Other concerns (e.g. chemical class)                                |                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | No other concnern                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Phase II Physical-chemical properties and fate                      | Phase II Physical-chemical properties and fate              | Phase II Physical-chemical properties and fate                                                                                                                                                                                                                                                                                                                                                                                                                                   | Phase II Physical-chemical properties and fate                                                                                                                                                                                                                                                                                                                                                                                                                                   | Phase II Physical-chemical properties and fate                                                                                                                                                                                                                                                                                                                                                                                                                                   | Phase II Physical-chemical properties and fate                                                                                                                                                                                                                                                                                                                                                                                                                                   | Phase II Physical-chemical properties and fate                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Study type                                                          | Test protocol                                               | Test protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Remarks                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Adsorption-Desorption                                               | OECD 106; EC 2001/59, C.19 Koc soil                         | OECD 106; EC 2001/59, C.19 Koc soil                                                                                                                                                                                                                                                                                                                                                                                                                                              | and log Koc values of perampanel at pH 7.5, based on and sewage sludge adsorption-reference data, are 5.1 x 10 2 and 2.71.                                                                                                                                                                                                                                                                                                                                                       | and log Koc values of perampanel at pH 7.5, based on and sewage sludge adsorption-reference data, are 5.1 x 10 2 and 2.71.                                                                                                                                                                                                                                                                                                                                                       | and log Koc values of perampanel at pH 7.5, based on and sewage sludge adsorption-reference data, are 5.1 x 10 2 and 2.71.                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Ready Biodegradability Test                                         | OECD 301; EC 92/69/EEC, Part C; ISO 9439                    | OECD 301; EC 92/69/EEC, Part C; ISO 9439                                                                                                                                                                                                                                                                                                                                                                                                                                         | The relative degradation values calculated from the measurements performed during the test period of 28 days revealed no significant degradation of perampanel (1% to                                                                                                                                                                                                                                                                                                            | The relative degradation values calculated from the measurements performed during the test period of 28 days revealed no significant degradation of perampanel (1% to                                                                                                                                                                                                                                                                                                            | Not readily biodegradable See further data from * Phase II Tier A and Tier B assessment.                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems    | OECD 308                                                    | OECD 308                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 2%). In the toxicity control, perampanel was found not to                                                                                                                                                                                                                                                                                                                                                                                                                        | 2%). In the toxicity control, perampanel was found not to                                                                                                                                                                                                                                                                                                                                                                                                                        | Not readily biodegradable See further data from * Phase II Tier A and Tier B assessment.                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                     |                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | inhibit microbial activity.                                                                                                                                                                                                                                                                                                                                                                                                                                                      | inhibit microbial activity.                                                                                                                                                                                                                                                                                                                                                                                                                                                      | inhibit microbial activity.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Phase II Tier A Effect Study type                                   | studies                                                     | studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Remarks                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Algal growth inhibition test                                        | Test protocol OECD 201; EEC directive 92/69, art C.3,1; ISO | Test protocol OECD 201; EEC directive 92/69, art C.3,1; ISO                                                                                                                                                                                                                                                                                                                                                                                                                      | NOEC                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | value Unit >1200 µg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Pseudo- kirchneriella subcapitata                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Daphnia magna acute toxicity test                                   | OECD 211; ISO 10706:2000 EC                                 | OECD 211; ISO 10706:2000 EC                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 50                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Daphnia magna reproduction test                           |                                                                  | NOEC                                                                                                                           | 220                                    | µg/L                                   |                                                                                                           |
|-----------------------------------------------------------|------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|----------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Toxicity test on egg and sac-fry stages of fathead minnow | OECD 210; EPA 850. 1400 ; EPA 712-C-96-121                       | LC 50 NOEC                                                                                                                     | >1300 40                               | µg/L                                   | Pimephales promelas                                                                                       |
| Fish early life stage test using fathead minnow           |                                                                  | NOEC LOEC                                                                                                                      | 60 160                                 | µg/L                                   | Pimephales promelas                                                                                       |
| Activated Sludge, Respiration Inhibition Test             | OECD 209; EEC Directive 67/ 548 amended 87/30; ISO Standard 8192 | EC 50                                                                                                                          | >100,000                               | µg/L                                   |                                                                                                           |
| Ratio                                                     | PEC ( μ g/L)                                                     | PNEC ( μ g/L)                                                                                                                  | PEC/PNEC                               | Trigger                                | Remarks                                                                                                   |
| PEC SURFACEWATER /PNEC WATER                              | 0.00096                                                          | 6                                                                                                                              | 0.00016                                | 1                                      | - recovery ~85% in the sediments of 2 water sediment systems. - sediment dwelling organism study required |
| PECS URFACEWATER /PNEC MICROORGANISM                      | 0.00096                                                          | 10,000                                                                                                                         | 0.000000096                            | 0.1                                    | - recovery ~85% in the sediments of 2 water sediment systems. - sediment dwelling organism study required |
| PEC GROUNDWATER /PNEC GROUNDWATER                         | 0.00024                                                          | 22                                                                                                                             | 0.000011                               | 1                                      | - recovery ~85% in the sediments of 2 water sediment systems. - sediment dwelling organism study required |
| *Phase II Tier A and Tier B assessment                    | *Phase II Tier A and Tier B assessment                           | *Phase II Tier A and Tier B assessment                                                                                         | *Phase II Tier A and Tier B assessment | *Phase II Tier A and Tier B assessment | *Phase II Tier A and Tier B assessment                                                                    |
| Study type                                                | Test protocol                                                    | Endpoint                                                                                                                       | value                                  | Unit                                   | Remarks                                                                                                   |
| sediment-water Chironomid (midge) toxicity test           | OECD 308 & 218                                                   | 28-day overall NOEC (for emergence ratio and development rate) 28-day overall EC 50 (for emergence ratio and development rate) | 820 >820                               | (mg/kg d.w.) (mg/kg d.w.)              | Chironomus riparius                                                                                       |
| Ratio PEC ( μ g/kg)                                       | PNEC ( μ g/L)                                                    | PNEC (μg/L)                                                                                                                    | PEC/PNEC                               | Trigger                                | Remarks                                                                                                   |
| PEC SEDIMENT /PNEC SEDIMENT                               | 0.011                                                            | 82                                                                                                                             | 0.00013                                | 1                                      | risk to sediment dwelling organisms is negligible.                                                        |

EC50 = half maximal effective concentration; LC50 = lethal concentration, median; NOEC = no observed effect  concentration,  LOEC  =  lowest-observed  effect  concentration;  PEC  =  predicted  environmental concentration, PNEC = predicted no effect concentration; d.w. = dry weight.

In view of both the indication and the extended population, the CHMP agrees that perampanel is not expected to pose a risk to the environment.

## 2.2.2. Discussion on non-clinical aspects

In view of both the indication and the extended population, the CHMP agrees that perampanel is not expected to pose a risk to the environment.

## 2.2.3. Conclusion on the non-clinical aspects

Based on the available data, perampanel is not expected to pose a risk to the environment. No further non-clinical data were considered necessary by the CHMP to support this application.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies:

Table2.7.3-3 Summary of Clinical Efficacy Studies

<!-- image -->

| Study          | Study Dates                                                  | Number of Sites/Countries                                                                                                                                                  | Study Design/Population                                                                                                                                                                | Diagnosis, Main Inclusion Criteria                                                                                                                                                                                       | Study Treatments                                                                                                                                                                                                    | No.Subjects by Arm                                                                                                                                                                                                                                                                                          | Efficacy Endpoint(s)                                                                                                                                                            |
|----------------|--------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| E2007-G000-311 | 16 Nov 2016 to 20 Jul 2018                                   | Total of 80 sites emrolled subjects in: Belgium (4), France (6), Humgary (4), Japan (23), Korea (6), and Umited (5), Latvia (l), Poland (3), Spain States of America (28). | Multicenter, open-label, single-amm shudy with an Extension Phase. Three study phases: 4-week Pretreatment 33-week Extension Phase, 23- to 25-week Treatment Phase, Phase.             | Subjects 24 to <12 years with diaguosed epilepsy with POS with or without secondarily or PGTCS according to the LAE generalized seizures and receiving stable Classification of Epileptic Seizures doses of 1 to 3 AEDs. | Subjects on concomitant EIAED Perampanel oral suspension 4 mg/day up to 16 mg/day. For up to 12 mg/day. Japan only 2 mg/day concomitant EIAED: Perampanel oral Subjects not on suspension 2 mg/day up to 12 mg/day. | As of 20 Jl 2018, Core Study: 180 (149 P0S/31 PGTCS POS cohort; SGTC subset of [54 subjects in subset of PGTC 24 subjects in PGTC ofIGE cohort]) Extension Phase A: 136 (116 POS/20 PGTCS [43 subjects in SGTC subset of pOS cohort; 15 subjects in PGTC ofIGE subset of PGTC cohort]) Extension Phase B:1* | Percent change in 28-day seizure frequency. Responder rate, proportion of defined as the frequency. subjects with a 50% decrease in 28-day seizue Seizure-fee rate. CGI at EOT. |
| E2007-G000-232 | Jan 2012 to May 2014 (Core Study) Feb 2015 (Extension Phase) | Core Study: 22 sites initiated and 15 sites emrolled subjects in the United States of America. Extension Phase: 14 sites in the United States of America.                  | Multicenter, multiple ascending dose, open-label study with an Extension Phase. Three study phases: 2-week Pretreatment Phase, 11-to 15-week Treatment Phase, 45-week Extension Phase. | Subjects ≥2 to <12 years with diaguosed epilepsy with any type of seizure according to Epileptic Seizures the ILAE Classification of and receiving stable doses of 1 to 3 AEDs.                                          | Perampanel oral suspension 0.015 mg/kg up to 0.18 mg/kg. Perampanel given bedtime. QD by mouth at                                                                                                                   | Core Study: 50 (any seizure type); of these, 3 had PGIC ofIGE Extension Phase: 41 (any seizure type); of these, 3 had PGTC ofIGE                                                                                                                                                                            | Percent change in 28-day seizure frequency Responder rate, defined as the proportion of subjects with a 50% decrease in 28-day seizue frequency. Seizure-free rate CGIC at EOT  |

AED=antiepileptic drug, CGI=Climical Global Impression, CGIC=Climical Global Impression of Change, ELAED=enzyme-inducing antiepileptic dng, EOS=End of Study, PGTCS=primary generalized tonic-clonic seizures, POS=partial-onset seizwes, QD=once daily.

+As of 20 Jul 2018, 1 subject had entered Extension B but was emrolled in error as the subject was over 12 years of age. Drug was dispensed at Visit 12 and the subject's participation in the shudy was tenminated at the next visit (EOS).

## 2.3.2. Pharmacokinetics

From the initial MAA dossier, the pharmacokinetic (PK) properties of Fycompa (E2007) in adults and adolescents are well known and the key properties are summarized below:

- E2007 absorption is rapid and complete (F near 100%) with negligible first-pass metabolism
- E2007 is highly bound to plasma proteins (95%), Vd in healthy volunteers average 77 L and blood to plasma ratio was 0.55-0.59

<div style=\"page-break-after: always\"></div>

- E2007  is  extensively  metabolized  via  primary  oxidation  and  sequential  glucuronidation.  The metabolism is mediated primarily by CYP3A. Average t1/2 of perampanel was 105 hours, when dosed in combination with the strong inducer carbamazepine, the average t1/2 was 25h.
- E2007 exhibit dose linearity between 2 to 12 mg.

In order to support the proposed paediatric extension of indication, using an extrapolation of adult and adolescent efficacy to patients aged 2 years and older, the MAH conducted 2 open-label studies:

- -an exploratory Phase 2 study (Study E2007-G000-232 or Study 232) which included data from subjects from patients with epilepsy from 2 to &lt;12 years of age and,

-  a  pivotal  long-term open-label Phase 3 study (Study E2007-G000-311 or Study 311) in paediatric patients aged 4 to &lt; 12 years old with inadequately controlled POS and PGTC seizures

## Summary of clinical pharmacology studies in paediatric subjects

| Study Number   | Study Title                                                                                                                                                                                                                                                                                                                                                    |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| E2007-G000-232 | An Open-Label Pilot Study With an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Pediatric Subjects From 2 to Less Than 12 Years of Age With Epilepsy                                                           |
| E2007-G000-311 | An Open-Label, Multicenter Study with an Extension Phase to Evaluate the Safety. Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral Suspension when Administered as an Adjunctive Therapy in Pediatric Subjects (Age 4 to less than 12 years) withInadequately Controlled Partial-Onset Seizures or Primary Generalized Tonic-Clonic Seizures |

One population  PK  (popPK)  model  was  developed using  all  available  PK  data  of  perampanel  (adult, adolescent, paediatric and POS or PGTC indications).

In addition, two population PK/PD (PopPKPD) models (efficacy) were developed for each indication (POS and  PGTC)  apart.  For  safety,  graphical  PK/PD  exploration  was  first  performed  followed  by  logistic regression analysis.

## Methods

## LC-MS/MS method (Study 311)

The determination of E2007 in human plasma (sodium heparine) was done using an LC-MS/MS method (BTM-1717-R0), similar to the method BTM-1076-R0 using at the time of the initial MAA submission. Except the sample volume (25 µL) performance of the validated method BTM-1717-R0 were similar to that of the initial BTM-1076-R0 method in terms of accuracy, precision, selectivity, dilution integrity, reproducibility, matrix effect and stability. The LLOQ was set at 1.0 ng/mL and the ULOQ at 500 ng/mL. Five QC levels were considered for the validation method at 1, 3, 50, 380 and 3800 ng/mL, however only three were considered for the determination of perampanel PK data from Study 311 (QC at 3, 5, 380  ng/mL).  For  samples  above  ULOQ  a  10-fold  dilution  was  applied.  Long  term  stability  was demonstrated for at least 636 days stored at -20°C. Incurred sample reanalysis was performed and showed satisfactory results.

<div style=\"page-break-after: always\"></div>

## Blood Biological matrix (Study 232)

A bioanalytical method using dried blood spot (DBS) was developed for the quantification of perampanel blood concentration. The blood sample was put on 2 DBS cards (1 original and 1 back-up card). On each card there were 4 spots, each was filled with approximately 20µL, giving a total of 80 µL per card. One dry blood sample spot (20µL) per time point was analysed using a validated DBS method with LC/MSMS method to determine blood concentration. Blood plasma perampanel concentrations were converted to plasma concentrations using a blood/plasma ratio of 0.88.

Performance of the developed method are provided in the table 'Summary of perampanel analytical method validation in human blood' hereafter. LLOQ and ULOQ were set at 1 and 500 ng/mL respectively. Four QC levels were considered, at 1, 3, 250 and 400 ng/mL with particularly good performance, intrarun precision (CV%) less than 15% for LLOQ and less than 7% for the others QC; and inter-run precision (CV%) less than 10%. Long term stability was demonstrated at 363 days at room temperature.

<div style=\"page-break-after: always\"></div>

## Summary of perampanel analytical method validation in human blood

| Reference compound                     | perampanel                                                                                     | perampanel                                                                                                       | perampanel                                                                                     | perampanel                                                                                     |
|----------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Internal standard                      | ['C:]-perampanel                                                                               | ['C:]-perampanel                                                                                                 | ['C:]-perampanel                                                                               | ['C:]-perampanel                                                                               |
| Species Matrix (anticoagulant)         | Human blood (sodium heparin)                                                                   | Human blood (sodium heparin)                                                                                     | Human blood (sodium heparin)                                                                   | Human blood (sodium heparin)                                                                   |
| Extraction method                      | DBS Extraction with MeOH/UHQ water (90/10, v/v)                                                | DBS Extraction with MeOH/UHQ water (90/10, v/v)                                                                  | DBS Extraction with MeOH/UHQ water (90/10, v/v)                                                | DBS Extraction with MeOH/UHQ water (90/10, v/v)                                                |
| Detection method                       | LC-MS/MS                                                                                       | LC-MS/MS                                                                                                         | LC-MS/MS                                                                                       | LC-MS/MS                                                                                       |
| Concentration range                    | From 1 to 500 ng/mL                                                                            | From 1 to 500 ng/mL                                                                                              | From 1 to 500 ng/mL                                                                            | From 1 to 500 ng/mL                                                                            |
| Regression (weighting)                 | Linear (1/x²)                                                                                  | Linear (1/x²)                                                                                                    | Linear (1/x²)                                                                                  | Linear (1/x²)                                                                                  |
| Sample volume                          | 20 μL                                                                                          | 20 μL                                                                                                            | 20 μL                                                                                          | 20 μL                                                                                          |
|                                        | Tested concentration (ng/mL)                                                                   | Tested concentration (ng/mL)                                                                                     | Tested concentration (ng/mL)                                                                   | Tested concentration (ng/mL)                                                                   |
|                                        | 1                                                                                              | 3                                                                                                                | 250                                                                                            | 400                                                                                            |
| Intra-run precision (Cv%)              | 13.00 3.88 6.38                                                                                | 5.04 4.31 6.65                                                                                                   | 3.59 3.34 4.22                                                                                 | 2.66 2.56 5.00                                                                                 |
| Intra-run deviation (%)                | 0.0 3.0 -6.0                                                                                   | -7.3 0.7 0.3                                                                                                     | 0.7 -0.8 -3.5                                                                                  | 4.1 -2.6 -2.3                                                                                  |
| Inter-run precision (Cv%) n=18         | 9.09                                                                                           | 6.46                                                                                                             | 3.93                                                                                           | 4.62                                                                                           |
| Inter-run deviation (%) n=18           | -1.0                                                                                           | -2.0                                                                                                             | -1.2                                                                                           | -0.3                                                                                           |
| Specificity Carry over IS contribution | Interference ≤ 10.2% was observed for perampanel and ≤ 0.2% for IS before each predose samples | 3 S0 (i.e., blanks) need to be injected after the ULOQ and Mean interference ≤ 6.3% of the LLOQ was observed for | Interference ≤ 10.2% was observed for perampanel and ≤ 0.2% for IS before each predose samples | Interference ≤ 10.2% was observed for perampanel and ≤ 0.2% for IS before each predose samples |
| 2-fold dilution factor                 | Validated, provided a specific dilution process is used.                                       | Validated, provided a specific dilution process is used.                                                         | Validated, provided a specific dilution process is used.                                       | Validated, provided a specific dilution process is used.                                       |
| Matrix effect                          | Between 0.9 and 1 for perampanel and IS                                                        | Between 0.9 and 1 for perampanel and IS                                                                          | Between 0.9 and 1 for perampanel and IS                                                        | Between 0.9 and 1 for perampanel and IS                                                        |
| Recovery                               | Between 77.9% and 88.5% for perampanel and between 87.5% and 94.7% for IS                      | Between 77.9% and 88.5% for perampanel and between 87.5% and 94.7% for IS                                        | Between 77.9% and 88.5% for perampanel and between 87.5% and 94.7% for IS                      | Between 77.9% and 88.5% for perampanel and between 87.5% and 94.7% for IS                      |

Incurred sample reanalysis showed satisfactory results according to the applicant with 72% of the ISR which met the acceptance criteria (+/- 20%);

## Population Pharmacokinetic/Pharmacodynamic analysis

Population PK (PopPK) and PK/PD (PopPKPD) analysis were performed with Nonmem® software (version 7.3.0). The analyses consisted of a PopPK model for perampanel on data from all subjects (paediatric, adolescent  and  adult  populations)  whatever  the  indication  (POS  or  PGTC),  and  several  continuous PopPKPD model developed for each indication.

Analysis  were  conducted  using  the  FOCEI  (PopPK  model)  and  FOCE  or  Laplacian  method  (PopPKPD models). Covariate selection was based on a standard stepwise forward/backward procedure. Final model

<div style=\"page-break-after: always\"></div>

evaluation consisted of several GOF (Goodness of fit) plots, predictive performance was evaluated using VPC, pc-VPC and model validation using a bootstrap analysis.

However since the extrapolation exercise is based on PK only, results from the PopPK/PD models for both indication POS and PGTC are not presented hereafter.

## Pharmacokinetics in target population

## Study 232

This was a multicenter, multiple ascending dose, open-label study with an Extension Phase conducted to evaluate the PK and to generate preliminary safety, tolerability, and efficacy data for perampanel oral suspension when given as an adjunctive therapy in paediatric subjects from 2 to &lt;12 years of age with epilepsy.  Subjects  were  enrolled into  2  cohorts  depending upon  age  at  the time  of  consent/assent: Cohort 1 consisted of subjects from 7 to &lt;12 years of age and Cohort 2 consisted of subjects from 2 to &lt;7 years of age (please also refer to 2.4.1. Clinical efficacy/Main Studies for additional details).

## Study 311

This was a multicenter, open-label single-arm study in children (aged 4 to &lt;12 years) with inadequately controlled POS or PGTC seizures. The study consisted of a Core Study and Extension Phase (Extension A) for subjects globally with an additional Extension Phase (Extension B) available for subjects enrolled in Japan and countries where an extended access program could not be implemented. Subjects were stratified by age (≥4 to &lt;7 years, 7 to &lt;12 years) with at least 30% of subjects planned to be enrolled in the ≥4 t o &lt;7 year age group for each seizure type (ie, at least 36 with POS and at least 12 with PGTC seizures). (please also refer to 2.4.1. Clinical efficacy/Main Studies for additional details).

<div style=\"page-break-after: always\"></div>

## Population Pharmacokinetic Model

Two Pop PK model reports,  CPMS-E2007-007R-v1  and  CPMS-E2007-015R-v2,  were  provided.  Since CPMS-E2007-007R-v1 have been reviewed twice following EMA/CHMP/SAWP/330293/2015, EMA/CHMP/SAWP/330294/2015  and  EMA/CHMP/SAWP/17398/2018  from  which  several  issues  were highlighted, the MAH performed a new PopPK model in CPMS-E2007-015R-v2 which was subsequently updated in CPMS-E2007-015-v3 which is detailed here after.

## PK dataset

A summary of the PK dataset is presented in following table, where PK data from Study 232 were not accounted for due to analytical issues.

## Summary of number of subjects and observation records in Population PK dataset

| Study                       | Population       |   Subjects (n) |   Observation Records Included (n) |   Observation Records Excluded (n) |
|-----------------------------|------------------|----------------|------------------------------------|------------------------------------|
| 20 Phase 1 Studies (Adults) | Healthy Subjects |            706 |                              17548 |                                 28 |
| 235 (Adolescents)           | Refiractory POS  |             78 |                                339 |                                  3 |
| 304 (Adolescents & Adults)  | POS              |            193 |                               1090 |                                  0 |
| 305 (Adolescents & Adults)  | POS              |            183 |                               1047 |                                  0 |
| 306 (Adolescents & Adults)  | POS              |            394 |                               2259 |                                  0 |
| 311 (Paediatmics)           | POS              |            130 |                                373 |                                  0 |
| 311 (Paediatrics)           | PGICS            |             26 |                                 73 |                                  0 |
| 332 (Adolescents & Adults)  | PGTCS            |             73 |                                205 |                                  7 |
| 335 (Adolescents & Adults)  | POS              |            511 |                               1331 |                                 21 |

POS=Partial onset seizure; PGTCS= primary generalized tonic-clonic seizue

For the paediatric population (Study 311), PK data consisted of sparse PK sampling at several occasions, 1 blood sample for the determination of plasma perampanel concentrations during Visits 7, (Week 15), 8 (Week 19), and 9 (Week 23) and at early discontinuation.

-

For studies performed in the adult and adolescent population, PK data consisted of rich PK sampling (20 Phase  1  studies)  performed  in  healthy  subjects  and  sparse  PK  sampling  at  steady  state  at  several occasions (Studies 235, 304, 305, 306, 332 and 335).

Therefore, for:

- -the  POS  indication,  paediatric  PK  information  consisted  of  n=373  observations  from  130 paediatric subjects vs n =6415 observations from 1359 adult and adolescent subjects.
- -the PGTC indication, paediatric PK information consisted of n=73 observations from 26 paediatric subjects vs n =205 observations from 73 adult and adolescent subjects.

Healthy subjects account for n= 17548 observations for 706 subjects.

The table below presents a summary of the baseline characteristics of the studied populations. Only n=4 paediatric subjects were aged 2 to &lt; 4 years (Study 232), n= 59 aged 4 to &lt; 7 years, and n=135 aged 7 to &lt; 12 years against n=1432 aged &gt; 12 years.

<div style=\"page-break-after: always\"></div>

## Summary of the baseline characteristics of the studied patient's population

Patients (N=1630)

| Covariate (unit)              | Mean (SD)                                                                                                                     | Median                                                                                                                        | Range (Min-Max)                                                                                                               |
|-------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| Age (years)                   |                                                                                                                               |                                                                                                                               |                                                                                                                               |
| 2 to < 4 (n=4)                | 2.75 (0.50)                                                                                                                   | 3.00                                                                                                                          | 2.0-3.0                                                                                                                       |
| 4 to <7 (n=59）                | 5.62 (0.71)                                                                                                                   | 5.00                                                                                                                          | 4.0-6.0                                                                                                                       |
| 7 to < 12 (n=135)             | 9.10 (1.39)                                                                                                                   | 9.00                                                                                                                          | 7.0-11.0                                                                                                                      |
| 12 to < 18 (n=226)            | 14.65 (1.75)                                                                                                                  | 15.0                                                                                                                          | 12.0-17.0                                                                                                                     |
| 18 and older (n=1206)         | 23.1 (3.05)                                                                                                                   | 23.0                                                                                                                          | 18.0-28                                                                                                                       |
| Overall (n=1630)              | 29.5 (15.0)                                                                                                                   | 28                                                                                                                            | 2-74                                                                                                                          |
| Weight (kg)                   |                                                                                                                               |                                                                                                                               |                                                                                                                               |
| 2 to < 4 (n=4)                | 15.7 (1.92)                                                                                                                   | 15.4                                                                                                                          | 13.8-18.3                                                                                                                     |
| 4 to<7(n=59）                  | 21.3 (4.81)                                                                                                                   | 20.1                                                                                                                          | 12.2-39.5                                                                                                                     |
| 7 to <12(n=135)               | 33.3 (12.7)                                                                                                                   | 28.7                                                                                                                          | 16.3-90.9                                                                                                                     |
| 12 to < 18 (n=226)            | 55.4 (16.1)                                                                                                                   | 52.0                                                                                                                          | 21.0-125                                                                                                                      |
| 18 and older(n=1206)          | 64.6 (16.8)                                                                                                                   | 61.0                                                                                                                          | 27.8-160                                                                                                                      |
| Overall (n=1630)              | 62.6 (21.6)                                                                                                                   | 61.5                                                                                                                          | 12.2-160                                                                                                                      |
| Alanine transaminase (1/n1)   | 20.4 (14.0)                                                                                                                   | 17                                                                                                                            | 4-184                                                                                                                         |
| Aspartate transaminase (IU/L) | 21.9 (9.36)                                                                                                                   | 20                                                                                                                            | 7-141                                                                                                                         |
| Creatinine Clearance (u!/Tu)  | 116.5 (32.3)                                                                                                                  | 112.6                                                                                                                         | 19.5-340.2                                                                                                                    |
| Seizure Type                  | POS =1523: PGTCS = 107                                                                                                        | POS =1523: PGTCS = 107                                                                                                        | POS =1523: PGTCS = 107                                                                                                        |
| Dose                          | Range: 0.5-16mg                                                                                                               | Range: 0.5-16mg                                                                                                               | Range: 0.5-16mg                                                                                                               |
| Sex                           | Females = 829; Males = 801                                                                                                    | Females = 829; Males = 801                                                                                                    | Females = 829; Males = 801                                                                                                    |
| Race                          | Caucasian = 804; Black/Affo-American = 25; Asian = 320; Japanese = 240; Chinese=204, American Indian/Alaskan/Other/Missing=37 | Caucasian = 804; Black/Affo-American = 25; Asian = 320; Japanese = 240; Chinese=204, American Indian/Alaskan/Other/Missing=37 | Caucasian = 804; Black/Affo-American = 25; Asian = 320; Japanese = 240; Chinese=204, American Indian/Alaskan/Other/Missing=37 |

More than half of the patient dataset were treated with an AEDs inducers (carbamazepine, oxcarbazepine and phenytoin) as shown in the following table.

<div style=\"page-break-after: always\"></div>

## Summary of co-administered AEDs

|               |   All Subjects (N =2336) | All Subjects (N =2336)   | Patients (N = 1630)   | Patients (N = 1630)   |
|---------------|--------------------------|--------------------------|-----------------------|-----------------------|
| AED           |                       11 | %                        |                       | %                     |
| Carbamazepine |                      540 | 23.1                     | 540                   | 33.1                  |
| Levetiracetam |                      571 | 24.4                     | 571                   | 35.0                  |
| Lamotrigine   |                      486 | 20.8                     | 486                   | 29.8                  |
| Oxcarbazepine |                      247 | 10.6                     | 247                   | 15.2                  |
| Topiramate    |                      331 | 14.2                     | 331                   | 20.3                  |
| Valproic acid |                      567 | 24.3                     | 567                   | 34.8                  |
| Clobazam      |                      206 | 8.82                     | 206                   | 12.6                  |
| Phenytoin     |                      130 | 5.57                     | 130                   | 8.0                   |
| Phenobarbital |                       96 | 4.11                     | 96                    | 5.9                   |
| Primidone     |                       17 | 0.73                     | 17                    | 1.0                   |
| Zonisamide    |                      136 | 5.82                     | 136                   | 8.3                   |
| Inducers      |                      917 | 39.3                     | 917                   | 56.3                  |

Inducers include carbamazevine. oxcarbazeDine and phenvtoin.

## Results

A population PK model for perampanel was previously developed using pooled data from 20 Phase 1 studies in healthy subjects. Perampanel was best described by a 2 compartment model with first order absorption and linear elimination parameterized in terms of CL/F, V2/F, Q/F and V3/F, Ka and ALAG1 (lag-time in  absorption).  Since  HS  received  the  tablet  or  the  suspension  formulation  in  the presence/absence of food, Ka was parameterized accordingly. IIV were estimated on all PK parameters except ALAG1. RUV was modelled using a combined error model (proportional and additive). Results of the PK parameter estimates are provided in following Error! Reference source not found. .

## Base Phase 1 Population PK model estimates of perampanel (Phase 1 studies)

| Parameter                                   | Point Estimate   | %RSE   | 95% CI      |
|---------------------------------------------|------------------|--------|-------------|
| Apparentclearance:CL/F                      |                  |        |             |
| Basal CL/F (L/h)                            | 0.625            | 2.10   | 0.599-0.651 |
| Apparentcentralvolumeofdistribution:V2/F    |                  |        |             |
| Basal V2/F (L)                              | 27.6             | 3.66   | 25.6-29.6   |
| Inter-compartmentClearance:Q/F              |                  |        |             |
| Basal Q/F (L/h)                             | 8.81             | 3.75   | 8.16 -9.46  |
| Apparentperipheralvolumeofdistribution:V3/F |                  |        |             |
| Basal V3/F (L)                              | 46.5             | 2.15   | 44.5 - 48.5 |

<div style=\"page-break-after: always\"></div>

| Ka (1/h)                         |       |        |             |
|----------------------------------|-------|--------|-------------|
| Ka for tablet fasted (1/h)       | 4.23  | 6.24   | 3.71 - 4.75 |
| Ka for tablet fed (1/h)          | 0.431 | 6.64   | 0.375 0.487 |
| Ka for suspension fasted (1/h)   | 3.26  | 6.38   | 2.85 -3.67  |
| Ka for suspension fed (1/h)      | 0.316 | 6.77   | 0.274-0.358 |
| ALAG1                            |       |        |             |
| ALAG1 (θs: h)                    | 0.229 | 0.0686 | 0.229-0.229 |
| Inter-individualvariability(%CV) |       |        |             |
| CL/F                             | 51.0  | 6.35   |             |
| V2/F                             | 58.9  | 4.81   |             |
| Q/F                              | 55.4  | 5.99   |             |
| V3/F                             | 40.1  | 6.46   |             |
| Ka                               | 120   | 6.65   |             |
| Residual variability             |       |        |             |
| Proportional (%CV)               | 21.8  | 0.463  |             |
| Additive (ng/mL)                 | 1.36  | 2.05   |             |

Abbreviations: %RSE: percent relative standard error of the estimate = SE/parameter estimate * 100;

CL/F = apparent clearance; V2/F = apparent central volume of distribution; Q/F=inter-compartment clearance; Ka = first order absorption rate constant; V3/F = apparent peripheral volume of distribution; ALAG1 = lag time in absorption; L = litre; h = hour; WGT = body weight; CI = confidence interval; %CV = Square root of variance *100.

In the current analysis, this PK model was used as a starting point for PK model development with pooled data from all the available clinical studies (Phase 1, 2 and 3). Several steps were considered to build the Base PK model (all data), implementation of IOV on CL/F and fixed allometric scaling coefficient of 0.75 for CL/F for patients under 18 years old as shown in the following table.

<div style=\"page-break-after: always\"></div>

## Summary of base PK model building for perampanel (All data)

| Model                      | Model Description                                                                                                                                          | OFV        | Comments                                                                                                                                     |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| PK_Basel_All_FixedKa_NoIOV | Base PK model for all data with fixed values for Ka, ALAGl and IIV on Ka from base model from Phase 1 data, no IOV on CL and with a combined RV model      | 186653.195 | Reference Model                                                                                                                              |
| PK_Base2_All_FixedKa_IOVCL | Base PK model for all data with fixed values for Ka and ALAG1 from base model from Phase 1 data, with IOV on CL and a combined RV model                    | 186128.549 | IOV on CL resulted in significant reduction in OFV                                                                                           |
| PK_All_FixedScalAll        | Fixed scaling of 0.75 on CL and Q and 1 for V2 and V3                                                                                                      | 186142.256 | Fixed scaling on all parameters resulted in an increase in OFV compared to model PK_Base2_All _FixedKa _10VCL                                |
| PK_All_FixedScalingAge17   | Fixed scaling of 0.75 for Q and 1 for V2 and V3, fixed scaling of 0.75 for CL for subjects aged<18 years and no scaling on CL for subjects aged ≥ 18 years | 185936.983 | No scaling on CL for subjects aged≥ 18 years and fixed scaling of 0.75 on CL for subjects <18 years resulted in significant reduction in OFV |
| PK_All_FixedScalingAge17   |                                                                                                                                                            |            | Model selected as intermediate PKmodel for subsequent covariate analysis                                                                     |

Ka = first order absorption rate constant; V3/F = apparent peripheral volume of distribution; ALAG1 = lag time in absorption; IIV = inter-individual variability; IOV = inter-occasion variability; RV = residual variability.

According to the MAH, since eta-shrinkage on CL/F was particularly low (-6.41 %) but above 50% for other  parameters,  covariate-parameter  relationships  were  only  tested  on  CL/F  with  all  available covariates.

Using univariate analysis following graphical  exploration  of  ETA-CL/F  vs  covariates,  gender,  ,  blackafrican race, type of seizure (POS or PGTC) and population (healthy vs patient) were first tested prior to the evaluation of the effect of concomitant AED administration on CL/F. Then after backward elimination the effects of gender and phenobarbital/topiramate, phenytoine/oxcarbazepine and carbamazepine was retained in the final model. Final PK parameter estimates are provided in the following table.

<div style=\"page-break-after: always\"></div>

## Final population PK parameter estimates of perampanel- All data

| Parameter                                                        | Point Estimate                                                   | %RSE                                                             | 95% CI                                                           |
|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| Apparent clearance: CL/F=OcL                                     |                                                                  |                                                                  |                                                                  |
| Basal CL/F for Subjects Aged ≥ 18 Years (L/h)                    | 0.646                                                            | 1.63                                                             | 0.625-0.667                                                      |
| Apparent clearance: CL/F=0cL*(WGT/44.95)0.75                     |                                                                  |                                                                  |                                                                  |
| Basal CL/F for Subjects Aged < 18 Years (L/h)                    | 0.613                                                            | 2.69                                                             | 0.581-0.645                                                      |
| Effect of phenobarbital or topiramate on CL/F (ratio)            | 1.22                                                             | 2.75                                                             | 1.15 -1.29                                                       |
| Effect of phenytoin or oxcarbazepine on CL/F (ratio)             | 1.97                                                             | 2.79                                                             | 1.86-2.08                                                        |
| Effect of carbamazepine on CL/F (ratio)                          | 3.04                                                             | 1.97                                                             | 2.92-3.16                                                        |
| Effect of sex on CL/F (ratio)                                    | 0.815                                                            | 2.02                                                             | 0.783-0.847                                                      |
| Apparent central volume of distribution: V2/F= Ov2*(WGT/67.2)    | Apparent central volume of distribution: V2/F= Ov2*(WGT/67.2)    | Apparent central volume of distribution: V2/F= Ov2*(WGT/67.2)    | Apparent central volume of distribution: V2/F= Ov2*(WGT/67.2)    |
| Basal V2/F (L)                                                   | 25.2                                                             | 3.46                                                             | 23.5-26.9                                                        |
| Inter-compartment Clearance: Q/F= Oq*(WGT/67.2)075               | Inter-compartment Clearance: Q/F= Oq*(WGT/67.2)075               | Inter-compartment Clearance: Q/F= Oq*(WGT/67.2)075               | Inter-compartment Clearance: Q/F= Oq*(WGT/67.2)075               |
| Q (L/h)                                                          | 8.37                                                             | 3.26                                                             | 7.83-8.91                                                        |
| Apparent peripheral volume of distribution: V3/F= Ov3*(WGI/67.2) | Apparent peripheral volume of distribution: V3/F= Ov3*(WGI/67.2) | Apparent peripheral volume of distribution: V3/F= Ov3*(WGI/67.2) | Apparent peripheral volume of distribution: V3/F= Ov3*(WGI/67.2) |
| Basal V3/F (L)                                                   | 43.8                                                             | 1.88                                                             | 42.2 -45.4                                                       |
| Absorption Rate Constant: Ka                                     | Absorption Rate Constant: Ka                                     | Absorption Rate Constant: Ka                                     | Absorption Rate Constant: Ka                                     |
| Ka for tablet fasted (1/h)                                       | 4.23                                                             | Fixed                                                            |                                                                  |
| Ka for tablet fed (1/h)                                          | 0.431                                                            | Fixed                                                            |                                                                  |
| Ka for suspension fasted (1/h)                                   | 3.26                                                             | Fixed                                                            |                                                                  |
| Ka for suspension fed (1/h)                                      | 0.316                                                            | Fixed                                                            |                                                                  |

<div style=\"page-break-after: always\"></div>

Lag Time in Absorption: ALAGl

| ALAG1 (h)                          | 0.229   | Fixed   |
|------------------------------------|---------|---------|
| Inter-individual variability(%C V) |         |         |
| CL/F                               | 45.9    | 3.23    |
| V2/F                               | 59.7    | 4.33    |
| Q/F                                | 54.7    | 5.15    |
| V3/F                               | 37.4    | 6.16    |
| Ka                                 | 120     | Fixed   |
| Inter-occasion variability (%CV)   |         |         |
| CL/F                               | 14.8    | 0.0218  |
| Residual variability               |         |         |
| Proportional (%CV)                 | 19.9    | 0.402   |
| Additive (ng/mL)                   | 1.41    | 1.86    |

Abbreviations: %RSE: percent relative standard error of the estimate = SE/parameter estimate * 100; CL/F = apparent clearance, V2/F = apparent central volume of distribution; Q=inter-compartment clearance; Ka = first order absorption rate constant; V3/F = apparent peripheral volume of distribution; ALAG1 = duration of zero order absorption; h = hour; WGT = body weight; CI = confidence interval; %CV = Square root of variance *100.

Overall PK parameters were estimated with a good precision (RSE &lt;10%).

The final population PK model for perampanel contained the statistically significant effects of body weight on V2/F, Q/F and V3/F with fixed allometric scaling for all subjects and on CL/F for subjects aged &lt; 18 years of age only, sex and the concomitant medications of AEDs carbamazepine, oxcarbazepine/phenytoin,  and  topiramate/phenobarbital  (significant  AEDs),  on  perampanel  CL/F. Carbamazepine resulted in a 3.04-fold increase in CL/F whereas co-administration of oxcarbazepine or phenytoin  resulted  in  1.97-fold  increases  in  CL/F.  Co-administration  of  topiramate  or  phenobarbital increases perampanel CL/F by 1.22-fold. CL/F was 18.5% lower in females compared to males. These results are consistent with those from previous analyses. In the final PK model, the basal estimate for CL/F was slightly lower in subjects &lt; 18 years old compared to adults (0.613 vs 0.646 L/h).

## Model Evaluation

Goodness-of-fit plots for the final PK model for perampanel are presented hereafter (without inducers) for study 311.

GOF for Study 311 (without inducers)

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Visual Predictive check (VPC)

pcVPC were presented by studies in the following figure. According to the MAH, the majority of the observed concentrations are within the 90% prediction intervals for all data.

## pcVPC for Study 311

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Simulation  to  assess  PK  extrapolation  to  PEDIATRIC  subjects  aged  4  to  &lt;  12  years  and  Dosing recommendations

To further assess the effect of body weight on the exposure to perampanel during the maintenance period  (i.e.,  at  steady  state)  PK  simulations  in  subjects  aged  &lt;  18  years  were  performed,  using parameter estimates from the final PK model (N=100), for subjects at body weights of &lt; 20 kg, 20 to &lt; 30 kg, 30 to &lt; 40 kg, 40 to &lt; 60 kg and   60 kg, based on median weights within these ranges from the actual population PK analysis dataset.

The median bodyweights used for the simulations for the following body weight categories &lt; 20 kg, 20 to &lt; 30 kg, 30 to &lt; 40 kg, 40 to &lt; 60 kg and ≥ 60  kg  were 18.5, 24.4, 36.2, 53.0 and 74.4 kg, respectively.

Simulations were performed based on dosing during maintenance dosing of 4 mg and 6 mg perampanel once daily to subjects &lt; 20 kg body weight, 6 mg and 8 mg perampanel once daily to subjects 20 to &lt; 30 kg bodyweight and 8 mg perampanel once daily to all other subjects. Simulations were performed by using parameter estimates from the final PK model.

Based on the simulations for body weight group, descriptive statistics of model derived AUCss, Css,max and Css,min for each body weight/dose category were determined and are presented in the following table. In addition, box and whisker plots for model derived AUCss, Css,max and Css,min for each body weight/dose category are presented in the figure below.

<div style=\"page-break-after: always\"></div>

Perampanel predicted PK exposure parameters during maintenance period following once daily dosing of tablets to adults and oral suspension to pediatric subjects without concomitant inducers

| Weight Category   | Dose   | Mean   | SD    | Min   | Max   | %CV   | P5   | P50   | P95   |
|-------------------|--------|--------|-------|-------|-------|-------|------|-------|-------|
| AUC (ng*hr/mL)    |        |        |       |       |       |       |      |       |       |
| <20 kg            | 4 mg   | 14143  | 5599  | 2240  | 29300 | 27060 | 39.6 | 7006  | 12900 |
| < 20 kg           | 6 mg   | 20584  | 9465  | 6370  | 56000 | 49630 | 46.0 | 8226  | 18850 |
| 20 to <30kg       | 6 mg   | 16173  | 8161  | 3610  | 60800 | 57190 | 50.5 | 6979  | 14800 |
| 20 to <30kg       | 8 mg   | 22920  | 11708 | 6700  | 72700 | 66000 | 51.1 | 7957  | 21150 |
| 30 to < 40kg      | 8 mg   | 16214  | 7154  | 4480  | 43700 | 39220 | 44.1 | 6458  | 14850 |
| 40 to < 60kg      | 8 mg   | 12356  | 6190  | 3980  | 36300 | 32320 | 50.1 | 4931  | 10950 |
| ≥ 60 kg           | 8 mg   | 14257  | 6468  | 3930  | 37500 | 33570 | 45.4 | 4899  | 12750 |
| Css,max (ng/mL)   |        |        |       |       |       |       |      |       |       |
| ≤20 kg            | 4 mg   | 879    | 320   | 277   | 1940  | 1663  | 36.4 | 400   | 832   |
| < 20 kg           | 6 mg   | 1282   | 506   | 369   | 3020  | 2651  | 39.5 | 558   | 1205  |
| 20 to < 30kg      | 6 mg   | 1053   | 494   | 376   | 3710  | 3334  | 46.9 | 436   | 1005  |
| 20 to<30kg        | 8 mg   | 1409   | 654   | 407   | 3890  | 3483  | 46.4 | 542   | 1325  |
| 30 to < 40kg      | 8 mg   | 999    | 412   | 310   | 2490  | 2180  | 41.2 | 397   | 939   |
| 40 to <60kg       | 8 mg   | 751    | 347   | 243   | 1930  | 1687  | 46.2 | 317   | 683   |
| ≥60 kg            | 8 mg   | 858    | 378   | 256   | 2110  | 1854  | 44.1 | 310   | 786   |
| Css,min (ng/mL)   |        |        |       |       |       |       |      |       |       |
| <20 kg            | 4 mg   | 374    | 168   | 26    | 894   | 868   | 44.9 | 154   | 349   |
| < 20 kg           | 6 mg   | 554    | 294   | 148   | 1520  | 1372  | 53.1 | 180   | 502   |
| 20 to < 30kg      | 6 mg   | 442    | 253   | 39    | 1690  | 1651  | 57.1 | 114   | 412   |
| 20 to <30kg       | 8 mg   | 617    | 353   | 118   | 1990  | 1872  | 57.2 | 192   | 540   |
| 30 to < 40kg      | 8 mg   | 421    | 200   | 90    | 1100  | 1010  | 47.5 | 147   | 372   |
| 40 to <60kg       | 8 mg   | 331    | 191   | 65    | 1140  | 1075  | 57.8 | 109   | 294   |
| ≥60 kg            | 8 mg   | 385    | 194   | 89    | 1130  | 1041  | 50.4 | 144   | 355   |

<div style=\"page-break-after: always\"></div>

## Predicted perampanel AUCss (up) and Css, max (down) vs weight category

<!-- image -->

<div style=\"page-break-after: always\"></div>

Compared to adults of body weight and Css, max (down) vs weight categoryuring maintenance, the simulations demonstrated comparable exposure based on AUCss, Cmax,ss and Cmin,ss will be achieved with a target dose of 4 mg once daily administered to paediatric subjects of bodyweight &lt; 20 kg, with a target dose of 6 mg/once daily administered to paediatric subjects of bodyweight 20 to &lt; 30 kg and with a target dose of 8 mg/day for paediatric subjects with body weight of 30 to &lt; 60 kg.

## 2.3.3. Discussion on clinical pharmacology

The pharmacokinetic of perampanel has been well characterized in adult patients

The  proposed  extension  of  the  indication  in  the  pediatric  population  (2  to  &lt;  12  years)  have  been addressed according to the paediatric investigation part of perampanel clinical development. In support of an extrapolation of adult and adolescent efficacy to patients aged 2 to &lt; 12 years, the MAH conducted an exploratory Phase 2 study (Study 232) in patients aged 2 to &lt;12 years with POS or PGTC, and a pivotal Phase 3 study (Study 311) in patients aged 4 to &lt; 12 years with POS or PGTC.

Both Study 232 and Study 311 used validated micromethods to measure perampanel concentration, however two bioanalytical methods were developed. A DBS method for Study 232 was used where perampanel concentration was quantified in human blood samples, then concentration in human plasma was derived using a blood plasma ratio factor of 0.88 which appear far from that determined by a dedicated in vitro study method (initial MAA) of 0.55. In addition to this discrepancy, the DBS method claimed  to  be  reproducible,  seems  not.  Therefore  the  validity  of  the  PK  data  from  study  232  was questioned, two concerns was raised from which no clear evidence was provided by the applicant to definitively  consider  these  PK  data  as  reliable  as  claimed.  A  conventional  bioanalytical  method  was applied for Study 311 and this method show satisfactory results and is considered validated.

Initially a population PK model using PK data from 20 Phase 1 studies in adults, 6 Phase 2/3 in adult and adolescent patients, and the two studies in the paediatric population (Study 232 and Study 311) was developed (Report CPMS-E2007-015R-v2). Overall, the developed PK model seemed to fit for purpose, however several uncertainties remained with regards to the covariate screening procedure, the weight effect on clearance and its predictive performance particularly. These issues appeared critical since an adequate PopPK model is needed to support extrapolation From that PK model, a simulation study was performed using individual derived exposure parameters of perampanel. To allow a comparison between groups of different age strata the MAH have proposed a metric, the dose normalized AUCss at 8 mg. From that analysis a clear over-exposure was predicted in the age group 4 to &lt;7 years vs above 18 years as shown below suggesting that a weight effect on clearance should be accounted for.

As second Population PK model was therefore requested where PK data from Study 232 were asked to be discarded, and weight effect on clearance should be accounted for only in the pediatric population &lt;18 years (Report CPMS-E2007-015R-v3). The main result from that analysis was the clear weight effect on perampanel clearance from which a dosing schedule in the paediatric population aged 4 to &lt;12 years based on body weight group (&lt; 20 kg, 20-30 kg and &gt; 30 kg) was proposed and accepted.

Only 4 patients aged 2 &lt; 4 years with 4 PK observations were included in Study 232. These patients received perampanel dose up to 2.5 mg which are considered far from the target dose of 8 mg. The paucity of the PK data and PD data (efficacy/safety) in this age group associated to the uncertainties associated to the quantification method are not in favor to use a full or a partial extrapolation approach at this stage.

## 2.3.4. Conclusions on clinical pharmacology

Following a wealth population PK analysis, the MAH proposal to use a dosing schedule in the paediatric

<div style=\"page-break-after: always\"></div>

population aged 4 to &lt;12 years based on body weight group (&lt; 20 kg, 20-30 kg and &gt; 30 kg) is acceptable.

## 2.4. Clinical efficacy

## 2.4.1. Main studies

## Study E2007-G000-232

## Methods

This study is a multicenter, multiple ascending dose, open-label study with an extension phase conducted to evaluate PK and to generate preliminary safety, tolerability, and efficacy data for perampanel oral suspension when given as an adjunctive therapy in pediatric patients from 2 to &lt;12 years of age with a diagnosis of epilepsy with any type of seizure according to the International League Against Epilepsy's (ILAE) Classification of Epileptic Seizures., including patients with PGTC of IGE (n=3).

Patients were enrolled into 2 cohorts depending upon age at the time of consent/assent:

- -Cohort 1 consisted of patients 7 to &lt;12 years of age,
- -Cohort 2 consisted of patients 2 to &lt;7 years of age.

The Core Study consisted of 2 phases:

- -Pretreatment Phase: The Pretreatment Phase lasted up to 2 weeks in duration, during which patients were assessed for their eligibility to participate in the study.
- -Treatment Phase: The Treatment Phase consisted of 3 periods: Titration (7 weeks), Maintenance (4 weeks), and Follow-up (4 weeks; for those patients not rolling over to the Extension Phase of the study, for those patients who early terminate from the study, and for all patients completing the Extension Phase).
- o Titration

<!-- image -->

During the 7-week Titration Period, patients received perampanel oral suspension once daily. Patients started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg or until the maximum tolerated dose based on tolerability was reached. The maximum total daily dose a patient will be allowed is 12 mg.

Doses are based on mg/kg of body weight and calculated from adult doses assuming an adult body weight of 70 kg

## Starting dose (Week 0) -Visit 2 - 0.015 mg/kg ~ (1 mg/70 kg)

Titration #1 (Week 1) -Visit 3- 0.03 mg/kg ~ (2 mg/70 kg)

Titration #2 (Week 2) - (no visit) - 0.06 mg/kg ~ (4 mg/70 kg)

<div style=\"page-break-after: always\"></div>

Titration #3 (Week 3) - Visit 4 - 0.09 mg/kg ~ (6 mg/70 kg) Titration #4 (Week 4) - (no visit) - 0.12 mg/kg ~ (8 mg/70 kg) Titration #5 (Week 5) - Visit 5- 0.15 mg/kg ~ (10 mg/70 kg)

Titration #6 (Week 6) - (no visit) - 0.18 mg/kg ~ (12 mg/70 kg)

At the completion of the Titration Period, patients began the Maintenance Period of the Treatment Phase.

- o Maintenance/Follow-Up

During the 4-week Maintenance Period, patients continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period.

Patients continued taking this dose level QD for the duration of the Maintenance Period of the Treatment Phase.

Patients who did not roll over into the Extension Phase or those who discontinued from the study were required  to  complete  the Follow-up  Period  4  weeks  after  the  last  dose  of  treatment,  as  part  of  the Treatment Phase of the Core Study. During this period, patients did not receive study drug.

- -Extension Phase

All patients who completed all scheduled visits up to and including the final visit of the Treatment Phase (Visit 8) were eligible to participate in the Extension Phase of the study.

The Extension Phase consisted of 2 periods: Maintenance (41 weeks) and Follow-up (4 weeks).

Patients continued taking perampanel oral suspension once daily at the dose level achieved at the end of the Treatment Phase. The maximum daily dose level patients could receive was 0.18 mg/kg; the maximum total daily dose a patient was allowed was 12 mg. For patients who rolled over into the Extension Phase, the last visit of the Maintenance Period in the Treatment Phase of the Core Study was the first visit of the Extension Phase.

During the Extension Phase, changes of concomitant AEDs (addition, deletion, or adjustment in dose) were allowed. However, if changes did occur, patients were to be carefully monitored, especially when switching between an inducer AED (ie, EIAED) and a non-inducer AED (ie, non-EIAED).

## Study participants

The key inclusion criteria were male or female, from 2 to &lt;12 years of age, had a diagnosis of epilepsy with any type of seizure according to the ILAE Classification of Epileptic Seizures. Diagnosis should have been established at least 6 months prior to Visit 1, by clinical history and an EEG that was consistent with epilepsy; normal interictal EEGs were allowed provided that the patient met the other diagnosis criterion (ie, clinical history), had not a progressive cause of epilepsy and had 1 or more seizure(s) during the 4 weeks prior to Visit 1

Regarding treatment, they had been on their current concomitant AED regimen for 2 months or more with a stable dose for at least 4 weeks prior to Visit 1 and no more than half of patients in each age cohort were allowed to be treated with stable doses of 1 perampanel -inducing AED (ie, carbamazepine, oxcarbazepine, and phenytoin).

Choice of patient population / Sample size

It was planned to enroll approximately 48 male and female patients from 2 to &lt;12 years of age who had a diagnosis of epilepsy with any type of seizure according to the International League Against Epilepsy's (ILAE) Classification of Epileptic Seizures. Patients who did not meet all the inclusion criteria or who met any of the exclusion criteria were not eligible to receive study drug.

## Treatments

Perampanel was administered orally and once daily. Dosing occurred at bedtime.

Dosing  and  administration  of  perampanel  in  Study  232  was  based  on  the  efficacy  and  safety  data obtained for perampanel doses up to 12 mg/day studied in patients (12 years and above) with refractory POS in 3 randomized, double-blind, placebo-controlled, parallel-group Phase 3 studies: Study 304 and Study 305 (8 and 12 mg/day perampanel) and Study 306 (2, 4, and 8 mg/day perampanel).

<div style=\"page-break-after: always\"></div>

## Objectives

Primary objective: To evaluate the pharmacokinetics of perampanel in pediatric patients (age 2-11 years) with refractory epilepsy as adjunctive therapy.

Secondary objectives: To evaluate the safety and tolerability of perampanel as well as its efficacy given as an adjunctive therapy in pediatric patients (age 2-11)

## Outcomes/endpoints

## Primary endpoint: PK

The population PK/PD approach will be used to explore the exposure-response relationship for efficacy and most frequent AE(s).

Main secondary endpoints: safety and efficacy

- -Safety assessments: AEs, SAEs, clinical laboratory values, vital with time(s) of assessment signs, ECGs, physical and neurological examinations, and photosensitivity questionnaire. Growth will be assessed by measurement of height and weight, and by thyroid and insulin-like growth factor1 (IGF-1) testing. A suicidality scale questionnaire (Columbia-Suicide Severity Rating Scale [CSSRS])  will  also  be  administered  for  patients  aged  6  years  and  older  at  the  time  of consent/assent.
- -Exploratory Efficacy Variables: Percentage change in seizure frequency compared to the baseline and the proportion of responders, seizure-free status, and clinical global impression of change.

## Sample size

## Randomisation

Not applicable (Open-label study)

## Blinding (masking)

## Statistical methods

For the Core Study, summary statistics were displayed for all efficacy parameters.

The FAS (full analysis set) was the group of patients who received study drug, had any seizure frequency data during the 2-week Pretreatment Phase plus the 4 weeks prior to the Pretreatment Phase, and during the Treatment Phase.

For the Extension Phase, all efficacy analyses were performed on the FAS, defined as all patients who took at least 1 dose of perampanel during the Extension Phase, and had any seizure frequency data during the 2-week Pretreatment Phase plus the 4 weeks prior to Pretreatment Phase of the Core Study and had any seizure frequency data during the Extension Phase.

For this study, the efficacy seizure endpoints were the percent change in 28-day seizure frequency during treatment compared to baseline, responder rate during the Maintenance Period, and seizure-free status during the Maintenance Period.

The baseline 28-day seizure frequency for the primary analyses used seizure data from the 2-week Pretreatment Phase.

The  responder  rate  during  the  Maintenance  Period  used  the  last  observation  carried  forward-type imputation.

The seizure-free status during the Maintenance Period was only calculated for patients who completed the Maintenance Period (ie, those who completed the Core Study).

CGIC scores at end of treatment (EOT) were summarized. The EOT value was the last non-missing value while on-treatment.

<div style=\"page-break-after: always\"></div>

## Study E2007-G000-311

## Methods

This study is an ongoing multicenter, open-label singlearm study in children (ages ≥4 to &lt;12 years) with inadequately controlled POS or PGTCS receiving 1 to 3 other AEDs.

<!-- image -->

The study consists of a Core Study and Extension Phase.

## -Pre-treatment phase

The Pretreatment Phase consisted of a Screening/Baseline Period that lasted up to 4 weeks ±3 days outside  of  Japan.  Patients  in  Japan  were  required  to  complete  4  full  weeks  ±3  days  of  the Screening/Baseline Period. Patients were stratified by age range (≥4 to &lt;7 years, 7 to &lt;12 years) with at least 30% of patients planned to be enrolled in the ≥4 to &lt;7 year age group for each seizure type (ie, at least 36 with POS and at least 12 with PGTCS).

## -Treatment phase

The duration of the Treatment Phase was up to 27 weeks and included 3 periods: Titration (up to 11 weeks), Maintenance (up to 12 weeks), and Follow-up (up to 4 weeks; only for those patients who did not roll over into the Extension Phase).

## o Titration

During the Titration Period, patients were stratified by the presence or absence of concomitant EIAEDs. The perampanel dose was titrated up to 16 mg per day whether an EIAED is administered.

The Titration Period had a duration of up to 11 weeks, during which multiple dose adjustments were allowed in order to identify each patient's optimum dose. All visits were done within ±3 days of the schedule.

<div style=\"page-break-after: always\"></div>

According to the investigator's clinical judgment, patients who experienced intolerability at any dose remained at the same dose or had their dose decreased 1 dose level down to the previously tolerated dose.  Multiple  dose  adjustments  were  allowed  during  the  Titration  Period.  Upon  completion  of  the Titration Period, patients entered the Maintenance Period.

## o Maintenance

During the Maintenance Period, patients continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. Multiple dose adjustments were allowed if a patient experienced intolerable AE(s) or a higher dose was deemed to be beneficial.

During the Titration and Maintenance Periods, all dose adjustments were done via one dose level up or down. Patients who could not tolerate a minimum of a 2-mg dose must have discontinued from the study.

- -Follow-up/Extension phase

All patients who completed all scheduled visits up to and including Visit 9 of the Core Study were eligible to participate in Extension phase.

Extension phase consisted of a Maintenance Period (up to 29 weeks) and a Follow-up Period (up to 4 weeks).

During the Maintenance Period of Extension phase, patients continued with their optimal perampanel dose (ie, the dose level the patients maintained at the completion of the Core Study).

Addition, deletion, and dose changes to concomitant AEDs were allowed during the Maintenance Period of Extension phase. Conversion-to-monotherapy on perampanel was also permitted at the discretion of the investigator, if it was considered appropriate to maintain seizures control.

## Study participants

The key inclusion criteria were male or female, from 4 to &lt;12 years of age, with a diagnosis of epilepsy with POS with or without SG seizures or PGTCS according to the ILAE Classification of Epileptic Seizures (1981). Diagnosis should have been established at least 6 months prior to Visit 1 by clinical history and an EEG that was consistent with the diagnosis; normal interictal EEGs were allowed provided that the patient met the other diagnosis criterion (ie, clinical history). They had a minimum weight of 16 kg (35 lb). A progressive cause of epilepsy was ruled out. During the 12 weeks ±3 days prior to Visit 2, patients must have had ≥1 POS or 1 PGTC seizure. Only simple POS with motor signs, complex POS, and complex POS with secondary generalization were counted toward this inclusion for POS.

Regarding the treatment, they had been on stable doses of 1 to a maximum of 3 approved AEDs. Doses must have been stable for at least 4 weeks before Visit 1; in the case where a new AED regimen was initiated for a patient, the dose must have been stable for at least 8 weeks prior to Visit 1. Only 1 EIAED (defined as carbamazepine, phenytoin, oxcarbazepine, or eslicarbazepine) out of the maximum of 3 AEDs was allowed (a vagal nerve stimulator was counted as 1 of the 3 allowed AEDs).

## Treatments

Perampanel was administered orally and once daily. Dosing occurred at bedtime.

Patients will be stratified by concomitant use of enzyme inducing antiepileptic drugs EIAEDs:

1) The starting dose for patients not on concomitant EIAEDs is 2 mg/day with a titration one week later to 4 mg/day, followed by biweekly titration steps to 6 mg/day, 8 mg/day 10 mg/day and 12 mg/day, or until MTD is reached.

2) The starting dose for patients on concomitant EIAEDs is 4 mg/day followed by weekly titration to 6 mg/day and 8 mg/day, followed by biweekly titration to 10 mg/day, 12 mg/day, 14 mg/day and 16 mg/day or until MTD is reached.

## Objectives

## Primary Objective

To evaluate the safety and tolerability of perampanel oral suspension when administered as an adjunctive therapy in children (age 4 to &lt;12 years) with inadequately controlled partial-onset seizures (POS) or primary generalized tonic-clonic (PGTC) seizures.

Secondary Objectives

<div style=\"page-break-after: always\"></div>

- -1.  To  characterize  the  pharmacokinetics  (PK)  of  perampanel  and  the  relationship  between perampanel plasma concentrations, efficacy, and safety using population PK/pharmacodynamics (PD) modeling
- -2. To evaluate the effects of perampanel on cognition, behavior, visuomotor skills, and growth and development in children during short-term (23 weeks) and long-term (up to 52 weeks) treatment
- -3. To evaluate the frequency of EEG abnormalities during awake and sleep state during 52 weeks of treatment
- -4. To evaluate suicidal ideation and suicidal behavior in children 6 years to &lt;12 years as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS) during 52 weeks of treatment
- -5. To evaluate the efficacy of perampanel as measured by the median percent change per 28 days in  seizure  frequency,  by  the  proportion  of  responders  (≥25%,  ≥50%,  and  ≥75%),  and  by  the proportion of patients who were seizure-free for POS, PGTC, and Generalized Tonic-Clonic seizures
- -6. To assess the effects of perampanel on the Clinical Global Impression (CGI), as measured by CGI of Change (CGIC)

## Outcomes/endpoints

## Efficacy

Seizure diaries were used to collect daily seizure counts. All seizure types were counted.

## PK

Plasma  concentrations  of  perampanel  were  determined  via  collection  of  blood  samples  during  the Maintenance Phase using a sparse sampling technique at specified visits for subsequent population PK analysis.(See PK part of this report)

## Safety

The safety and tolerability includes incidence of treatment emergent adverse events (TEAEs) and SAEs, laboratory parameters, vital signs and ECG parameters of perampanel oral suspension in children (age 4 to &lt;7 years and ≥7 years to &lt;12 years) with POS or PGTC.

Safety was assessed by monitoring and recording all AEs and serious adverse events (SAEs).

Additional assessments included regular monitoring of hematology, blood chemistry, and urine values, regular measurements of vital signs, ECGs, and physical and neurological examinations.

Growth and development were assessed by weight, height, thyroid function tests, and insulin-like growth factor-1 (IGF-1).

For cognitive testing AldenKamp-Baker neuropsychological assessment schedule [ABNAS], behavioral questionnaires  (Child  Behavior  Checklist  [CBCL]),  and  visuomotor  skills  testing  using  the  Lafayette

## Grooved

Pegboard Test (LGPT) were performed.

An assessment of suicidal ideation and behavior using the C-SSRS was performed throughout the study for patients aged 6 years and older at the time of consent/assent. Suicidal ideation and behavior was monitored in patients less than 6 years at the time of consent/assent based upon clinical impression.

An EEG was performed over a minimum of 1-hour up to a 2-hour period in an awake and sleep state at specified visits.

The CGI (CGI Severity at Baseline Visit and CGI Change [CGIC] at subsequent visits) was assessed.

## Sample size

## Randomisation

Not applicable (Open-label study)

## Blinding (masking)

<div style=\"page-break-after: always\"></div>

## Statistical methods

The  percent  change  in  seizure  frequency  per  28  days  with  respect  to  baseline  assessment  was summarized using descriptive statistics (n, mean, median, minimum and maximum):

- -by age cohorts : 4 to &lt;7 years, ≥ 7 to &lt;12 years),
- -by disease cohorts : POS, PGTCS, SGTC seizures (a subset of the POS cohort, patients who had complex partial seizures with SGTC seizures at baseline),
- -by the presence or absence of concomitant EIAED.

Seizure types within each disease cohort are defined as follows:

- POS cohort:
- Total seizures, defined as the sum of all seizures, including POS, generalized and other seizures.
- Total POS defined as the sum of all POS, including simple partial seizures without motor signs, simple partial seizures with motor signs, complex partial seizures, and complex partial seizures with SG;
- Total complex partial seizures.
- The SGTC subset of the POS cohort: Complex partial seizures with secondary generalization.
- PGTC cohort:
- Total seizures, defined as the sum of all seizures, including PGTCS, absence seizures, myoclonic seizures, and other seizures;
- Tonic-clonic seizures
- Absence seizures
- Myoclonic seizures

Patients  who  completed  the  core  study  and  had  no  seizures  during  the  maintenance  period  were considered seizure-free.

The proportion of patients who were seizure-free and the proportion of responders based on decrease from baseline in 28-day seizure frequency of ≥ 50% were summarized using frequency count (number and percentage) by age cohorts (4 to &lt;7 years, ≥ 7 to &lt;12 years), by disease cohorts (POS, PGTCS, and SGTC seizures), and by the presence or absence of concomitant EIAED in the FAS.

The CGIC was summarized using frequency count (number and percentage) by age cohorts (4 to &lt;7 years, ≥ 7 to &lt;12 years), by disease cohorts (POS, PGTCS, and SGTC seizures), and by the presence or absence of concomitant EIAED in the FAS.

## Results of studies 311 and 232

## Participant flow

## Participant flow/recruitment study population for study 311

## Core study

Efficacy analyses in Core Study 311 were conducted using the full analysis set (FAS).

In Core Study 311, a total of 180 patients were included in the FAS (149 patients in the POS cohort, including 54 patients in the secondarily generalized tonic-clonic (SGTC), and 31 patients in the PGTC cohort, including 24 patients in the PGTCS of IGE subset of the PGTC cohort.

Of the 180 patients, 46 patients (40 patients with POS and 6 patients with PGTCS) were in the 4 to &lt;7 year age group and 134 patients (109 patients with POS and 25 patients with PGTCS) were in the ≥ 7 to &lt;12 year age group.

| Study 311           |   POS n = 149 | PGTCS (of which PGTCS of IGE = 22) n = 31   |
|---------------------|---------------|---------------------------------------------|
| 4-7 years, n = 46   |            40 | 6 (3 IGE patients actually)                 |
| 7-12 years, n = 134 |           109 | 25 (19 IGE patients actually)               |

<div style=\"page-break-after: always\"></div>

## Participant flow/recruitment study population for study 232

## Core study

For the Core Study, it was planned to enroll approximately 48 male and female patients from 2 to &lt;12 years of age who had a diagnosis of epilepsy.

Approximately 60 patients were screened with an aim to enroll at least 48 evaluable patients into 2 agematched cohorts with approximately 24 patients each (patients from ≥ 7 to &lt;12 years of age and patients from ≥ 2 to &lt;7 years of age).

Patients were enrolled at 15 centers in North America and were assigned to a single treatment group: perampanel oral suspension.

A total of 50 patients were treated with perampanel: 22 patients 2-7 years, and 28 patients 7-12 years). There were 3 patients in this study with PGTC of IGE (1 in Cohort 2 and 2 in Cohort 1).

| Study 232                     |   POS n = 41 | PGTCS (of which PGTCS of IGE = 3) n = 9   |
|-------------------------------|--------------|-------------------------------------------|
| 2-7 years (cohort 2), n = 22  |           16 | 6 (1 IGE patient actually)                |
| 7-12 years (cohort 1), n = 28 |           25 | 3 (2 IGE patients actually)               |

<div style=\"page-break-after: always\"></div>

## Participant flow/recruitment study population for patients with PGTCS of IGE across study 311 and study 232

The number of patients diagnosed with PGTCS and PGTCS of IGE in both studies are provided by age cohort:

Table2.5-1 NumberofSubjectsWithPGTcSandPGTcSofIGEbyStudyand AgeCohort

|           | Study311   | Study311       | Study232   | Study232       | Total    | Total          |
|-----------|------------|----------------|------------|----------------|----------|----------------|
| AgeCohort | PGTCS, n   | PGTCSof IGE, n | PGTCS, n   | PGTCSof IGE, n | PGTCS, n | PGTCSof IGE, n |
| ≥2 to<4   | 0          | 0              | 0          | 0              | 0        | 0              |
| ≥4 to <7  | 6          | 5              | 6          | 1              | 12       | 6              |
| ≥7 to<12  | 25         | 19             | 3          | 2              | 28       | 21             |
| Total     | 31         | 24             | 9          | 3              | 40       | 27             |

IGE = idiopathic generalized epilepsy, PGTCS = primary generalized tonic-clonic seizures.

Source:CoreStudy311Table14.1.1.5.1,SCSTable14.1.1.5.2,CoreStudy232Listing16.2.4.2.1.

## Recruitment

## Conduct of the study

## Baseline data

## Patient Demographics:

In Study 232, the age group of enrolled patients is ≥ 2 to &lt;12 years, with a median age of 7.5 years.

In Study 311, the age group of enrolled patients is ≥ 4 to &lt;12 years, with a median age of 8.0 years.

The patients ratio distribution between male and female is 68.0% for study 232 (2/3 of male patients) compared to 51.1% for study 311.

Weight, height, and body mass index (BMI) were similar across patients in both studies.

## Disease cohorts and Prior treatments:

The number of AEDs taken at baseline by disease cohort for Core Study 232 and Core Study 311 is summarized in Table 2.7.3-21.

Overall, a generally similar percentage of patients between Core Study 232 and Core Study 311 were taking a total of 1 AED (24.0% vs 19.4%, respectively), 2 AEDs (52.0% vs 55.6%, respectively), and 3 AEDs (24.0% vs 25.0%, respectively) at baseline.

The percentages of patients in Core Study 232 and Core Study 311 taking EIAEDs were 36.0% and 27.2%, respectively, and the percentages of patients in Core Study 232 and Core Study 311 for those not taking EIAEDs were 64.0% vs 72.8%, respectively.

<div style=\"page-break-after: always\"></div>

Table2.7.3-21 311-SafetyAnalysisSet

|                                         | Disease Cohort         | Disease Cohort     | Disease Cohort                   | Disease Cohort    | Disease Cohort                          | Disease Cohort       |
|-----------------------------------------|------------------------|--------------------|----------------------------------|-------------------|-----------------------------------------|----------------------|
|                                         | Study 232 (N=50)       | Study 311          | Study 311                        | Study 311         | Study 311                               | Study 311            |
| Type of Medication Numberof Medications | Any Seizure Iype n (%) | POS (N=149) (%) uI | SGTC* subset of POS (N=54) n (%) | PGTC (N=31) (%) u | PGTC ofIGE* subset of PGTC (N=24) n (%) | Totalb (N=180) n (%) |
| Inducer                                 | 18 (36.0)              | 47 (31.5)          | 12 (22.2)                        | 2 (6.5)           | 1 (4.2)                                 | 49 (27.2)            |
| 1 AED                                   | 2 (4.0)                | 13 (27.7)          | 4 (33.3)                         | 2 (100.0)         | 1 (100.0)                               | 15 (30.6)            |
| 2 AEDs                                  | 12 (24.0)              | 27 (57.4)          | 7 (58.3)                         | 0                 | 0                                       | 27 (55.1)            |
| 3 AEDs                                  | 4 (8.0)                | 7 (14.9)           | 1 (8.3)                          | 0                 | 0                                       | 7 (14.3)             |
| Noninducer                              | 32 (64.0)              | 102 (68.5)         | 42 (77.8)                        | 29 (93.5)         | 23 (95.8)                               | 131 (72.8)           |
| 1AED                                    | 10 (20.0)              | 14 (13.7)          | 7 (16.7)                         | 6 (20.7)          | 4 (17.4)                                | 20 (15.3)            |
| 2 AEDs                                  | 14 (28.0)              | 56 (54.9)          | 22 (52.4)                        | 17 (58.6)         | 15 (65.2)                               | 73 (55.7)            |
| 3 AEDs                                  | 8 (16.0)               | 32 (31.4)          | 13 (31.0)                        | 6 (20.7)          | 4 (17.4)                                | 38 (29.0)            |
| Total                                   | 50 (100)               | 149 (100.0)        | 54 (100.0)                       | 31 (100.0)        | 24 (100.0)                              | 180 (100.0)          |
| 1AED                                    | 12 (24.0)              | 27 (18.1)          | 11 (20.4)                        | 8 (25.8)          | 5 (20.8)                                | 35 (19.4)            |
| 2 AEDs                                  | 26 (52.0)              | 83 (55.7)          | 29 (53.7)                        | 17 (54.8)         | 15 (62.5)                               | 100 (55.6)           |
| 3 AEDs                                  | 12 (24.0)              | 39 (26.2)          | 14 (25.9)                        | 6 (19.4)          | 4 (16.7)                                | 45 (25.0)            |

PriortoStudy311Amendment 01,Version5.0(20Apr2017),subjects were alloweda maximumof2AEDs atBaseline.

AED=antiepileptic drug, IGE=idiopathic generalized epilepsy, N=total number of subjects in the sample group, n=number of subjects used in the analysis, PGTC=primary generalized tonic-clonic, POS=partial-onset seizures, SGTC=secondarily generalized tonic-clonic.

a: Subjects are assigned as POS or PGTC by the investigator. SGTC is the subset of POS subjects who recorded secondarily generalized seizures during the baseline period. PGTC of IGE is the subset of PGTC subjects with idiopathic generalized epilepsy.

b:Total=POS+PGTC.SGTCis a subsetofPOS.PGTC ofIGE is a subsetofPGTC

C: An inducer subject took atleast 1 inducing AED at baseline.Inducer AEDs include carbamazepine, oxcarbazepine, eslicarbazepine (Study 311 only), and phenytoin.All other AEDs are noninducerAEDs.

Source:Core Study232CSRTable14.1.4.3.2,Core Study 311CSRTable 14.1.4.3.2.1,Module 2.7.4Table14.1.4.3.2.1

## Patient Disposition and primary reason for discontinuation

This table presents the patient disposition and primary reason for discontinuation from both studies.

Table 2.7.3-23Subject Disposition and Primary Reasons for Discontinuation from Study 232 and Study 311 (CoreStudy)-All Treated Subjects

Percentages are based on the number of enrolled and treated subjects.

|                                            | Perampanel       | Perampanel   | Perampanel          | Perampanel   | Perampanel                 | Perampanel   |
|--------------------------------------------|------------------|--------------|---------------------|--------------|----------------------------|--------------|
|                                            | Study 232        | Study 311    | Study 311           | Study 311    | Study 311                  | Study 311    |
| Parameter                                  | Any Seizure Type | POS          | SGTC\" subset of POS | PGTC         | PGTC ofIGE* subset of PGTC | Totalb       |
| Treated, n (%)                             | 50 (100)         | 149 (100.0)  | 54 (100.0)          | 31 (100.0)   | 24 (100.0)                 | 180 (100.0)  |
| Completed Core Study, n (%)                | 42 (84.0)        | 122 (81.9)   | 48 (88.9)           | 24 (77.4)    | 18 (75.0)                  | 146 (81.1)   |
| Discontinued Core Study, n (%)             | 8 (16.0)         | 27 (18.1)    | 6 (11.1)            | 7 (22.6)     | 6 (25.0)                   | 34 (18.9)    |
| Primary reason for discontinuation', n (%) |                  |              |                     |              |                            |              |
| Adverse event                              | 2 (4.0)          | 11 (7.4)     | 2 (3.7)             | 3 (9.7)      | 2 (8.3)                    | 14 (7.8)     |
| Lost to follow-up                          | 1 (2.0)          | 0            | 0                   | 0            | 0                          | 0            |
| Subject choice                             | 1 (2.0)          | 6 (4.0)      | 1 (1.9)             | 1 (3.2)      | 1 (4.2)                    | 7 (3.9)      |
| Inadequate therapeutic effect              | 1 (2.0)          | 6 (4.0)      | 0                   | 2 (6.5)      | 2 (8.3)                    | 8 (4.4)      |
| Withdrawal of consent                      | 1 (2.0)          | 1 (0.7)      | 1 (1.9)             | 1 (3.2)      | 1 (4.2)                    | 2 (1.1)      |
| Other                                      | 2 (4.0)          | 3 (2.0)      | 2 (3.7)             | 0            | 0                          | 3 (1.7)      |

CRF=case report form, IGE=idiopathic generalized epilepsy, N=total number of subjects in the sample group, n=number of subjects used in the analysis, PGTC=primary generalized tonic-clonic, POS=partial-onset seizures, SGTC=secondarily generalized tonic-clonic.

a: Subjects are assigned as POS or PGTC by the investigator. SGTC is the subset of POS subjects who record Secondarily Generalized Seizures during the baseline period. PGTC of IGE is the subset of PGTC subjects with idiopathic generalized epilepsy.

b:Total=POS +PGTC.SGTC is a subset of POS.PGTC ofIGE is a subset ofPGTC.

C: As reported on the Subject Disposition CRF.

Source: Core Study 232 CSR Table 14.1.1.3,Core Study 311 CSR Table 14.1.1.5.1, Module 2.7.4 Table 14.1.1.5.1.

## Numbers analysed

## Outcomes and estimation

## Efficacy results for Study E2007-G000-311

In Study 311, the majority of patients (overall, 52.2%) had a mean daily dose of &gt; 4 to 8 mg/day. The same trend was observed across disease cohorts (POS, the SGTC subset of the POS cohort, and PGTC; however, in the PGTC of IGE subset of PGTC cohort, the majority of patients (58.3%) received a mean daily dose of &gt;8 to 12 mg/day).

<div style=\"page-break-after: always\"></div>

In patients without concomitant EIAEDs, the majority of patients had a mean daily perampanel dose of &gt;4 to 8 mg/day (56.1%). None received doses beyond 12 mg/day.

In patients receiving concomitant EIAEDs, the majority of patients had a mean daily perampanel dose of &gt;4 to 8 mg/day (41.7%) and &gt;8 to 12 mg/day (31.3%). Ten (20.8%) patients received perampanel doses of &gt;12 to 16 mg/day.

The following tables summarized the main descriptive efficacy results for this study.

Table 2.7.3-4 Seizure Frequency per 28 Days and Percent Change During Treatment Summary for Age Cohort by Each Disease Cohort - Full Analysis Set

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 2.7.3-5 SeizureFrequencyper 28Days andPercent ChangeDuring Treatment Summary for Age Cohort by Each Disease Cohort-Core Full Analysis Set-PGTC Cohort

Only subjects who had at least 1 seizure during the baseline period are included in the analysis.

<!-- image -->

| Disease Cohort Analysis Seizures Analysis Window   | 4 to <7 Years (N=0)   | 4 to <7 Years (N=0)   | 7 to <12 Years (N=25)   | 7 to <12 Years (N=25)   | Total PGTC (N=31)   | Total PGTC (N=31)   |
|----------------------------------------------------|-----------------------|-----------------------|-------------------------|-------------------------|---------------------|---------------------|
| Statistic                                          | Actual                | Percent Change        | Actual                  | Percent Change          | Actual              | Percent Change      |
| IGE subjects                                       |                       |                       |                         |                         |                     |                     |
| PGTC seizures                                      |                       |                       |                         |                         |                     |                     |
| Pretreatment phase                                 |                       |                       |                         |                         |                     |                     |
| n1                                                 | 2                     |                       | 17                      |                         | 19                  |                     |
| Mean (SD)                                          | 2.5 (2.07)            |                       | 9.7 (14.72)             |                         | 8.9 (14.07)         |                     |
| Median                                             | 2.5                   |                       | 3.1                     |                         | 3.1                 |                     |
| Min, max                                           | 1.1, 4.0              |                       | 0.9,50.2                |                         | 0.9,50.2            |                     |
| Treatment phase                                    |                       |                       |                         |                         |                     |                     |
| n1                                                 | 2                     | 2                     | 17                      | 17                      | 19                  | 19                  |
| Mean (SD)                                          | 8.0 (8.80)            | 580.5 (900.92)        | 9.7 (15.73)             | 226.6 (1098.02)         | 9.5 (14.99)         | 263.8 (1062.66)     |
| Median                                             | 8.0                   | 580.5                 | 0.9                     | -81.9                   | 1.7                 | -56.5               |
| Min, max                                           | 1.7, 14.2             | -56.5, 1217.6         | 0.0,47.4                | -100.0,4470.6           | 0.0, 47.4           | -100.0,4470.6       |
| 95% CI for median                                  |                       | (-56.5, 1217.6)       |                         | (-100.0, -24.7)         |                     | (-100.0, -17.7)     |
| Non-IGE subjects                                   |                       |                       |                         |                         |                     |                     |
| PGTC seizures                                      |                       |                       |                         |                         |                     |                     |
| Pretreatment phase                                 |                       |                       |                         |                         |                     |                     |
|                                                    | 1                     |                       | 2                       |                         | 3                   |                     |
| Mean (SD)                                          | 0.3 (NC)              |                       | 6.5 (3.54)              |                         | 4.5 (4.35)          |                     |
| Median                                             | 0.3                   |                       | 6.5                     |                         | 4.0                 |                     |
| Min, max                                           | 0.3,0.3               |                       | 4.0, 9.0                |                         | 0.3,9.0             |                     |
| Treatment phase                                    |                       |                       |                         |                         |                     |                     |
| n1                                                 | 1                     | 1                     | 2                       | 2                       | 3                   | 3                   |
| Mean (SD)                                          | 0.0 (NC)              | -100.0 (NC)           | 2.3 (2.75)              | -45.0 (72.25)           | 1.5 (2.36)          | -63.4 (60.14)       |
| Median                                             | 0.00                  | -100.0                | 2.3                     | -45.0                   | 0.4                 | -96.1               |
| Min, max                                           | 0.0,0.0               | -100.0,-100.0         | 0.4,4.2                 | -96.1, 6.1              | 0.0,4.2             | -100.0, 6.1         |
| 95% CI for median                                  |                       | (NC, NC)              |                         | (-96.1, 6.1)            |                     | (-100.0, 6.1)       |
| Total PGTC subjects PGTC seizures                  |                       |                       |                         |                         |                     |                     |
| Pretreatment phase                                 |                       |                       |                         |                         |                     |                     |
| n                                                  | 3                     |                       | 19                      |                         | 22                  |                     |
| Mean (SD)                                          | 1.8 (1.94)            |                       | 9.4 (13.94)             |                         | 8.3 (13.19)         |                     |
| Median                                             | 1.1                   |                       | 3.1                     |                         | 3.1                 |                     |
| Min, max                                           | 0.3,4.0               |                       | 0.9,50.2                |                         | 0.3, 50.2           |                     |
| Treatment phase                                    |                       |                       |                         |                         |                     |                     |
|                                                    | 3                     | 3                     | 19                      | 19                      | 22                  | 22                  |
| Mean (SD)                                          | 5.3 (7.74)            | 353.7 (748.46)        | 8.9 (15.03)             | 198.00 (1038.90)        | 8.4 (14.17)         | 219.2 (990.69)      |
| Median                                             | 1.7                   | -56.5                 | 0.9                     | -81.9                   | 1.3                 | -69.2               |
| Min, max                                           | 0.0, 14.2             | -100.0, 1217.6        | 0.0, 47.4               | -100.0,4470.6           | 0.0, 47.4           | -100.0,4470.6       |
| 95% CI for median                                  |                       | (-100.0, 1217.6)      |                         | (-100.0, -17.7)         |                     | (-100.0, -17.7)     |

CI=confidence interval, IGE=idiopathic generalized epilepsy, max=maximum, Min=minimum, N=total mumber of subjects in the sample group, n=mumber of subjects in the specified group, PGTC=primary generalized tonic-clonic. Source:Module 2.7.3 Table 14.2.1.1.1.

<div style=\"page-break-after: always\"></div>

Table 2.7.3-7 Responder Rate During Maintenance-LOcF for Age Cohort by Each Disease Cohort - Full Analysis Set

| Disease Cohort Analysis Seizures Responder Frequency   | 4 to <7 Year's (N=46)   | 7 to <12 Year's (N=134)   | Total (N=180)   |
|--------------------------------------------------------|-------------------------|---------------------------|-----------------|
| POS                                                    |                         |                           |                 |
| Total PoS seizures                                     |                         |                           |                 |
| Equal or greater than 50%                              |                         |                           |                 |
| Yes, n (%)                                             | 18 (45.0)               | 51 (47.2)                 | 69 (46.6)       |
| No, n (%)                                              | 22 (55.0)               | 57 (52.8)                 | 79 (53.4)       |
| Total                                                  | 40 (100.0)              | 108 (100.0)               | 148 (100.0)     |
| Seizure-free                                           |                         |                           |                 |
| Yes, n (%)                                             | 3 (7.5)                 | 14 (13.0)                 | 17 (11.5)       |
| No, n (%)                                              | 37 (92.5)               | 94 (87.0)                 | 131 (88.5)      |
| Total                                                  | 40 (100.0)              | 108 (100.0)               | 148 (100.0)     |
| PGTC                                                   |                         |                           |                 |
| PGTC seizures                                          |                         |                           |                 |
| Equal or greater than 50%                              |                         |                           |                 |
| Yes, n (%)                                             | 2 (66.7)                | 12 (63.2)                 | 14 (63.6)       |
| No, n (%)                                              | 1 (33.3)                | 7 (36.8)                  | 8 (36.4)        |
| Total                                                  | 3 (100.0)               | 19 (100.0)                | 22 (100.0)      |
| Seizure-free                                           |                         |                           |                 |
| Yes, n (%)                                             | 2 (66.7)                | 10 (52.6)                 | 12 (54.5)       |
| No, n (%)                                              | 1 (33.3)                | 9 (47.4)                  | 10 (45.5)       |
| Total                                                  | 3 (100.0)               | 19 (100.0)                | 22 (100.0)      |
| SGTC                                                   |                         |                           |                 |
| SG seizures                                            |                         |                           |                 |
| Equal or greater than 50%                              |                         |                           |                 |
| Yes, n (%)                                             | 12 (70.6)               | 23 (62.2)                 | 35 (64.8)       |
| No, n (%)                                              | 5 (29.4)                | 14 (37.8)                 | 19 (35.2)       |
| Total                                                  | 17 (100.0)              | 37 (100.0)                | 54 (100.0)      |
| Seizure-free                                           |                         |                           |                 |
| Yes, n (%)                                             | 3 (17.6)                | 7 (18.9)                  | 10 (18.5)       |
| No, n (%)                                              | 14 (82.4)               | 30 (81.1)                 | 44 (81.5)       |
| Total                                                  | 17 (100.0)              | 37 (100.0)                | 54 (100.0)      |

## Efficacy results for Study E2007-G000-232

The following table summarizes the main descriptive efficacy results for this study.

Efficacy was measured by evaluating seizure frequency, responder rate, seizure-free rate and CGIC. A total of 50 patients were treated with perampanel in Study 232 (22 patients in Cohort 2 and 28 patients in Cohort 1), and all 50 patients were included in the FAS.

There were 3 patients in this study with PGTC of IGE (1 in Cohort 2 and 2 in Cohort 1).

<div style=\"page-break-after: always\"></div>

Table 2.7.3-20 Key Efficacy Results from Study 232 (Core Study) - Full Analysis Set

|                                                                                 | Cohort 2 ≥2 to <7 Years N=22                                                    | Cohort 1 ≥7 to <12 Year's N=28                                                  | Total N=50                                                                      |
|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Percent change in seizure frequency from Baseline to end of the Treatment Phase | Percent change in seizure frequency from Baseline to end of the Treatment Phase | Percent change in seizure frequency from Baseline to end of the Treatment Phase | Percent change in seizure frequency from Baseline to end of the Treatment Phase |
| Overall seizures                                                                |                                                                                 |                                                                                 |                                                                                 |
| 1n                                                                              | 22                                                                              | 26                                                                              | 48                                                                              |
| Mean (SD)                                                                       | -36.9 (54.13)                                                                   | 130.5 (342.45)                                                                  | 53.7 (266.07)                                                                   |
| Median                                                                          | -43.6                                                                           | -33.9                                                                           | -36.0                                                                           |
| Overall partial seizures                                                        |                                                                                 |                                                                                 |                                                                                 |
| 11                                                                              | 17                                                                              | 23                                                                              | 40                                                                              |
| Mean (SD)                                                                       | -47.8 (63.02)                                                                   | 62.0 (378.24)                                                                   | 15.4 (292.16)                                                                   |
| Median                                                                          | -82.5                                                                           | -46.8                                                                           | -55.8                                                                           |
| Overall generalized seizures                                                    |                                                                                 |                                                                                 |                                                                                 |
| 1n                                                                              | 13                                                                              | 9                                                                               | 22                                                                              |
| Mean (SD)                                                                       | -42.6 (73.91)                                                                   | 382.7 (425.67)                                                                  | 131.4 (343.46)                                                                  |
| Median                                                                          | -53.1                                                                           | 305.4                                                                           | -35.8                                                                           |
| Unclassified seizures                                                           |                                                                                 |                                                                                 |                                                                                 |
| n                                                                               | 3                                                                               | 2                                                                               | 5                                                                               |
| Mean (SD)                                                                       | 14.5 (176.10)                                                                   | -67.3 (46.25)                                                                   | -18.2 (134.35)                                                                  |
| Median                                                                          | -73.7                                                                           | -67.3                                                                           | -73.7                                                                           |
| Responder rate during the Maintenance-LOCF Period                               |                                                                                 |                                                                                 |                                                                                 |
| Overall seizures                                                                |                                                                                 |                                                                                 |                                                                                 |
| Total number (%) of subjects                                                    | 22 (100)                                                                        | 26 (100)                                                                        | 48 (100)                                                                        |
| Number (%) of respondersa                                                       | 16 (72.7)                                                                       | 14 (53.8)                                                                       | 30 (62.5)                                                                       |
| Overall partial seizures                                                        |                                                                                 |                                                                                 |                                                                                 |
| Total number (%) of subjects                                                    | 17 (100)                                                                        | 23 (100)                                                                        | 40 (100)                                                                        |
| Number (%) of respondersa                                                       | 14 (82.4)                                                                       | 14 (60.9)                                                                       | 28 (70.0)                                                                       |
| Overall generalized seizures                                                    |                                                                                 |                                                                                 |                                                                                 |
| Total number (%) of subjects                                                    | 13 (100)                                                                        | 9 (100)                                                                         | 22 (100)                                                                        |
| Number (%) of respondersa                                                       | 10 (76.9)                                                                       | 3 (33.3)                                                                        | 13 (59.1)                                                                       |
| Unclassified seizures                                                           |                                                                                 |                                                                                 |                                                                                 |
| Total number (%) of subjects                                                    | 3 (100)                                                                         | 2 (100)                                                                         | 5 (100)                                                                         |
| Number (%) of respondersa                                                       | 2 (66.7)                                                                        | 2 (100)                                                                         | 4 (80.0)                                                                        |
| Seizure-free status during the MaintenancePeriod                                | Seizure-free status during the MaintenancePeriod                                |                                                                                 |                                                                                 |
| Overall seizures                                                                |                                                                                 |                                                                                 |                                                                                 |
| Total number (%) of subjects                                                    | 20 (100)                                                                        | 22 (100)                                                                        | 42 (100)                                                                        |
| Number (%) of seizure-free subjects                                             | 3 (15.0)                                                                        | 6 (27.3)                                                                        | 9 (21.4)                                                                        |
| Overall partial seizures                                                        |                                                                                 |                                                                                 |                                                                                 |
| Total number (%) of subjects                                                    | 20 (100)                                                                        | 22 (100)                                                                        | 42 (100)                                                                        |
| Number (%) of seizure-free subjects                                             | 10 (50.0)                                                                       | 10 (45.5)                                                                       | 20 (47.6)                                                                       |
| Overall generalized seizures                                                    |                                                                                 |                                                                                 |                                                                                 |
| Total number (%) of subjects                                                    | 20 (100)                                                                        | 22 (100)                                                                        | 42 (100)                                                                        |
| Number (%) of seizure-free subjects                                             | 11 (55.0)                                                                       | 17 (77.3)                                                                       | 28 (66.7)                                                                       |
| Unclassified seizures                                                           |                                                                                 |                                                                                 |                                                                                 |
| Total number (%) of subjects                                                    | 20 (100)                                                                        | 22 (100)                                                                        | 42 (100)                                                                        |
| Number (%) of seizure-free subjects                                             | 20 (100)                                                                        | 21 (95.5)                                                                       | 41 (97.6)                                                                       |

## Results from the extension study

## Study 311

Core Study 311 is completed and data from Extension Phase Study 311 are interim, with a data cutoff date of 20 Jul 2018.

The efficacy results during the extension phase were provided for five 13-weeks periods until the last period at 53-65 weeks of the extension phase. The median percent change in seizure frequency, the

<div style=\"page-break-after: always\"></div>

responder rate and the seizure-free status were assessed for each 13-weeks period, for each disease cohort and for each age range.

## Study 232

In the Study 232 Extension Phase, efficacy was measured using the same endpoints as in the Core Study.

Of the 42 patients who completed the Core Study, a total of 41 patients continued into the Extension Phase (22 patients in Cohort 1 and 19 patients in Cohort 2).

The 3 patients with PGTC of IGE completed the Core Study and entered the Extension Phase, but did not complete it due to patient choice (1 patient) and unable to adhere to study protocol (2 patients).

## Ancillary analyses

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Summary of Efficacy for trial E2007-G000-311

| Title: phase 3 clinical study to evaluate safety, tolerability, pharmacokinetics, and PK/PD relationship of perampanel suspension when administered as an adjunctive therapy in paediatric patients (4-12 years)   | Title: phase 3 clinical study to evaluate safety, tolerability, pharmacokinetics, and PK/PD relationship of perampanel suspension when administered as an adjunctive therapy in paediatric patients (4-12 years)                                                                                                                                                                               | Title: phase 3 clinical study to evaluate safety, tolerability, pharmacokinetics, and PK/PD relationship of perampanel suspension when administered as an adjunctive therapy in paediatric patients (4-12 years)                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                   | E2007-G000-311                                                                                                                                                                                                                                                                                                                                                                                 | E2007-G000-311                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Design                                                                                                                                                                                                             | Open-label, multicentre, uncontrolled, single-arm study with an extension phase to evaluate safety, tolerability, pharmacokinetics, and PK/PD relationship of perampanel suspension when administered as an adjunctive therapy in paediatric patients (from 4 to less than 12 years of age) with inadequately controlled partial onset seizures or Primary Generalized Tonic- Clonic Seizures. | Open-label, multicentre, uncontrolled, single-arm study with an extension phase to evaluate safety, tolerability, pharmacokinetics, and PK/PD relationship of perampanel suspension when administered as an adjunctive therapy in paediatric patients (from 4 to less than 12 years of age) with inadequately controlled partial onset seizures or Primary Generalized Tonic- Clonic Seizures.                                                                                                                                                                                              |
| Design                                                                                                                                                                                                             | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                        | Treatment: up to 27 weeks (up to 11-week Titration; 12-week Maintenance; 4-week FU for patients not continuing into Extension Phase)                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                             | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                                                                      | 4 weeks ± 3 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Design                                                                                                                                                                                                             | Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                   | 33 weeks (29-week Maintenance+ 4-week Follow- up).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Hypothesis                                                                                                                                                                                                         | Exploratory: descriptive statistics for efficacy and safety                                                                                                                                                                                                                                                                                                                                    | Exploratory: descriptive statistics for efficacy and safety                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Treatments groups                                                                                                                                                                                                  | perampanel                                                                                                                                                                                                                                                                                                                                                                                     | Oral administration Patients will be stratified by concomitant use of enzyme inducing antiepileptic drugs (EIAEDs): 1. The starting dose for patients not on concomitant EIAEDs is 2 mg/day with a titration one week later to 4 mg/day, followed by bi-weekly titration steps to 6 mg/day, 8 mg/day 10 mg/day and 12 mg/day, or until MTD is reached. 2. The starting dose for patients on concomitant EIAEDs is 4 mg/day followed by weekly titration to 6 mg/day and 8 mg/day, followed by bi-weekly titration to 10 mg/day, 12 mg/day, 14 mg/day and 16 mg/day or until MTD is reached. |
| Treatments groups                                                                                                                                                                                                  | No placebo                                                                                                                                                                                                                                                                                                                                                                                     | No placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions                                                                                                                                                                                          | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                               | Safety and tolerability of perampanel oral suspension (administered at least for up to 52 weeks) summarized by age cohorts (4 to < 7 years, ≥7 years to <12 years).                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|               | 1. Secondary endpoint   | To characterize the PK of perampanel and the relationship between perampanel plasma concentrations, efficacy, and safety using population PK/PD modelling (see study 12)                                                                                                                                                                                                          |
|---------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|               | 2. Secondary endpoint   | The population PK and PK/PD approach to be used to explore the exposure-response relationship for efficacy and most frequent AE(s).                                                                                                                                                                                                                                               |
|               | 3. Secondary endpoint   | To evaluate physical (including height, weight, thyroid hormones and IGF1) and cognitive development, behaviour using scales validated for paediatric patients: A-B Neuropsychological Assessment Schedule (ABNAS) if validated for use in paediatric patients, behavioural questionnaires (CBCL), and visuomotor skills testing using the Lafayette Grooved Pegboard Test (LGPT) |
|               | 4. Secondary endpoint   | To evaluate EEGs (minimum 1hr- maximum 2hrs) recorded awake and asleep at Baseline, Month 3, and Month 12. Comparison of post-baseline EEGs to the pre- treatment one to assess eventual worsening and the presence of abnormalities not present at baseline.                                                                                                                     |
|               | 5. Secondary endpoint   | To evaluate the activity of perampanel as captured on seizure diaries and measured by the median percent change per 28 days in seizure frequency and the proportion of responders (~50% reduction in seizures)                                                                                                                                                                    |
|               | 6. Secondary endpoint   | Median percent change in seizure frequency and proportion of responders (50% responders defined as ~50% decrease in seizure frequency) during the Treatment Phase compared to baseline seizure frequency                                                                                                                                                                          |
| Database lock | Extension study ongoing | Extension study ongoing                                                                                                                                                                                                                                                                                                                                                           |

## Results and Analysis

Analysis description

Analysis population and time point

description

Descriptive statistics and estimate

variability

Descriptive statistics and estimate

variability

Descriptive statistics for efficacy

At least 160 patients with POS or PGTCS at 80 sites in the US, EU, and Asia

Pacific were planned to be enrolled perampanel

Number of patients

Percent change in seizure

frequency per 28

days (POS)

95% CI for median

&gt;50% responder rate (POS)

Seizure free status (POS)

perampanel

Number of patients

4 to &lt;7 years cohort

40

-42.7

[-56.3;-26.3]

45.0%

7.5%

4 to &lt;7 years cohort

3

7 to &lt;12 years cohort

108

-40.1

[-53.3;-30.8]

47.2%

13.0%

7 to &lt;12 years cohort

19

total

148

-40.1

[-53.0;-31.4]

46.6%

11.5%

total

22

<div style=\"page-break-after: always\"></div>

| Percent change in seizure frequency per 28 days (PGTCS)   | -56.5           | -81.9          | - 69.2         |
|-----------------------------------------------------------|-----------------|----------------|----------------|
| 95% CI for median                                         | [-100.0;1217.6] | [-100.0;-17.7] | [-100.0;-17.7] |
| >50% responder rate (PGTCS)                               | 66.7%           | 63.2%          | 63.6%          |
| Seizure free status (PGTCS)                               | 66.7%           | 52.6%          | 54.5%          |

## Analysis performed across trials (meta-analysis)

In  addition  to  studies  232  and  311,  the  Applicant  submitted  a  meta-analysis  of  the  literature  to substantiate the possibility of extrapolating efficacy from adults to paediatric patients with PGTCS.

## Objective of this meta-analysis:

A  meta-analysis  of  published  studies  was  performed  to  determine  whether  the  efficacy  of  AEDs  in adolescents and adults with primary generalized tonic-clonic seizures (PGTCS) could be used to predict the efficacy of some AEDs in the pediatric population (4 - 11 years of age) with PGTCS.

## Results from this meta-analysis provided by the MAH:

Efficacy measures were consistent between adults and children with PGTCS among the 7 adjunctive drug therapy trials for lamotrigine (LTG), topiramate (TPM), and perampanel. The median percent change in reduction of PGTCS frequency between drug and placebo was consistently in favor of the drug treatment group across trials and similar between the children and adult subgroups. Furthermore, the estimated risk ratios in the 50% or greater responder rate between drug and placebo groups were comparable between the children and adult subgroups consistently favored the drug group across trials.

## 2.4.2. Discussion on clinical efficacy

For the current submission, the MAH proposes to extend the approved Fycompa indications to children aged 2 years and older through extrapolation of adult and adolescent efficacy data to the paediatric population.

The extrapolation of perampanel efficacy in adults to the paediatric population is mainly supported by clinical data from two clinical studies:

-  Study  311:  a  phase  3  open-label,  uncontrolled  trial,  performed  to  assess  the  exposure-efficacy relationship of perampanel as adjunctive therapy in 180 paediatric patients (aged 4 to 11 years old) with inadequately controlled POS or PGTC seizures. Patients were titrated over 11 weeks to a target dose of 8 mg/day or the maximum tolerated dose (not to exceed 12 mg/day) for patients not taking EIAED (carbamazepine, oxcarbazepine, eslicarbazepine and phenytoin) or 12 mg/day or the maximum tolerated dose (not to exceed 16 mg/day) for patients taking an EIAED.

- Study 232: a phase 2 pilot, open-label, uncontrolled, ascending-dose trial, performed to evaluate the PK and preliminary safety, tolerability, and efficacy of perampanel oral suspension when given as an adjunctive therapy in paediatric patients ( ≥ 2 to &lt;12 years) with epilepsy.

In the main study 311, in the POS cohort (n=148), the median change in seizure frequency per 28 days was -40.1%, the 50% or greater responder rate was 46.6%, and seizure-free rate was 11.5%. In the SGTCS cohort (n=54, subset of the POS cohort), the median change in seizure frequency per 28 days was -58.7%, the 50% or greater responder rate was 64.8%, and seizure-free rate was 18.5%.

In the PGTCS cohort (n=22), the median change in seizure frequency per 28 days was -69.2%, the 50% or greater responder rate was 63.6%, and seizure-free rate was 54.5%. Similar results were obtained in a subset of patients with PGTCSs in IGE (56.5%, 63.2%, and 52.6%, respectively). Considering the small number of patients, these results should however be considered cautiously.

For both studies 311 and 232, for up to nearly 1 year, efficacy was observed during the extension phase: the rate of median change in seizure frequency per 28 days, the 50% or greater responder rate and

<div style=\"page-break-after: always\"></div>

seizure-free rate were overall consistent with those observed during the maintenance phase of the core studies. However, these results should be considered cautiously as the number of patients decreased gradually until the end of the extension phases.

Some factors like the number of baseline AED and the administration of EIAED  were assessed and although the efficacy showed a reduction with the number of baseline associated AEDs as well as with the concomitant administration of inducer drugs, the observed efficacy results are consistent with those observed during the core studies. However, these results should also be considered cautiously because of the open-label trial design.

In line with the guideline on clinical investigation of medicinal products in the treatment of epileptic disorders (CHMP/EWP/566/98 Rev.2/Corr) and the statement ' Focal epilepsies especially cryptogenic and symptomatic, and idiopathic generalized epilepsies, with absences, myoclonic and/or generalized convulsive seizures, where the efficacy of AEDs seems to be comparable in childhood and adulthood. Focal epilepsies in children older than 4 years old have a similar clinical expression to focal epilepsies in adolescents and adults. In refractory focal epilepsies, the results of efficacy trials performed in adults could to some extent be extrapolated to children provided the dose is established' , it is agreed that the efficacy in POS for children from 4-year-old could be extrapolated from the results in adults, provided the dosing regimen is established and justified.

Initially, there were uncertainties on the dosing scheme for patients. These were subsequently resolved and the dose in the various age groups determined as a weight-based dose for three weight categories: &lt;20kg, 20 to &lt; 30 kg and &gt; 30 kg (see Discussion on clinical pharmacology above).

Although the efficacy data show a positive effect on the median seizure frequency reduction, on the responder rate and on the seizure-free status in the POS cohort, in the SGTCS subset of the POS cohort and in the PGTCS cohort for both age groups (2 to &lt;7 years and 7 to &lt;12 years), these efficacy results from both single-arm open labelled studies remain only of supportive nature. Further data were therefore provided and discussed.

The CHMP considered that for the treatment of POS and SGTCS, the clinical efficacy observed through descriptive data from study 311 was overall reassuring. The efficacy results could be considered clinically meaningful for both age cohorts (4 to &lt;7 years and 7 to&lt;12 years). The efficacy between adults and children &gt; 4 years of age in the treatment of POS and SGTCS seems comparable and acceptable from a clinical point of view. In line with the guideline, the effect of perampanel on POS, with or without SGTCS, could be extrapolated from adults to children &gt; 4 years of age, provided the dose is established. The CHMP agreed that the number of subjects was large enough to consider that these observed clinical results were sufficient for an established dosing regimen, based on PK/PD extrapolation from adults to the target population, to be accepted.

Regarding patients with PGTCS, although the clinical efficacy observed through descriptive data from study 311 is overall in favour of perampanel, the CHMP agreed that the small number of paediatric subjects less than 7 years of age (only 4 patients &lt;7 years) made the clinical relevance disputable and did not allow to yield any conclusion in the PGTCS indication for this paediatric population under 7 years of age.

This  is  in  line  with  the  Scientific  Advice  ' the  similarity  of  therapeutic  response  cannot  be  ensured, especially in the youngest children, as the brain is maturing until 7 years of age with different hyper or hypoexcitability  thresholds  depending  on  the  area  considered '.  It  was  also  noted  that  the  PDCO recommended that,  f rom studies  9  (311)  and  7  (232),  at  least  40  patients  to  be  evaluable  for  primary endpoint with PGTCS, including at least 12 patients (30%) in the age group of 4 to &lt;7 years, and 28 patients in the 7 to &lt; 12 years of age (PIP EMEA-000467-PIP01-08). T herefore, the number of patients was not enough in PGTCS and in PGTCS of IGE for the 4-7 age range.

Regarding patients aged 2 to &lt;4 years old, the pilot study 232 included 5 patients aged 2 to &lt;4 years old (one patient discontinued early and 4 patients completed study) and the main clinical phase 3 study 311, containing the majority of supportive efficacy data, only included children from 4 years old. No information regarding the efficacy of perampanel in patients aged 2 to 4 years of age was available from the main study and the CHMP therefore agreed that the data were too limited to extend the indication in patients below 4 years of age.

## 2.4.3. Conclusions on the clinical efficacy

Following  the  review  of  the  available  data,  the  CHMP  concluded  that  the  extension  of  indication  of perampanel for the treatment of partial onset seizure (POS), with or without secondary generalized tonicclonic seizures (SGTCS) was considered acceptable in children (from 4 to &lt; 12 years of age) with the weight-based established dosing regimen.

<div style=\"page-break-after: always\"></div>

The extension of indication for the treatment of primary generalised tonic-clonic (PGTC) seizures in patients from 7 years of age and older with idiopathic generalized epilepsy (IGE) was also considered acceptable in children (from 7 to &lt; 12 years of age) with the weight-based established dosing regimen. For primary PGTCS in IGE, the data in the paediatric population less than 7 years of age are too limited to allow for a solid estimate of the actual efficacy.

In paediatric patients aged 2 to &lt;4 years of age, no indication is approvable since the extrapolation, based on data from PK/PD was not considered acceptable in this age group and the efficacy data were too limited.

## 2.5. Clinical safety

## Introduction

The safety profile of perampanel in pediatric patients with POS and PGTCS is based on data from the 2 open-label studies 311 and 232.

## Post-marketing use

All safety data received by the MAH are from worldwide sources. Using the available wholesale data on the number of tablets sold and 8 mg as the WHO Defined Daily Dose for FYCOMPA, it is estimated that there have been approximately 45 million patient-days of exposure from product launch through 22 Jul 2018.

The post-marketing safety profile of FYCOMPA has been consistent with the safety profile observed during the original clinical studies. The most frequently reported spontaneous AEs in patients receiving FYCOMPA are dizziness, somnolence, and aggression followed by irritability and seizure. A literature review has not identified any new safety concerns.

Since initial marketing approval, there have been 2 additions to the safety profile. Suicidal ideation and suicide  attempt  were  added  as  uncommon  events  to  Section  4.8,  Undesirable  effects  and  Severe cutaneous adverse reactions (SCARs) including drug reaction with eosinophilia and systemic symptoms (DRESS)  was  added  in  Section  4.4  Special  warnings  and  precautions  for  use  and  in  Section  4.8 Undesirable effects in Post-marketing use.

There were no significant changes in the frequency and severity of previously identified adverse reactions or important risks.

## Patient exposure

Table 2.7.4-8 Combined Extent of Exposure From Both Core and Extension Study 232 and Study 311

<!-- image -->

|                   | Study232                   | Study232                      | Study232     | Study 311                  | Study 311                     | Study 311    | Combined No. of Subjects With at Least   |
|-------------------|----------------------------|-------------------------------|--------------|----------------------------|-------------------------------|--------------|------------------------------------------|
|                   | Age Cohort                 | Age Cohort                    | Total        | Age Cohort                 | Age Cohort                    | Total        |                                          |
| Extent ofExposure | ≥2 to <7 Years (=19) n (%) | ≥7 to <12 Year's (N=22) n (%) | (N=41) n (%) | 4 to <7 Years (N=46) n (%) | ≥7 to <12 Year's (=134) n (%) | (=180) n (%) | 61Ionthsof Exposure                      |
| >26 weeks         | NA                         | NA                            | NA           | 34 (73.9)                  | 97 (72.4)                     | 131 (72.8)   | 166a                                     |
| >28 weeks         | 15 (78.9)                  | 20 (90.9)                     | 35 (85.4)    | 29 (63.0)                  | 86 (64.2)                     | 115 (63.9)   | 166a                                     |

N = total number of subjects in the sample group, n = number of subjects used in the analysis, NA = not available.

a:Sum oftotal number ofsubjects in“&gt;28 weeks\"row in Study 232 and“&gt;26 weeks\"row in Study 311.

Source:Study232ExtensionPhaseTable14.3.1.1.1,Study311ExtensionPhaseTable14.3.1.1.2.

## Extension phase

Patients eligible to participate in Extension phase of Study 311 were those who completed the Core Study.

A total of 146 patients completed the Core Study; 136 patients enrolled into Extension phase.

<div style=\"page-break-after: always\"></div>

As of the cutoff date of 20 Jul 2018, 132 patients have been treated. Of these, 83 patients are ongoing, 40 patients have completed, and 9 patients have discontinued: 4 patients discontinued due to an AE, 2 patients withdrew by choice, and 3 patients discontinued due to inadequate therapeutic effect.

## Extension phase

A total of 42 patients completed the Core Study; 41 patients entered the Extension Phase and 27 patients completed the Study 232 Extension Phase.

Table 2.7.4-9 Cumulative Extent of Exposure by Disease Cohort-Core Study 311: SafetyAnalysis Set

<!-- image -->

|                              | Disease Cohort   | Disease Cohort   | Disease Cohort              | Disease Cohort   |
|------------------------------|------------------|------------------|-----------------------------|------------------|
| Extent of Exposure           | POS (N=149)      | PGTC (N=31)      | SGTC (Subset of POS) (N=54) | Total (N=180)    |
| Any exposurea, n (%)         | 149 (100.0)      | 31 (100.0)       | 54 (100.0)                  | 180 (100.0)      |
| >1 day                       | 149 (100.0)      | 31 (100.0)       | 54 (100.0)                  | 180 (100.0)      |
| >1 week                      | 148 (99.3)       | 31 (100.0)       | 53 (98.1)                   | 179 (99.4)       |
| >2 weeks                     | 146 (98.0)       | 31 (100.0)       | 53 (98.1)                   | 177 (98.3)       |
| >3 weeks                     | 145 (97.3)       | 31 (100.0)       | 52 (96.3)                   | 176 (97.8)       |
| >4 weeks                     | 142 (95.3)       | 30 (96.8)        | 52 (96.3)                   | 172 (95.6)       |
| >8 weeks                     | 134 (89.9)       | 29 (93.5)        | 50 (92.6)                   | 163 (90.6)       |
| >10 weeks                    | 133 (89.3)       | 28 (90.3)        | 50 (92.6)                   | 161 (89.4)       |
| >12 weeks                    | 131 (87.9)       | 27 (87.1)        | 50 (92.6)                   | 158 (87.8)       |
| >14 weeks                    | 130 (87.2)       | 26 (83.9)        | 49 (90.7)                   | 156 (86.7)       |
| >16 weeks                    | 129 (86.6)       | 26 (83.9)        | 49 (90.7)                   | 155 (86.1)       |
| >18 weeks                    | 129 (86.6)       | 26 (83.9)        | 49 (90.7)                   | 155 (86.1)       |
| >20 weeks                    | 121 (81.2)       | 23 (74.2)        | 49 (90.7)                   | 144 (80.0)       |
| >22 weeks                    | 106 (71.1)       | 18 (58.1)        | 44 (81.5)                   | 124 (68.9)       |
| >24 weeks                    | 10 (6.7)         | 3 (9.7)          | 7 (13.0)                    | 13 (7.2)         |
| >26 weeks                    | 3 (2.0)          | 1 (3.2)          | 2 (3.7)                     | 4 (2.2)          |
| Duration of exposureb(weeks) |                  |                  |                             |                  |
| 1n                           | 149              | 31               | 54                          | 180              |
| Mean (SD)                    | 20.6 (5.89)      | 20.2 (5.76)      | 21.6 (5.25)                 | 20.5 (5.86)      |
| Median                       | 23.0             | 22.4             | 23.0                        | 22.9             |
| Min, Max                     | 0,27             | 3,26             | 0,27                        | 0,27             |
| Number of subject-weeks      | 3071.6           | 626.3            | 1168.7                      | 3697.9           |

For remind, of the 180 patients, 46 patients (40 patients with POS and 6 patients with PGTCS) were in the 4 to &lt;7 year age group and 134 patients (109 patients with POS and 25 patients with PGTCS) were in the ≥ 7 to &lt;12 year age group.

| Study 311           |   POS n = 149 | PGTCS (of which PGTCS of IGE = 22) n = 31   |
|---------------------|---------------|---------------------------------------------|
| 4-7 years, n = 46   |            40 | 6 (3 IGE patients actually)                 |
| 7-12 years, n = 134 |           109 | 25 (19 IGE patients actually)               |

<div style=\"page-break-after: always\"></div>

Table 2.7.4-11 Extent of Exposure - Core Study 232: Safety Analysis Set

|                                         | Perampanel                     | Perampanel                       | Perampanel     |
|-----------------------------------------|--------------------------------|----------------------------------|----------------|
| Extent of Exposure                      | Cohort 2 ≥2 to <7 Years (N=22) | Cohort 1 ≥7 to <12 Year's (N=28) | Total (N=50)   |
| Duration of exposure? (weeks)           |                                |                                  |                |
| n                                       | 22                             | 28                               | 50             |
| Mean (SD)                               | 10.8 (1.34)                    | 9.3 (3.73)                       | 10.0 (2.99)    |
| Median                                  | 11.1                           | 11.0                             | 11.0           |
| Min, Max                                | 5.9, 12.0                      | 0.3,12.0                         | 0.3, 12.0      |
| Number of subject-weeksb                | 236.86                         | 261.14                           | 498.00         |
| Maximum dose received (mg/kg)           |                                |                                  |                |
| n                                       | 22                             | 28                               | 50             |
| Mean (SD)                               | 0.149 (0.0409)                 | 0.121 (0.0654)                   | 0.133 (0.0573) |
| Median                                  | 0.16                           | 0.16                             | 0.16           |
| Min, Max                                | 0.05, 0.19                     | 0.01,0.18                        | 0.01, 0.19     |
| Maximum dose received (mg/kg), n (%)    |                                |                                  |                |
| ≤0.03                                   | 0                              | 4 (14.3)                         | 4 (8.0)        |
| >0.03 to 0.06                           | 2 (9.1)                        | 5 (17.9)                         | 7 (14.0)       |
| >0.06 to 0.12                           | 4 (18.2)                       | 4 (14.3)                         | 8 (16.0)       |
| >0.12 to 0.15                           | 3 (13.6)                       | 1 (3.6)                          | 4 (8.0)        |
| >0.15                                   | 13 (59.1)                      | 14 (50.0)                        | 27 (54.0)      |
| MaintenancePeriod                       |                                |                                  |                |
| Mean daily dose (mg/kg)                 |                                |                                  |                |
| 1n1                                     | 20                             | 22                               | 42             |
| Mean (SD)                               | 0.144 (0.0405)                 | 0.140 (0.0537)                   | 0.142 (0.0473) |
| Median                                  | 0.16                           | 0.18                             | 0.17           |
| Min, Max                                | 0.06, 0.18                     | 0.02,0.18                        | 0.02,0.18      |
| Mean daily dose (mg/kg) Category, n (%) |                                |                                  |                |
| ≤0.03                                   | 0                              | 1 (3.6)                          | 1 (2.0)        |
| >0.03 to 0.06                           | 2 (9.1)                        | 3 (10.7)                         | 5 (10.0)       |
| >0.06 to 0.12                           | 5 (22.7)                       | 3 (10.7)                         | 8 (16.0)       |
| >0.12 to 0.15                           | 3 (13.6)                       | 3 (10.7)                         | 6 (12.0)       |
| >0.15                                   | 10 (45.5)                      | 12 (42.9)                        | 22 (44.0)      |

A total of 50 patients were treated with perampanel: 22 patients 2-7 years, and 28 patients 7-12 years). There were 3 patients in this study with PGTC of IGE (1 in Cohort 2 and 2 in Cohort 1).

| Study 232                     |   POS n = 41 | PGTCS (of which PGTCS of IGE = 3) n = 9   |
|-------------------------------|--------------|-------------------------------------------|
| 2-7 years (cohort 2), n = 22  |           16 | 6 (1 IGE patient actually)                |
| 7-12 years (cohort 1), n = 28 |           25 | 3 (2 IGE patients actually)               |

<div style=\"page-break-after: always\"></div>

## Adverse events

Safety was assessed by monitoring and recording all AEs and serious adverse events (SAEs).

Additional assessments included regular monitoring of hematology, blood chemistry, and urine values, regular measurements of vital signs, ECGs, and physical and neurological examinations.

Growth and development were assessed by weight, height, thyroid function tests, and insulin-like growth factor-1 (IGF-1).

Cognitive  testing  (Aldenkamp-Baker  neuropsychological  assessment  schedule  [ABNAS]),  behavioral questionnaires  (Child  Behavior  Checklist  [CBCL]),  and  visuomotor  skills  testing  using  the  Lafayette Grooved

Pegboard Test (LGPT) were performed.

An assessment of suicidal ideation and behavior using the C-SSRS was performed throughout the study for patients aged 6 years and older at the time of consent/assent. Suicidal ideation and behavior was monitored in patients less than 6 years at the time of consent/assent based upon clinical impression.

An EEG was performed over a minimum of 1-hour up to a 2-hour period in an awake and sleep state at specified visits (baseline, month 3 and month 12).

## Treatment-emergent adverse events

Treatment emergent adverse events are presented and discussed for Study 311 (Core and Extension) and Study 232 (Core and Extension).

Of note, a TEAE is defined as an AE that emerges from the date of first dose of study drug to 28 days after last end date of dose in prescribed dose entry, having been absent at pretreatment (Baseline) or reemerges  during  treatment,  having  been  present  at  pretreatment  (Baseline)  but  stopped  before treatment, or worsens in severity during treatment relative to the pretreatment state, when the AE is continuous.

Patients with 2 or more adverse events in the same system organ class (or with the same preferred term) is counted only once for that system organ class (or preferred term).

<div style=\"page-break-after: always\"></div>

Table 2.7.4-21 Overview of Treatment-Emergent Adverse Events by Disease Cohort - Core Study 311: Safety Analysis Set

|                                                                                | Disease Cohort    | Disease Cohort    | Disease Cohort                    | Disease Cohort      |
|--------------------------------------------------------------------------------|-------------------|-------------------|-----------------------------------|---------------------|
| Category                                                                       | POS (N=149) n (%) | PGTC (N=31) n (%) | SGTC (Subset of POS) (N=54) n (%) | Total (N=180) n (%) |
| TEAEs                                                                          | 134 (89.9)        | 26 (83.9)         | 53 (98.1)                         | 160 (88.9)          |
| Treatment-related TEAEs                                                        | 95 (63.8)         | 25 (80.6)         | 36 (66.7)                         | 120 (66.7)          |
| Severe TEAEs                                                                   | 10 (6.7)          | 4 (12.9)          | 4 (7.4)                           | 14 (7.8)            |
| SeriousTEAEs                                                                   | 23 (15.4)         | 4 (12.9)          | 13 (24.1)                         | 27 (15.0)           |
| Deaths                                                                         | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Other SAEs                                                                     | 22 (14.8)         | 4 (12.9)          | 13 (24.1)                         | 26 (14.4)           |
| Life threatening                                                               | 0                 | 0                 | 0                                 | 0                   |
| Requires inpatient hospitalization or prolongation of existing hospitalization | 21 (14.1)         | 4 (12.9)          | 13 (24.1)                         | 25 (13.9)           |
| Persistent or significant disability or incapacity                             | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Congenital anomaly/birth defect                                                | 0                 | 0                 | 0                                 | 0                   |
| Important medical events                                                       | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| TEAEs leading to study drug dose adjustment                                    | 69 (46.3)         | 15 (48.4)         | 24 (44.4)                         | 84 (46.7)           |
| TEAEs leading to study drug withdrawal                                         | 14 (9.4)          | 3 (9.7)           | 2 (3.7)                           | 17 (9.4)            |
| TEAEs leading to study drug dose increase                                      | 0                 | 1 (3.2)           | 0                                 | 1 (0.6)             |
| TEAEs leading to study drug dose reduction                                     | 60 (40.3)         | 13 (41.9)         | 22 (40.7)                         | 73 (40.6)           |
| TEAEs leading to study drug dose interruption                                  | 0                 | 0                 | 0                                 | 0                   |

<div style=\"page-break-after: always\"></div>

Table 2.7.4-22 Overview of Treatment-Emergent Adverse Events in Core Study311 and Extension Phase by Disease Cohort:Core Safety Analysis Set

|                                                                                | Disease Cohort    | Disease Cohort    | Disease Cohort                    | Disease Cohort      |
|--------------------------------------------------------------------------------|-------------------|-------------------|-----------------------------------|---------------------|
| Category                                                                       | POS (N=149) n (%) | PGIC (N=31) n (%) | SGTC (Subset of POS) (N=54) n (%) | Total (N=180) n (%) |
| TEAEs                                                                          | 136 (91.3)        | 26 (83.9)         | 53 (98.1)                         | 162 (90.0)          |
| Treatment-related TEAEs                                                        | 97 (65.1)         | 25 (80.6)         | 36 (66.7)                         | 122 (67.8)          |
| Severe TEAEs                                                                   | 12 (8.1)          | 5 (16.1)          | 4 (7.4)                           | 17 (9.4)            |
| Serious TEAEs                                                                  | 27 (18.1)         | 5 (16.1)          | 14 (25.9)                         | 32 (17.8)           |
| Deaths                                                                         | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Other SAEs                                                                     | 26 (17.4)         | 5 (16.1)          | 14 (25.9)                         | 31 (17.2)           |
| Life threatening                                                               | 0                 | 0                 | 0                                 | 0                   |
| Requires inpatient hospitalization or prolongation of existing hospitalization | 25 (16.8)         | 5 (16.1)          | 14 (25.9)                         | 30 (16.7)           |
| Persistent or significant disability or incapacity                             | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Congenital anomaly/birth defect                                                | 0                 | 0                 | 0                                 | 0                   |
| Important medical events                                                       | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| TEAEs leading to study drug dose adjustment                                    | 72 (48.3)         | 17 (54.8)         | 24 (44.4)                         | 89 (49.4)           |
| TEAEs leading to study drug withdrawal                                         | 16 (10.7)         | 5 (16.1)          | 2 (3.7)                           | 21 (11.7)           |
| TEAEs leading to study drug dose increase                                      | 0                 | 1 (3.2)           | 0                                 | 1 (0.6)             |
| TEAEs leading to study drug dose feduction                                     | 62 (41.6)         | 13 (41.9)         | 22 (40.7)                         | 75 (41.7)           |
| TEAEs leading to study drug dose interruption                                  | 0                 | 0                 | 0                                 | 0                   |

## MedDRA Version 21.0.

Subjects were classified as POS or PGTC seizures by the investigator. SGTC is the subset of POS subjects who record secondarily generalized seizures during the Baseline period.

For each row category, a subject with two or more adverse events in that category is counted only once.

MedDRA = Medical Dictionary for Regulatory Activities, N = total number of subjects in the sample group. n = number of subjects with an event, PGTC = primary generalized tonic-clonic, POS = partial-onset seizures, SAE = serious adverse event, SGTC = secondarily generalized tonic-clonic, TEAE = treatment-emergent adverse event.

Source:Study 311 ExtensionPhase Table 14.3.1.2.1.1.

<div style=\"page-break-after: always\"></div>

Table 2.7.4-24 Overview of Treatment-Emergent Adverse Events in the Core Study 232 - Safety Analysis Set

|                                                                                | Perampanel                            | Perampanel                             | Perampanel         |
|--------------------------------------------------------------------------------|---------------------------------------|----------------------------------------|--------------------|
| Category                                                                       | Cohort 2 ≥2 to <7 Yeal's (N=22) n (%) | Cohort 1 ≥7 to <12 Year's (N=28) n (%) | Total (N=50) (%) u |
| All TEAEs                                                                      | 22 (100)                              | 27 (96.4)                              | 49 (98.0)          |
| Treatment-related TEAEsa                                                       | 19 (86.4)                             | 22 (78.6)                              | 41 (82.0)          |
| Severe TEAEs                                                                   | 3 (13.6)                              | 3 (10.7)                               | 6 (12.0)           |
| Treatment-emergent SAEs                                                        | 3 (13.6)                              | 5 (17.9)                               | 8 (16.0)           |
| Deathsb                                                                        | 0                                     | 0                                      | 0                  |
| Other SAEsc                                                                    | 3 (13.6)                              | 5 (17.9)                               | 8 (16.0)           |
| Life threatening                                                               | 0                                     | 0                                      | 0                  |
| Required inpatient hospitalization or prolongation of existing hospitalization | 3 (13.6)                              | 4 (14.3)                               | 7 (14.0)           |
| Persistent or significant disability or incapacity                             | 0                                     | 0                                      | 0                  |
| Congenital anomaly/birth defect                                                | 0                                     | 0                                      | 0                  |
| Important medical events                                                       | 0                                     | 2 (7.1)                                | 2 (4.0)            |
| TEAEs leading to study drug dose adjustment                                    | 9 (40.9)                              | 8 (28.6)                               | 17 (34.0)          |
| TEAEs leading to study drug withdrawal                                         | 1 (4.5)                               | 2 (7.1)                                | 3 (6.0)            |
| TEAEs leading to study drug dose increases                                     | 1 (4.5)                               | 0                                      | 1 (2.0)            |
| TEAEs leading to study drug dose reduction                                     | 8 (36.4)                              | 6 (21.4)                               | 14 (28.0)          |
| TEAEs leading to study drug dose interruption                                  | 1 (4.5)                               | 0                                      | 1 (2.0)            |

<div style=\"page-break-after: always\"></div>

Table 2.7.4-25 Overview of Treatment-Emergent Adverse Events in Study 232 Extension - Safety Analysis Set

|                                                                                | Perampanel                           | Perampanel                            | Perampanel         |
|--------------------------------------------------------------------------------|--------------------------------------|---------------------------------------|--------------------|
| Category                                                                       | Cohort 2 ≥2 to<7 Year's (N=19) n (%) | Cohort 1 ≥7 to<12 Year's (N=22) n (%) | Total (N=41) n (%) |
| TEAES                                                                          | 19 (100)                             | 22 (100)                              | 41 (100)           |
| Treatment-related TEAEs?                                                       | 16 (84.2)                            | 21 (95.5)                             | 37 (90.2)          |
| SevereTEAEs                                                                    | 6 (31.6)                             | 5 (22.7)                              | 11 (26.8)          |
| Treatment-emergentSAEs                                                         | 6 (31.6)                             | 7 (31.8)                              | 13 (31.7)          |
| Deaths                                                                         | 0                                    | 0                                     | 0                  |
| Other SAEs                                                                     | 6 (31.6)                             | 7 (31.8)                              | 13 (31.7)          |
| Life threatening                                                               | 0                                    | 0                                     | 0                  |
| Required inpatient hospitalization or prolongation of existing hospitalization | 6 (31.6)                             | 7 (31.8)                              | 13 (31.7)          |
| Persistent or significant disability or incapacity                             | 0                                    | 0                                     | 0                  |
| Congenital anomaly/birth defect                                                | 0                                    | 0                                     | 0                  |
| Important medical events                                                       | 0                                    | 1 (4.5)                               | 1 (2.4)            |
| TEAEs leading to study drug dose adjustment                                    | 10 (52.6)                            | 7 (31.8)                              | 17 (41.5)          |

|                                               | Perampanel                            | Perampanel                             | Perampanel         |
|-----------------------------------------------|---------------------------------------|----------------------------------------|--------------------|
| Category                                      | Cohort 2 ≥2 to <7 Year's (N=19) n (%) | Cohort 1 ≥7 to <12 Year's (N=22) n (%) | Total (N=41) n (%) |
| TEAEs leading to study drug withdrawal        | 3 (15.8)                              | 2 (9.1)                                | 5 (12.2)           |
| TEAEs leading to study drug dose increase     | 1 (5.3)                               | 0                                      | 1 (2.4)            |
| TEAEs leading to study drug dose reduction    | 8 (42.1)                              | 6 (27.3)                               | 14 (34.1)          |
| TEAEs leading to study drug dose interruption | 2 (10.5)                              | 0                                      | 2 (4.9)            |

Common adverse events in study 311

<div style=\"page-break-after: always\"></div>

Table 2.7.4-26 Treatment-Emergent Adverse Events Occurring in ≥5% of Subjects Overall - Core Study 311: Safety Analysis Set

|                                                      | Disease Cohort    | Disease Cohort    | Disease Cohort                    | Disease Cohort      |
|------------------------------------------------------|-------------------|-------------------|-----------------------------------|---------------------|
| MedDRA System Organ Class Preferred Term             | POS (N=149) n (%) | PGTC (N=31) n (%) | SGTC (Subset of POS) (N=54) n (%) | Total (N=180) n (%) |
| Subjects with any TEAE                               | 134 (89.9)        | 26 (83.9)         | 53 (98.1)                         | 160 (88.9)          |
| Gastrointestinal disorders                           | 40 (26.8)         | 11 (35.5)         | 19 (35.2)                         | 51 (28.3)           |
| Diarrhoea                                            | 8 (5.4)           | 3 (9.7)           | 3 (5.6)                           | 11 (6.1)            |
| Vomiting                                             | 16 (10.7)         | 4 (12.9)          | 7 (13.0)                          | 20 (11.1)           |
| General disorders and administration site conditions | 34 (22.8)         | 6 (19.4)          | 10 (18.5)                         | 40 (22.2)           |
| Fatigue                                              | 8 (5.4)           | 1 (3.2)           | 2 (3.7)                           | 9 (5.0)             |
| Pyrexia                                              | 20 (13.4)         | 3 (9.7)           | 7 (13.0)                          | 23 (12.8)           |
| Infections and infestations                          | 81 (54.4)         | 11 (35.5)         | 35 (64.8)                         | 92 (51.1)           |
| Gastroenteritis                                      | 11 (7.4)          | 2 (6.5)           | 6 (11.1)                          | 13 (7.2)            |
| Influenza                                            | 15 (10.1)         | 0                 | 8 (14.8)                          | 15 (8.3)            |
| Nasopharyngitis                                      | 32 (21.5)         | 3 (9.7)           | 16 (29.6)                         | 35 (19.4)           |
| Upper respiratory tract infection                    | 10 (6.7)          | 1 (3.2)           | 2 (3.7)                           | 11 (6.1)            |
| Nervous system disorders                             | 80 (53.7)         | 21 (67.7)         | 29 (53.7)                         | 101 (56.1)          |
| Dizziness                                            | 18 (12.1)         | 5 (16.1)          | 7 (13.0)                          | 23 (12.8)           |
| Headache                                             | 9 (6.0)           | 4 (12.9)          | 1 (1.9)                           | 13 (7.2)            |
| Somnolence                                           | 42 (28.2)         | 5 (16.1)          | 17 (31.5)                         | 47 (26.1)           |
| Psychiatric disorders                                | 55 (36.9)         | 11 (35.5)         | 17 (31.5)                         | 66 (36.7)           |
| Aggression                                           | 15 (10.1)         | 1 (3.2)           | 2 (3.7)                           | 16 (8.9)            |
| Irritability                                         | 18 (12.1)         | 5 (16.1)          | 8 (14.8)                          | 23 (12.8)           |

Common adverse events in study 232

<div style=\"page-break-after: always\"></div>

Table 2.7.4-29Treatment-EmergentAdverseEvents Occurring in at Least 10%of Subjects inEither Cohortin theCoreStudy232,bySoc and PT-Safety Analysis Set

<!-- image -->

|                                                      | Perampanel                            | Perampanel                            | Perampanel         |
|------------------------------------------------------|---------------------------------------|---------------------------------------|--------------------|
| MIedDRASOC PT                                        | Cohort 2 ≥2 to <7 Year's (N=22) n (%) | Cohort l ≥7 to <12 Years (N=28) n (%) | Total (N=50) n (%) |
| Subjects with any TEAE                               | 22 (100)                              | 27 (96.4)                             | 49 (98.0)          |
| Gastrointestinal disorders                           | 6 (27.3)                              | 11 (39.3)                             | 17 (34.0)          |
| Vomiting                                             | 3 (13.6)                              | 5 (17.9)                              | 8 (16.0)           |
| Abdominal pain upper                                 | 0                                     | 4 (14.3)                              | 4 (8.0)            |
| General disorders and administration site conditions | 13 (59.1)                             | 12 (42.9)                             | 25 (50.0)          |
| Pyrexia                                              | 8 (36.4)                              | 4 (14.3)                              | 12 (24.0)          |
| Fatigue                                              | 1 (4.5)                               | 8 (28.6)                              | 9 (18.0)           |
| Irritability                                         | 3 (13.6)                              | 5 (17.9)                              | 8 (16.0)           |
| Infections and infestations                          | 9 (40.9)                              | 8 (28.6)                              | 17 (34.0)          |
| Upper respiratory tract infection                    | 3 (13.6)                              | 2 (7.1)                               | 5 (10.0)           |
| Investigations                                       | 4 (18.2)                              | 7 (25.0)                              | 11 (22.0)          |
| Weight increased                                     | 1 (4.5)                               | 3 (10.7)                              | 4 (8.0)            |
| Metabolism and nutrition disorders                   | 4 (18.2)                              | 6 (21.4)                              | 10 (20.0)          |
| Increased appetite                                   | 0                                     | 3 (10.7)                              | 3 (6.0)            |
| Nervous system disorders                             | 15 (68.2)                             | 14 (50.0)                             | 29 (58.0)          |
| Somnolence                                           | 4 (18.2)                              | 3 (10.7)                              | 7 (14.0)           |
| Dizziness                                            | 3 (13.6)                              | 2 (7.1)                               | 5 (10.0)           |
| Psychiatric disorders                                | 9 (40.9)                              | 12 (42.9)                             | 21 (42.0)          |
| Aggression                                           | 3 (13.6)                              | 1 (3.6)                               | 4 (8.0)            |
| Respiratory, thoracic and mediastinal disorders      | 8 (36.4)                              | 3 (10.7)                              | 11 (22.0)          |
| Cough                                                | 3 (13.6)                              | 1 (3.6)                               | 4 (8.0)            |

## Adverse Events of Special Interest

The occurrence of TEAEs of special interest was assessed in detail: TEAEs Related to Abuse Potential, TEAEs  Related  to  Alertness  and  Cognition,  TEAEs  Related  to  Hostility/Aggression,  TEAEs  Related  to Psychosis and Psychotic Disorders, TEAEs Related to Status Epilepticus/Convulsions, TEAEs Related to Laboratory Abnormalities, Cardiac and ECG TEAEs, TEAEs Related to Rash, TEAEs related to Falls and TEAEs Related to Suicidal Ideation and Behavior.

TEAEs Related to Abuse Potential: 3 accidental overdose; no patient reported an abuse potential related SAE.patients

TEAEs Related to Alertness and Cognition: the most commonly reported TEAEs related to alertness and cognition were somnolence and aggression . Some patients discontinued, some TEAE led to a reduction in study drug dose, and some other reported a SAE.

<div style=\"page-break-after: always\"></div>

## TEAEs Related to Hostility/Aggression:

The most common events for most subgroups were irritability and aggression .

There were also cases of agitation, psychomotor hyperactivity, laceration and anger.

Although  the  sample  size  across  subgroups  was  too  small  for  definitive  conclusions,  differences  in incidences of TEAEs were observed. The incidence of TEAEs for patients taking 1 baseline AED was higher (45.7%) than that for patients taking 2 or 3 baseline AEDs (26.0% and 28.9%).

A higher incidence of TEAEs was observed in the non-EIAED subgroup compared to the EIAEDs subgroup (33.6% versus 22.4%).

The incidence of TEAEs was overall similar in patients taking AEDs with sodium channel MOA versus mixed action MOA (25.0% and 20.0%).

## TEAEs Related to Psychosis and Psychotic Disorders (in 12 patients for both studies)

The most common TEAE in this category related to psychosis/psychotic disorders was 5 bradyphrenia . There was also 3 abnormal behaviors . One visual hallucination was considered serious, related to study drug and led to study discontinuation.

Table2.7.4-46 Treatment-Emergent Adverse Events by Narrow and Broad MedDRA SMQ Terms Related to Psychosis/Psychotic Disorders by Disease Cohort: Decreasing Frequency -Core Study 311 - Safety Analysis Set

|                        | Disease Cohort    | Disease Cohort    | Disease Cohort                    | Disease Cohort      |
|------------------------|-------------------|-------------------|-----------------------------------|---------------------|
| PreferredTerm          | POS (N=149) n (%) | PGTC (N=31) n (%) | SGTC (Subset of POS) (N=54) n (%) | Total (N=180) n (%) |
| Subjects with any TEAE | 6 (4.0)           | 1 (3.2)           | 0                                 | 7 (3.9)             |
| Bradyphrenia           | 5 (3.4)           | 0                 | 0                                 | 5 (2.8)             |
| Abnormalbehaviour      | 0                 | 1 (3.2)           | 0                                 | 1 (0.6)             |
| Affect lability        | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |

Table 2.7.4-47 Treatment-Emergent Adverse Events by Narrow and Broad MedDRA SMQ Terms Related to Psychosis and Psychotic Disorderin Extension Study 232-SafetyAnalysis Set

|                          | Perampanel                           | Perampanel                            | Perampanel         |
|--------------------------|--------------------------------------|---------------------------------------|--------------------|
| MedDRA SOC PT            | Cohort 2 ≥2 to <7 Years (N=19) n (%) | Cohort 1 ≥7 to <12 Years (N=22) n (%) | Total (N=41) n (%) |
| Subjects with any TEAE   | 4 (21.1)                             | 1 (4.5)                               | 5 (12.2)           |
| Nervous System Disorders | 1 (5.3)                              | 0                                     | 1 (2.4)            |
| Speech Disorder          | 1 (5.3)                              | 0                                     | 1 (2.4)            |
| Psychiatric Disorders    | 3 (15.8)                             | 1 (4.5)                               | 4 (9.8)            |
| Abnormal Behaviour       | 1 (5.3)                              | 1 (4.5)                               | 2 (4.9)            |
| Echolalia                | 1 (5.3)                              | 0                                     | 1 (2.4)            |
| Hallucination            | 1 (5.3)                              | 0                                     | 1 (2.4)            |

## TEAEs Related to Status Epilepticus/Convulsions:

In study 311, overall, 20 (11.1%) patients experienced TEAEs by MedDRA SMQ convulsions, 14 (9.4%) patients in the POS cohort including 7 (13.0%) patients in the SGTC subset, and 6 (19.4%) patients in the PGTC cohort.

<div style=\"page-break-after: always\"></div>

The  most  common  TEAEs  in  this  category  were seizure , epilepsy, focal  dyscognitive  seizures , generalised tonic-clonic seizure , petit mal epilepsy , and seizure cluster .

The other TEAEs related to status epilepticus/convulsions were atonic seizures, postictal state, and status epilepticus (each reported by 1 [0.6%] patient).

Three patients discontinued the study due to seizure . Two patients (one in the POS and one in the PGTCS of IGE subset, both in ≥ 7 to &lt;12 years, and without concomitant EIAEDs) reported a status epilepticus/convulsions-related AE with a PT of seizure, and 1 patient (in the POS, 4 to &lt;7 years, without concomitant EIAEDs) reported a status epilepticus/convulsions-related AE with a PT of focal dyscognitive seizure  leading  to  drug  withdrawal.  The  patients with  a  SAE  of  generalised  tonic-clonic  seizure discontinued the study.

In Study 232, 1 patient in Cohort 2 had an event of grand mal convulsion. This event was mild in severity and possibly related to study drug; the event led to withdrawal from the study and resolved.

## TEAEs Related to Laboratory Abnormalities

In  study  311 ,  no  patient experienced  TEAEs  related  to  drug-related  hepatic  disorders .  No patients discontinued the study or the study drug, or reported a SAE related to this category of TEAE.

In  study  232,  events  reported  in  more  than  1  patient included blood  uric  acid  decreased and thrombocytopenia in  3  patients each,  and metabolic  acidosis,  neutropenia, and thyroxine decreased in 2 patients each.

The  events  of  blood  alkaline  phosphatase  increased,  total  bile  acids  increased,  and  urine  bilirubin increased that occurred in 1 patient resulted in discontinuation. These 3 events were non serious, mild in intensity, possibly related to study drug, and did not resolve at the time of discontinuation.

All events were non serious except for an event of hypoglycemia, reported in the Follow-up Period in one patient (Cohort 1), which was a SAE. The event was moderate in severity and considered to be possibly related to study drug; treatment was given, and the event resolved.

<div style=\"page-break-after: always\"></div>

## Cardiac and ECG TEAEs

In study 311, cardiac and ECG TEAEs were reported in 2 patients in the POS cohort. The PTs of lower respiratory tract congestion and viral myocarditis were reported. Patient 1501108, a 4 year-old male died on Day 68 during the Core Study having contracted severe viral myocarditis the same day . The event was assessed by the investigator as unrelated to study drug.

A 4-year-old female patient had lower respiratory tract congestion (reported term, discrete brachial congestion) during the Core Study. The event was not considered serious, and was assessed by the investigator as unrelated to study drug.

One  patient had  a  TEAE  of mental  status  changes ,  which  was  included  in  the  sub-SMQ  of cardiomyopathy. The event was reported as a severe SAE that was not related to study drug; study drug was interrupted and the SAE resolved.

In study 232, the most common TEAE related to cardiac and ECG results was mental status changes (in 2 patients in Cohort 2), which was the only event that was reported in more than 1 patient overall.

## TEAEs Related to Rash

In study 311, 26 patients experienced TEAEs related to rash , 22 patients in the POS cohort including 7 in the SGTC subset and 4 patients in the PGTC cohort. The most common TEAEs related to rash were rash, eczema, and urticaria.

No patients reported a SAE related to rash.

One patient in the SGTC subset of the POS cohort discontinued the study due to drug eruption.

In the extension phase, 7 additional patients in the POS cohort including 3 patients in the SGTC subset reported a TEAE related to rash.

In Study 232, one patients had a TEAE of rash papular, which was not a SAE and did not led to treatment discontinuation.

In the extension phase of study 232, TEAE related to rash were reported in 3 patients in Cohort 2 and 1 patients in Cohort 1. None of these events were serious or resulted in study drug dose modification and none of the patient reported a positive skin reaction on the Photosensitivity Questionnaire.

NB: Photosensitivity Questionnaire, performed as part of safety evaluation in Study 232, showed that the majority of patients had no notable reaction, and none of the patients reported relevant SAEs or TEAEs that resulted in discontinuation of study drug. No safety  concerns related to photosensitivity reactions were identified in Study 232.

## TEAEs related to fall

In study 311, a total of 5 falls occurred, 2 in the POS disease cohort including 1 in the SGTC subset of the POS cohort, and 3 in the PGTC cohort. Of the falls in the PGTC cohort, 2 were reported in the PGTCS of IGE subset.

The 5 falls occurred during the Titration Phase .  No patient discontinued the study or the study drug, or reported a SAE related to falls. There were no additional falls during the Extension Phase

In Study 232, 2 patients in Cohort 2 and 1 patient in Cohort 1 experienced falls. All the events were non serious and resolved; no action was taken with study drug.

<div style=\"page-break-after: always\"></div>

## TEAEs Related to Suicidal Ideation and Behavior

In study 311, there were 23 TEAEs related to suicidal ideation and behavior reported by 20 patients. All  the  identified  TEAEs  were  mild  or  moderate. One  patient with  a  PT  of  altered  mood  was discontinued from study. No patient reported a suicidality-related SAE .

There was 1 patient (10 years old) in the PGTCS of IGE subset of the PGTC cohort, taking a 10 mg dose of perampanel, who reported 2 TEAEs related to suicidality (PT of suicidal ideation; suicidal thinking for this patient was also identified through Columbia-Suicide Severity Rating Scale (C-SSRS) questionnaire). These  TEAEs  were  mild  in  severity,  transient,  and  considered  related  to  the  study  drug  by  the investigator.

There  were  4  additional  TEAEs  reported  by  4  patients during  the  Extension  Phase:  psychomotor hyperactivity (2 reports), initial insomnia, and memory impairment; all events were mild or moderate.

In Study 232, 1 patient in Cohort 1 had a TEAE related to suicidal ideation and behavior; the event was not a SAE, did not result in treatment discontinuation or dose adjustment, was rated mild and not related to treatment by the investigator, and resolved without sequelae.

One patient in Cohort 2 and one patient in Cohort 1 had TEAEs related to suicidal ideation and behavior in the Extension Phase.

Table 2.7.4-1 Listing of Adverse Events Related to Suicidal Ideation and Behavior in Study 232 - Safety Analysis Set

| Subject Age (y), Sex, Race   | Study Phase/ Period of AE onset   | Dose at or Prior to AE Onset a   |   Duration of Treatment b (Days) | Preferred Term    | Study Day AE Started/ Stopped   | Severity/ Relationship to Study Drug   | Study Drug Action Taken/ Other Action Taken   | Outcome             |
|------------------------------|-----------------------------------|----------------------------------|----------------------------------|-------------------|---------------------------------|----------------------------------------|-----------------------------------------------|---------------------|
| 8, F,W                       | Extension/ Maintenance            | 0.023 mg/kg                      |                              119 | Suicidal ideation | 111/111                         | Severe/ Possibly Related               | Drug withdrawn/ Withdrawn from study          | Recovered/ Resolved |
| 6, F,W                       | Extension/ Maintenance            | 0.197 mg/kg                      |                              364 | Suicidal ideation | 226/227                         | Mild/ Possibly Related                 | Drug interrupted/ None                        | Recovered/ Resolved |
| 10, F,W                      | Core Study/ Titration             | 0.014 mg/kg                      |                              365 | Suicidal ideation | 3/3                             | Mild/ Not Related                      | Dose not changed/ None                        | Recovered/ Resolved |

## AESI in the specific age group 2 to 4 years of age from study 232:

Regarding the AESI in the specific age group 2 to 4 years of age, there were 5 patients aged 2 to &lt;4 years old in Study 232.

One patient was treated for a duration of 55 days before discontinuing early from the core study.

The other 4 patients completed the Core study and entered the Extension Phase.

Overall, their duration of treatment ranged from 27 to 52 weeks.

None of these patients were in the PGTCS of IGE subset.

The AESI were irritability, lethargy, oppositional defiant disorder and aggression.

Hereafter the listing of SAEs and AESIs in these subjects:

<div style=\"page-break-after: always\"></div>

Table 2.7.4-2 Listing of SAEs and AESIs in Subjects ≥ 2 Years to &lt;4 Years Old in Study 232

| Subject Age (y), Sex, Race   | Study Period of AE Onset   | Dose at or Prior to AE Onset   |   Duration of Treatment a (days) | MedDRA Preferred Term                     | Study Day AE Started/ Stopped   | Seriousness Criteria   | AESI   | Severity/Relationship to Study Drug   | Study Drug Action Taken/ Other Action Taken   | Outcome                     |
|------------------------------|----------------------------|--------------------------------|----------------------------------|-------------------------------------------|---------------------------------|------------------------|--------|---------------------------------------|-----------------------------------------------|-----------------------------|
| 2, M, W b                    | Core Study/ Titration      | 0.16 mg/kg                     |                               55 | Respiratory syncytial virus bronchiolitis | 44/48                           | Hosp                   | No     | Moderate/NR                           | Dose not changed/ Treatment given             | Recovered/ Resolved         |
| 2, M, B                      | Extension/ OL Maintenance  | 0.195 mg/kg                    |                              364 | Otitis media                              | 267/267                         | Hosp                   | No     | Severe/NR                             | Dose not changed/ Treatment given             | Recovered/ Resolved         |
| 3,M,W                        | Core Study/ Titration      | 0.145 mg/kg                    |                              189 | Irritability                              | 40/47                           | No                     | Yes    | Moderate/Poss                         | Dose reduced/ None                            | Recovered/ Resolved         |
| 3,M,W                        | Core Study/ Titration      | 0.145 mg/kg                    |                              189 | Lethargy                                  | 42/47                           | No                     | Yes    | Moderate/Poss                         | Dose reduced/ None                            | Recovered/ Resolved         |
| 3,M,W                        | Extension/ OL Maintenance  | 0.161 mg/kg                    |                              189 | Constipation                              | 103/110                         | Hosp                   | No     | Severe/Poss                           | Dose not changed/ None                        | Recovered/ Resolved         |
| 3,M,W                        | Extension/ OL Maintenance  | 0.177 mg/kg                    |                              189 | Gingival recession                        | 176/-                           | No                     | No     | Moderate/Poss                         | Drug withdrawn/ Withdrawn from study          | Not recovered/ Not resolved |
| 3,M,W                        | Extension/ OL Maintenance  | 0.177 mg/kg                    |                              189 | Oral mucosal discolouration               | 176/-                           | No                     | No     | Moderate/Poss                         | Drug withdrawn/ Withdrawn from study          | Not recovered/ Not resolved |
| 3,M,W                        | Core Study/ Titration      | 0.052 mg/kg                    |                              360 | Irritability                              | 17/-                            | No                     | Yes    | Mild/NR                               | Dose not changed/ None                        | Recovering/ Resolving       |
| 3,M,W                        | Core Study/ Titration      | 0.121 mg/kg                    |                              281 | Oppositional defiant disorder             | 44/-                            | No                     | Yes    | Mild/Poss                             | Dose not changed/ None                        | Not recovered/ Not resolved |
| 3,M,W                        | Extension/ OL Maintenance  | 0.094 mg/kg                    |                              281 | Aggression                                | 233/-                           | No                     | Yes    | Moderate/Prob                         | Drug withdrawn/ Withdrawn from study          | Recovering/ Resolving       |

<div style=\"page-break-after: always\"></div>

## Discontinuations

The below tables summarize the TEAEs that resulted in discontinuation of study drug by disease cohort in study 311.

Table 2.7.4-49 Treatment-Emergent Adverse Events Leading to Discontinuation of Study Drug by System Organ Class and Preferred Term by Disease Cohort - Safety Analysis Set

|                                                      | Disease Cohort    | Disease Cohort    | Disease Cohort                    | Disease Cohort      |
|------------------------------------------------------|-------------------|-------------------|-----------------------------------|---------------------|
| MedDRA System Organ Class Preferred Term             | POS (N=149) n (%) | PGTC (N=31) n (%) | SGTC (Subset of POS) (N=54) n (%) | Total (N=180) n (%) |
| Subjects with any TEAE                               | 14 (9.4)          | 3 (9.7)           | 2 (3.7)                           | 17 (9.4)            |
| General disorders and administration site conditions | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Gait disturbance                                     | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Infections and infestations                          | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Viral myocarditis                                    | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Injury, poisoning and procedural complications       | 0                 | 1 (3.2)           | 0                                 | 1 (0.6)             |
| Contusion                                            | 0                 | 1 (3.2)           | 0                                 | 1 (0.6)             |
| Nervous system disorders                             | 5 (3.4)           | 2 (6.5)           | 0                                 | 7 (3.9)             |
| Balance disorder                                     | 1 (0.7)           | 1 (3.2)           | 0                                 | 2 (1.1)             |
| Cognitive disorder                                   | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Dizziness                                            | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Dysarthria                                           | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Focal dyscognitive seizures                          | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Rasmussen encephalitis                               | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Seizure                                              | 1 (0.7)           | 1 (3.2)           | 0                                 | 2 (1.1)             |
| Psychiatric disorders                                | 8 (5.4)           | 2 (6.5)           | 1 (1.9)                           | 10 (5.6)            |
| Abnormal behaviour                                   | 0                 | 1 (3.2)           | 0                                 | 1 (0.6)             |
| Aggression                                           | 3 (2.0)           | 0                 | 0                                 | 3 (1.7)             |
| Anger                                                | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Anxiety                                              | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Bradyphrenia                                         | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Disruptive mood dysregulation disorder               | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Iritability                                          | 2 (1.3)           | 1 (3.2)           | 1 (1.9)                           | 3 (1.7)             |
| Mood altered                                         | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Skin and subcutaneous tissue disorders               | 1 (0.7)           | 0                 | 1 (1.9)                           | 1 (0.6)             |
| Drug eruption                                        | 1 (0.7)           | 0                 | 1 (1.9)                           | 1 (0.6)             |

Subject with 2 or more AEs in the same system organ class (or with the same preferred term) is counted only once for that system organ class (or preferred term).

MedDRA version 21.0.

<div style=\"page-break-after: always\"></div>

Table 2.7.4-50 Treatment-Emergent Adverse Events in Core Study and Extension Phase Leading to Discontinuation of Study Drug by System Organ Class and Preferred Term by Disease Cohort Core Safety Analysis Set - PGTC Cohort

|                                                      | Disease Cohort           | Disease Cohort     | Disease Cohort          |
|------------------------------------------------------|--------------------------|--------------------|-------------------------|
| MedDRA System Organ Class Preferred Term             | PGTCS ofIGE (N=24) n (%) | Non-IGE (N=) n (%) | Total PGTC (N=31) n (%) |
| Subjects with any TEAE                               | 4 (16.7)                 | 1 (14.3)           | 5 (16.1)                |
| General disorders and administration site conditions | 1 (4.2)                  | 0                  | 1 (3.2)                 |
| Fatigue                                              | 1 (4.2)                  | 0                  | 1 (3.2)                 |
| Injury, poisoning and procedural complications       | 1 (4.2)                  | 0                  | 1 (3.2)                 |
| Contusion                                            | 1 (4.2)                  | 0                  | 1 (3.2)                 |
| Nervous system disorders                             | 3 (12.5)                 | 0                  | 3 (9.7)                 |
| Balance disorder                                     | 1 (4.2)                  | 0                  | 1 (3.2)                 |
| Generalised tonic-clonic seizure                     | 1 (4.2)                  | 0                  | 1 (3.2)                 |
| Seizure                                              | 1 (4.2)                  | 0                  | 1 (3.2)                 |
| Psychiatric disorders                                | 1 (4.2)                  | 1 (14.3)           | 2 (6.5)                 |
| Abnormal behaviour                                   | 1 (4.2)                  | 0                  | 1 (3.2)                 |
| Irritability                                         | 0                        | 1 (14.3)           | 1 (3.2)                 |

Overall, such TEAEs were overall reported in 17/180 (9.4%) patients : 14/149 (9.4%) patients in the POS cohort, including 2/54 (3.7%) patients in the SGTC subset and 3/31 (9.7%) patients in the PGTC cohort.

The only  TEAEs  that  resulted  in  discontinuation  of  more  than  1  patient were balance disorder (2 patients;  1  patient in  each  cohort), seizure (2  patients;  1  patient in  each  cohort), aggression (3 patients in the POS cohort), and irritability (3 patients; 2 in the POS cohort including 1 patient in the SGTC subset, and 1 in the PGTC cohort).

TEAEs leading to discontinuation were reported by 4 additional patients during the Extension Phase, 2 patients in the POS cohort and 2 patients in the PGTC cohort.

Additional events included fatigue, ataxia, generalised tonic-clonic seizure, and visual hallucination reported by 1 patient each.

Overall, a total of 21 (11.7%) patients discontinued study drug due to TEAEs :  16  (10.7%) patients in the POS cohort including 2 (3.7%) patients in the SGTC subset, and 5 (16.1%) patients in the PGTC cohort.

In the PGTC cohort, 4 (16.7%) patients in the PGTCS of IGE subset and 1 (14.3%) patient in the nonIGE subset had TEAEs that resulted in discontinuation of study drug. All TEAEs in this category were reported by single patients.

In study 232, Overall, TEAEs leading to treatment discontinuation were reported in 3 (6.0%) patients (1 patient and 2 patients, respectively, in Cohort 2 and Cohort 1). None of the AEs leading to discontinuation were reported in more than 1 patient.

In  the  extension  study  232,  Treatment-emergent AEs  that  resulted  in  discontinuation  occurred  in  3 (15.8%) patients in Cohort 2 and 2 (9.1%) patients in Cohort 1. The only TEAE (PT) that resulted in discontinuation of more than 1 patient was aggression (1 patient in each cohort).

<div style=\"page-break-after: always\"></div>

## Adverse Drug Reactions

Adverse drug reactions (ADRs) are defined as TEAEs for which there is some basis to believe a causal relationship exists between the occurrence of the TEAE and the use of perampanel.

In the POS submission, identification of potential ADRs was based on an assessment of the full safety database for perampanel, including clinical studies in epilepsy and other indications. The methods used are described in detail in the summary of clinical safety.

The following ADRs resulted from this evaluation: dizziness, somnolence, fatigue, irritability, fall, nausea, ataxia, weight increased, vertigo, balance disorder, gait disturbance, anxiety, vision blurred, dysarthria, back pain, decreased appetite, aggression, diplopia, anger, increased appetite and confusional state.

For the PGTC seizure submission, the ADR analysis, which included the PGTC seizure data alone and the PGTC seizure data pooled with the data from the POS double-blind studies, did not indicate any new ADRs from those previously identified in the POS submission.

For this submission, TEAEs are consistent with TEAEs observed on perampanel treatment in adults and adolescents.

This review does not indicate any new ADRs for perampanel in this pediatric population.

## Serious adverse event/deaths/other significant events

One (0.7%) death was reported in the POS cohort. The subject was a 4 year old male in the POS cohort  with  concomitant  EIAEDs,  with  a  cause  of  death  (by  PT)  of  viral  myocarditis  determined  by autopsy. The TEAE was not considered related to the drug according to the investigator.

Table 2.7.4-3 Listing of All Deaths in Core Study and Extension Phase 311 - All Enrolled Subjects

| Subject Age (y), Sex Race   | Disease Cohort, With/ Withou t EIAED s   | Date of Death/ Study Day of Death a   |   Last Dose Prior to Death (mg) | Cause of Death (Investigator Term/Preferred Term)   | AE Start Date/Study Day   | AE Possibly Caused by Study Drug   |   Duration of Treatment b (Days) |   Day of Death in Relation to Last Dose c | TEAE?   |
|-----------------------------|------------------------------------------|---------------------------------------|---------------------------------|-----------------------------------------------------|---------------------------|------------------------------------|----------------------------------|-------------------------------------------|---------|
| 4,M                         | POS, w                                   | 2017- 12- 12/68                       |                               8 | Viral Myocarditis/ Viral Myocarditis                | 2017-12- 12/68            | No                                 |                               67 |                                         1 | Y       |

<div style=\"page-break-after: always\"></div>

Table2.7.4-33 Treatment-Emergent Serious Adverse Events by System Organ Class and Preferred Term - Core Study 311: Safety Analysis Set

|                                                      | Disease Cohort    | Disease Cohort    | Disease Cohort                    | Disease Cohort      |
|------------------------------------------------------|-------------------|-------------------|-----------------------------------|---------------------|
| MedDRASystem Organ Class PreferredTerm               | POS (=149) (%) uI | PGTC (N=31) n (%) | SGTC (Subset of POS) (N=54) n (%) | Total (N=180) n (%) |
| Subjects with any TESAE                              | 23 (15.4)         | 4 (12.9)          | 13 (24.1)                         | 27 (15.0)           |
| Gastrointestinal disorders                           | 2 (1.3)           | 0                 | 2 (3.7)                           | 2 (1.1)             |
| Dental caries                                        | 1 (0.7)           | 0                 | 1 (1.9)                           | 1 (0.6)             |
| Gastritis erosive                                    | 1 (0.7)           | 0                 | 1 (1.9)                           | 1 (0.6)             |
| General disorders and administration site conditions | 2 (1.3)           | 0                 | 1 (1.9)                           | 2 (1.1)             |
| Gait disturbance                                     | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Hyperthermia                                         | 1 (0.7)           | 0                 | 1 (1.9)                           | 1 (0.6)             |
| Infections and infestations                          | 10 (6.7)          | 2 (6.5)           | 7 (13.0)                          | 12 (6.7)            |
| Bronchitis                                           | 3 (2.0)           | 0                 | 3 (5.6)                           | 3 (1.7)             |
| Encephalitis                                         | 1 (0.7)           | 0                 | 1 (1.9)                           | 1 (0.6)             |
| Gastroenteritis                                      | 2 (1.3)           | 0                 | 2 (3.7)                           | 2 (1.1)             |
| Influenza                                            | 2 (1.3)           | 0                 | 2 (3.7)                           | 2 (1.1)             |
| Pneumonia                                            | 3 (2.0)           | 0                 | 1 (1.9)                           | 3 (1.7)             |
| Rhinovirusinfection                                  | 0                 | 1 (3.2)           | 0                                 | 1 (0.6)             |
| Urinary tract infection pseudomonal                  | 1 (0.7)           | 0                 | 1 (1.9)                           | 1 (0.6)             |
| Viral infection                                      | 0                 | 1 (3.2)           | 0                                 | 1 (0.6)             |
| Viral myocarditis                                    | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Musculoskeletal andconnectivetissuedisorders         | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Epiphysiolysis                                       | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Nervous system disorders                             | 9 (6.0)           | 4 (12.9)          | 5 (9.3)                           | 13 (7.2)            |
| Ataxia                                               | 1 (0.7)           | 0                 | 1 (1.9)                           | 1 (0.6)             |
| Dysarthria                                           | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Epilepsy                                             | 2 (1.3)           | 1 (3.2)           | 2 (3.7)                           | 3 (1.7)             |
| Focal dyscognitive seizures                          | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Generalised tonic-clonic seizure                     | 1 (0.7)           | 1 (3.2)           | 1 (1.9)                           | 2 (1.1)             |

<div style=\"page-break-after: always\"></div>

Table 2.7.4-33 Treatment-Emergent Serious Adverse Events by System Organ Class and Preferred Term-Core Study 311:Safety Analysis Set

|                                                 | Disease Cohort    | Disease Cohort    | Disease Cohort                    | Disease Cohort      |
|-------------------------------------------------|-------------------|-------------------|-----------------------------------|---------------------|
| MedDRA System Organ Class Preferred Term        | POS (N=149) n (%) | PGTC (N=31) n (%) | SGTC (Subset of POS) (N=54) (%) I | Total (N=180) n (%) |
| Petit mal epilepsy                              | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Rasmussen encephalitis                          | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Seizure                                         | 2 (1.3)           | 1 (3.2)           | 1 (1.9)                           | 3 (1.7)             |
| Seizure cluster                                 | 1 (0.7)           | 1 (3.2)           | 1 (1.9)                           | 2 (1.1)             |
| Somnolence                                      | 1 (0.7)           | 1 (3.2)           | 0                                 | 2 (1.1)             |
| Psychiatric disorders                           | 2 (1.3)           | 0                 | 0                                 | 2 (1.1)             |
| Aggression                                      | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Disruptive mood dysregulation disorder          | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Respiratory, thoracic and mediastinal disorders | 4 (2.7)           | 0                 | 2 (3.7)                           | 4 (2.2)             |
| Acute respiratory failure                       | 2 (1.3)           | 0                 | 1 (1.9)                           | 2 (1.1)             |
| Asthma                                          | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |
| Atelectasis                                     | 1 (0.7)           | 0                 | 1 (1.9)                           | 1 (0.6)             |
| Upper respiratory tract inflammation            | 1 (0.7)           | 0                 | 0                                 | 1 (0.6)             |

Overall, the number of treatment-emergent SAEs was low across the disease cohorts.

Treatment-emergent SAEs were reported in a total of 27 (15.0%) subjects overall, with 23 (15.4%) subjects in the POS cohort including 13 (24.1%) subjects in the SGTC subset of the POS cohort, and 4 (12.9%) subjects in the PGTC cohort.

Thirteen (28.3%) subjects with treatment-emergent SAEs were in 4 to &lt;7 years and 14 (10.4%) were in ≥ 7 to &lt;12 years age cohort in the core study 311. A higher number of subjects had treatment emergent SAEs  in  the  without  concomitant  EIAEDs  cohort  (22  [16.7%]  subjects)  compared  to  those  taking concomitant EIAEDs (5 [10.4%] subjects).

All  TESAEs  were  reported  by  1  or  2  subjects  across  all  cohorts,  with  the  exception  of  bronchitis, pneumonia, epilepsy and seizure which occurred in 3 (1.7%) subjects.

An additional 5 subjects reported SAEs during the Extension Phase, 4 subjects in the POS cohort including 1 subject in the SGTC subset, and 1 subject in the PGTC cohort. As of the data cut-off date of 20 Jul 2018, a total of 32 (17.8%) subjects experienced SAEs. This represents cumulative data and includes SAEs from both Core Study and Extension Phase.

In  the  PGTC  cohort,  3  subjects  in  the  PGTCS  of  IGE  subset  and  2  subjects  in  the  non-IGE  subset experienced SAEs. All SAEs were reported by single subjects.

## Laboratory findings and Other Safety Evaluations

## Laboratory parameters

There were no clinically important changes in hematology and clinical chemistry mean laboratory results values from Baseline to Week 23 for any cohort. Specifically, no clinically relevant changes were observed

<div style=\"page-break-after: always\"></div>

for glucose, triglycerides, and cholesterol. The laboratory results shift analyses revealed that shifts from normal to high or low were generally infrequent.

Twelve subjects had markedly abnormal laboratory hematology results, 2 with markedly abnormal low hemoglobin, and 10 with markedly abnormal low neutrophils.

Seven subjects had markedly abnormal laboratory clinical chemistry results. Five subjects had markedly abnormal high gamma glutamyl transferase (GGT), including 1 subject who also had markedly abnormal high alanine aminotransferase (ALT), 1 subject had markedly abnormal high potassium and 1 subject had markedly abnormal low sodium and calcium (Core Study 311 Table 32). No subjects had markedly abnormal laboratory urinalysis results.

There were no clinically important changes in mean urinalysis results values from baseline to Week 23 for any of the 3 disease cohorts. For urinalysis results, 6 (3.8%) subjects had shifts from normal values at Baseline to high values at EOT of the Core Study. The urinalysis results shift analysis revealed that the patterns of shifts were similar across the disease, age, and concomitant EIAEDs cohorts.

No laboratory abnormalities led to study discontinuation. No laboratory abnormalities were related to SAEs.

## Growth and neurodevelopmental assessments

Aldenkamp-Baker  Neuropsychological  Assessment  Schedule  (ABNAS)  scores  for  fatigue,  slowing, memory,  concentration,  motor-coordination  and  language  were  assessed.  Higher  scores  indicate  a worsening of these cognitive parameters.

Child Behavior Checklist (CBCL) is a tool to assess behavioral and emotional problems in children as reported by the primary caregiver.

Lafayette Grooved Pegboard Test (LGPT) is a tool to estimate the visuomotor skills. It is a manipulative dexterity test that consists of a metal matrix of 25 holes with randomly positioned slots. The subject was required to insert 25 pegs for 8 years or older or 10 pegs for under 8 years old for each hand. The task was timed up to a maximum of 300 seconds, and a shorter time to completion indicated increased dexterity.

There were no clinically significant results at the end of treatment in comparison to baseline as regards the three scores.

Subjects showed height and weight gain proportionate with the expected growth of subjects in this pediatric population. No meaningful embarrassing effects were observed in height and weight data.

Mean thyroid and insulin-like growth factor-2 and mean change from Baseline are recorded. Mean insulin-like growth factor-2 was lower at baseline and at end of treatment in Cohort 2 (2 to &lt;7 years) than in Cohort 1 (7 to &lt;12 years).

## Electroencephalogram

EEG analysis included 145 subjects with Asleep EEGs, and 154 subjects with Awake EEGs during the Core Study (baseline and Visit 9 [end of Core Study Treatment visit] or Early Discontinuation Visit). EEG data collected during the Extension Phase (ie, Visit 12 or Early Discontinuation Extension Phase) will be analyzed and presented in a separate report when the Extension is completed.

Overall, observed primary EEG endpoints (POS and PGTCS) were low at all visits, with only 2 cases of POS  being  observed,  and  no  cases  of  PGTCS  were  observed  during  the  baseline  or  Visit  9  EEG assessments. Therefore, the primary EEG endpoints of changes in the frequency of POS or PGTCS from baseline to Visit 9 were not determinable.

Results of secondary EEG endpoints of changes from baseline to Visit 9 in the frequency of absence seizures, atypical absence seizures, myoclonic seizures, seizure not able to be classified, secondarily generalized clonic seizures, and epileptiform activity are summarized as follows:

- Overall, observed seizures were low for most secondary endpoints, with no cases of myoclonic seizures or SGTC seizures reported at any visit.
- Six subjects were reported to have absence seizures in either the awake or sleep state. Three subjects were reported to have atypical absence seizures in either the awake or sleep state.

<div style=\"page-break-after: always\"></div>

- Thirteen subjects were reported to have not able to be classified seizures in either the awake or sleep state.
- No statistically significant changes from baseline to Visit 9 were observed in the mean number of absence seizures, unclassifiable seizures, or epileptiform activities (prevalence sharp waves, prevalence spike-slow waves, and rhythmic runs of spike-waves complexes ≥ 1 second).

Overall, there were no statistically significant changes in any of the EEG parameters measured following 23 weeks of perampanel treatment, compared to baseline. Similarly, no significant changes from baseline in any of the EEG parameters were observed between the ≥ 4 to &lt;7 years and ≥ 7 to &lt;12 years age subgroups and in the inducer and non-inducer subgroups. Therefore, EEG data collected so far do not suggest any safety concerns related to EEG abnormalities

## 2.5.1. Discussion on clinical safety

Overall, 160 (88.9%) patients experienced TEAEs. TEAEs occurred in 134 (89.9%) patients in the POS cohort including 53 (98.1%) patients in the SGTC subset of the POS cohort, and 26 (83.9%) subjects in the PGTC cohort.

Overall, 14 (7.8%) patients had severe TEAEs.

Treatment-related TEAEs were reported in 120 (66.7%) subjects overall, 95 (63.8%) subjects in the POS cohort including 36 (66.7%) patients in the SGTC subset and 25 (80.6%) patients in the PGTC cohort.

One (0.7%) patient in the POS cohort (a 4-year-old white male) died on Day 68 during the Core Study due to viral myocarditis; the death was not considered related to study drug.

There were 17 (9.4%) patients who had TEAEs leading to study drug withdrawal. Nearly half of the patients (46.7%) with TEAEs leading to study drug adjustment reduced their study drug dose (40.6%). Only 1 patient (0.6%) had drug dose increased.

There were no clinically significant results at the end of treatment in comparison to baseline as regards the scores of cognitive testing (ABNAS), child behavioral questionnaires (CBCL), and visuomotor skills testing (LGPT).

Patients  showed  height  and  weight  gain  proportionate  with  the  expected  growth  of  patients  in  this pediatric population. No meaningful embarrassing effects were observed in height and weight data.

Mean thyroid and insulin-like growth factor-2 and mean change from Baseline are recorded.

Mean insulin-like growth factor-2 was lower at baseline and at end of treatment in Cohort 2 (2 to &lt;7 years) than in Cohort 1 (7 to &lt;12 years).

It is noted that, in PGTCS, the safety profile of perampanel in children aged 2 years and &lt;7 years could not be assessed properly due to the scarcity of the number of patients studied.

No  new  adverse  event  was  reported  in  the  submitted  studies.  However,  according  to  the  guideline regarding the assessment of safety, a minimum of 100 children treated by the study drug should be followed for at least one year. Moreover short term and long-term studies should be designed to detect possible impact on brain development, learning, intelligence, growth, endocrine functions and puberty. In this application, only study 311 (open label, single arm, 136 children over 52 weeks in its extension phase) made it possible to meet these specifications. Study 232 (open label 41 children over 52 weeks in its extension phase) completed these data. The other studies included children 12 years and over.

Although the level of recruitment in paediatric studies is a known issue, the data safety collection is a major point,  in  particular  regarding  the  long-term  aspects  (neurodevelopment,  motor  development, cognition,  behaviour,  growth,  endocrine  functions  and  puberty).  There  were  some  uncertainties regarding the safety profile of perampanel that needed further clarifications and the effect of perampanel on neuropsychological aspects in a developing brain and on growth was considered as a concern which has to be specifically assessed in the paediatric population on a longer term manner (up to 1 year).

Consequently, according to the Guideline on clinical investigation of medicinal products in the treatment of  epileptic  disorders,  the  MAH  provided  additional  data  and  a  thorough  analysis  of  the  impact  of

<div style=\"page-break-after: always\"></div>

perampanel on brain development, learning, intelligence, growth, endocrine functions and puberty for the paediatric population. Adverse events reported in clinical studies and post-marketing data related to developmental disorders reported few numbers of cases in children less than 12 years but these effects were not identified until now for perampanel. This is a safety concern and it will be specifically monitored in  the  future  PSUR  (attention  deficit/hyperactivity  disorder,  learning  disability,  cognitive  disorder, disturbance in attention, precocious puberty).

Adverse events reported in children less than 12 years in clinical studies and post-marketing data related to behavioral disorders are consistent with the known safety profile of perampanel, highlighting a large number of aggression and drowsiness effects in children.

The literature review did not bring new information on the safety profile of perampanel in children &lt; 12 years.

The assessment of cognitive functions, behavior, visuomotor skill development, growth and endocrine functions did not seem to show clinically significant impact of perampanel. Puberty/sexual maturation and skeletal development neither, however this was assessed on a too small number of children to draw any robust conclusion. The MAH is therefore requested to continue to monitor these effects in the ongoing paediatric study (Studies 236) and in the future PSUR.

The relevant statements have been added in the SmPC regarding the higher incidence of some AE and some precautions were amended or added.

## 2.5.2. Conclusions on clinical safety

Based on the available safety data, the CHMP concludes that the safety profile in the extended paediatric population is acceptable and in line with the known safety profile of perampanel.

The highlighted safety concerns will continue to be monitored via the subsequent PSURs.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC advice on the submitted Risk Management Plan: the PRAC considered that the RMP version 4.5 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 4.5 with the following content:

## Safety concerns

<div style=\"page-break-after: always\"></div>

## Summary of Safety Concerns

| Important identified risks   | • Aggression • Interaction with levonorgestrel-containing contraceptives, and unintended pregnancy exposures • Suicidality   |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | • Hepatic disorders (excluding hepatic disorders induced by SCARs)                                                           |
| Missing information          | • Impact on cognition and growth in the paediatric population • Use in human pregnancy and lactation                         |

SCARs = severe cutaneous adverse reactions

## Pharmacovigilance plan

The following routine pharmacovigilance activities beyond adverse reactions reporting and signal detection should be performed.

Specific Adverse Reaction Follow-Up Questionnaires for Aggression and Suicidality and Exposure During Pregnancy

| Follow-Up Questionnaire                                                                        | Safety Concern(s)              | Purpose                                                                                   |
|------------------------------------------------------------------------------------------------|--------------------------------|-------------------------------------------------------------------------------------------|
| Questionnaire for reports of Aggression                                                        | Aggression                     | Follow-up questionnaire for serious reports of aggression to obtain complete information  |
| Questionnaire for reports of suicidal behaviour, ideation, attempt or self-injurious behaviour | Suicidality                    | Follow-up questionnaire for serious reports of suicidality to obtain complete information |
| Questionnaire for reports of exposure during pregnancy                                         | Use in pregnancy and lactation | Follow-up questionnaire to obtain complete information on pregnancy outcomes              |

## Other Forms of Routine Pharmacovigilance Activities for Pregnancy

| Description of Activity                                                                   | Safety Concern(s)                    | Objectives                                                                 | Milestones                                     |
|-------------------------------------------------------------------------------------------|--------------------------------------|----------------------------------------------------------------------------|------------------------------------------------|
| • Contribution to EURAP registry • Contribution to the UK Epilepsy and Pregnancy Registry | Use in human pregnancy and lactation | To collect data on pregnancy exposure and outcomes with the use of Fycompa | Review pregnancy information provided by EURAP |

EURAP=European and International Registry of Anti-Epileptic Drugs in Pregnancy.

<div style=\"page-break-after: always\"></div>

Overall,  data  presented  by  the  MAH  responded  to  the  concerns  raised  on  the  potential  effect  of perampanel  in  patients  under  12  years  of  age  regarding  impact  on  brain  development,  learning, intelligence, and growth and endocrine function, with the exception of puberty / sexual maturation and skeletal development which could not be evaluated in a sufficient number of these children.

Adverse events in patients under 12 years of age (reported from clinical studies, post marketing and literature  data)  related  to  behavioural  disorders  are  consistent  with  the  known  safety  profile  of perampanel,  highlighting  a  large  number  of  aggression  and  drowsiness  effects  in  these  patients. However, in few (clinical and post-marketing) cases, involving patients under 12 years of age, data about adverse  events  linked  to  developmental  disorders  were  reported.  Therefore,  cases  of  attention deficit/hyperactivity disorder, learning disability, cognitive disorder, disturbance in attention, precocious puberty should be closely monitored in future PSURs.

The MAH acknowledged that data regarding sexual development in subjects under 12 years of age have not been collected. However, it considered that perampanel did not have a clinically meaningful effect on puberty or sexual development in this population as Tanner staging assessments were conducted for up to 2 years in Study 235 or up to 4 years in Study 307 in subjects aged 12 to &lt;18 years and. The MAH also believed that whilst the onset of puberty and sexual development is occurring at younger ages, especially in females, assessment in the adolescent population is acceptable for assessing any possible effects of perampanel on puberty and sexual development. However, the PRAC and CHMP are of the view that these criteria should however be thoroughly followed in patients under 12 years of age, particularly in females, in the ongoing studies (236 and 238) for a sufficient timeframe, and in enough patients, to allow relevant conclusions. Also, studies 236 and 238 should provide additional data of the long-term effect of perampanel regarding ABNAS, CBCL and LGPT scores focusing on cognition, behavior, and dexterity.

No additional pharmacovigilance activities are deemed necessary.

## Risk minimisation measures

## Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                 | Risk Minimisation Measures                                                                                                                                                                   | Pharmacovigilance Activities                       |
|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| Important Identified Risks                                                                     | Important Identified Risks                                                                                                                                                                   | Important Identified Risks                         |
| Aggression                                                                                     | Routine risk minimisation measures: • SmPC Section 4.4, where recommendations for perampanel dose reduction or discontinuation are provided • SmPC Section 4.8 • PL Section 2 • PL Section 4 | Routine PV activities including targeted follow-up |
| Interaction with Levonorgestrel- Containing Contraceptives, and Unintended Pregnancy Exposures | Routine risk minimisation measures:                                                                                                                                                          | Routine PV activities                              |

<div style=\"page-break-after: always\"></div>

## Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                   | Risk Minimisation Measures                                                                                                                             | Pharmacovigilance Activities                                                                                 |
|------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
|                                                                  | • SmPC Section 4.4 • SmPC Section 4.5 • SmPC Section 4.6 • PL Section 2                                                                                |                                                                                                              |
| Suicidality                                                      | Routine risk minimisation measures: • SmPC Section 4.4, where advice for monitoring signs of suicidality is provided • SmPC Section 4.8 • PL Section 4 | Routine PV activities including targeted follow-up                                                           |
| Important Potential Risks                                        | Important Potential Risks                                                                                                                              |                                                                                                              |
| Hepatic Disorders (excluding hepatic disorders induced by SCARs) | Routine risk minimisation measures: • SmPC Section 4.4 • PL Section 2                                                                                  | Routine PV activities                                                                                        |
| Missing Information                                              | Missing Information                                                                                                                                    |                                                                                                              |
| Impact on cognition and growth in the paediatric population      | Routine risk minimisation measures: SmPC Section 4.8 and Section 5.1                                                                                   | Routine PV activities                                                                                        |
| Use in Human Pregnancy and Lactation                             | Routine risk minimisation measures: • SmPC Section 4.6 • PL Section 2                                                                                  | Routine PV activities including follow-up questionnaire to obtain complete information on pregnancy outcomes |

PL=Package Leaflet, PV=pharmacovigilance, SCARs = severe cutaneous adverse reactions, SmPC=Summary of Product Characteristics.

## 2.7. Update of the Product information

As a consequence of this new extension of indication, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Please refer the attachment 1 for further information.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package

<div style=\"page-break-after: always\"></div>

leaflet has been submitted by the MAH and has been found acceptable for the following reasons: the revised text is presented in the same layout as the existing PL, which has successfully passed both full and 'bridged' user testing and is intended for an age group where the caregiver would be responsible for administering the product to the patients.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Epilepsy affect individuals of all ages and are among the most common neurologic disorders. The annual cumulative incidence of epilepsy has been reported to be 67.77 per 100,000 persons and the point prevalence of active epilepsy of 6.38 per 1,000 persons (Fiest, et al., 2017). Although 8 to 10% of the population will experience a seizure during their lifetime, only 2 to 3% will go on to develop epilepsy. (Gavvala and Schuele, 2016).

According to the current International Classification of Epileptic Seizures, the classification of epileptic seizures depends upon the age of onset and clinical symptoms and signs. Both etiology (idiopathic, symptomatic  and  cryptogenic) and  localization (partial vs generalized) are considered crucial prerequisites for an adequate evaluation and treatment of epileptic disorders.

Recently proposed terminology by the International League Against Epilepsy (ILAE) has redefined POS as 'focal seizures' with a variety of seizure subtypes: focal aware seizures, focal impaired awareness seizures,  focal  motor  seizures,  focal  non-motor  seizures,  and  focal  to  bilateral  tonic-clonic  seizures (Fisher, 2017). The term POS will be used throughout this report.

Half of the epilepsies begin before the age of 18 and one fourth of these are intractable, having severe social  and  cognitive  consequences.  The  majority  of  paediatric  epilepsies  consist  of  age-dependent epilepsy  syndromes  whose  manifestations  are  affected  by  ongoing  brain  maturation.  Uncontrolled seizures are not only associated with noteworthy lifestyle limitations and social handicaps (e.g., loss of driving  privileges,  social  isolation,  difficulty  maintaining  employment),  but  can  result  in  significant adverse consequences, including severe trauma, depression, anxiety, and sudden death (Baranowski, 2018; Sadr, 2018).

Partial-onset (focal) seizures (POS) account for the majority of diagnosed cases of epilepsy (Hauser WA et al., 1996, Kotsopoulos IA et al., 2005). Childhood is the peak age of onset for seizures, particularly partial-onset seizures (POS) and Idiopathic Generalized Epilepsies (IGE).

As opposed to POS, PGTCS have apparent clinical or EEG onset in both hemispheres of the brain, with no clear focus or foci. PGTCS are associated with idiopathic generalized epilepsy and several generalized epilepsy syndromes. Onset of PGTCS typically starts in older children, adolescents, and young adults, but  does  present  in  children  as  young  as  2  years.  One  critical  EEG  hallmark  of  a  susceptibility  to generalized seizures, including PGTCS, are well-formed generalized spike-wave discharges. These are occasionally seen, but are not well developed, widely distributed and highly stereotyped until 2 to 3 years of age.

Occurrence  of  generalized  tonic-clonic  seizures  (GTCS)  is  one  of  the  most  important  risk  factors  of seizure-related complications and comorbidities in patients with epilepsy. Their prevention is therefore an important aspect of therapeutic management both in idiopathic generalized epilepsies and in focal epilepsies.  Because  of  the  complications  related  to  GTCS,  including  increased  risk  of  SUDEP,  their prevention is an important aspect of therapeutic management both in idiopathic generalized epilepsies and in partial epilepsies.

<div style=\"page-break-after: always\"></div>

## 3.1.2. Available therapies and unmet medical need

Antiepileptic drugs (AEDs) are the main treatment option. Over the past 20 years, several AEDs have been developed with the objective of improving efficacy, tolerability, and ease of use when compared with classic currently-used AEDs such as carbamazepine, phenytoin, valproic acid, phenobarbital, and benzodiazepines.

Approximately 60 % of newly diagnosed patients are seizure-free with monotherapy and an additional 10-20% with polytherapy. It follows that about 30% of patients are not satisfactorily controlled. In addition, many patients suffer from significant adverse effects.

It has been shown that the efficacy of antiepileptic drugs (AEDs) varies across epilepsy syndromes, with some AEDs efficacious against focal seizures with secondary GTCS (sGTCS) but aggravating primary GTCS (pGTCS). In patients with SGTCS, all AEDs approved in the treatment of focal epilepsies might be used.

The AED efficacious against focal seizures are mostly granted in adults and adolescents. Only some of the AED are indicated as adjunctive therapy in children 2 years of age and older (clonazepam, clobazam, lamotrigine, topiramate, levetiracetam) or in children 4 years of age and older (lacosamide). It is to be noted that the enzyme-inducing AED like carbamazepine, phenytoin and phenobarbital may aggravate primary GTCS.

In patients with PGTCS, evidence-based data support the preferential use of valproic acid, lamotrigine, levetiracetam and topiramate.

Therefore, there is an unmet medical need for a safe and effective treatment option for children from 2 to  12  years  of  age  in  the  POS  as  well  as  in  the  PGTCS  treatment.  This  need  is  increased  with  the restrictions in the use of valproate (VPA), especially in girls, as the treatment of choice for PGTCS of IGE.

## 3.1.3. Main clinical studies

For the current submission, the MAH proposes to widen the approved indications to children aged 2 years and older through extrapolation of adult and adolescent efficacy and pediatric pharmacokinetic (PK) data derived from the open-label Phase 3 study E2007-G000-311 (Study 311) in patients aged 4 to &lt;12 years with inadequately controlled POS or PGTC seizures and from the Phase 2 study E2007-G000-232 (Study 232), which analyzed PK data from patients with epilepsy aged 2 to &lt;12 years.

## 3.2. Favourable effects

The clinical efficacy observed through descriptive data from study 311 seems overall at a rate comparable to that seen in adults and adolescents &gt;12 years of age for the treatment of partial onset seizure (POS) and  secondary  generalized  tonic-clonic  seizures  (SGTCS).  The  efficacy  results  could  be  considered clinically meaningful for this cohort in both age cohorts (4 to &lt;7 years and 7 to&lt;12 years).

## For the POS cohort,

The median percent change in seizure frequency per 28 days as compared to baseline for total POS seizures was -40.1% (total, n = 148), -42.7% (age 4 to &lt;7 years, n = 108) and -40.1% (age 7 to &lt;12 years, n = 40). The results are considered clinically meaningful for the POS cohort as the number of patients  was  rather  large;  as  an  indirect  comparison,  this  median  percent  change  in  adults  and adolescents &gt;12 years of age was -35% for 8 mg as well as for 12 mg daily.

There were 69 (46.6%) subjects with a responder rate of 50% or greater of whom 18 (45.0%) subjects aged 4 to &lt;7 years, and 51 (47.2%) subjects aged 7 to &lt;12 years.

<div style=\"page-break-after: always\"></div>

As an indirect comparison, in adults and adolescents &gt;12 years of age, the responder rate in the POS cohort is around 35% when the 3 phase III studies are considered.

The overall seizure free status was achieved in 17 (11.5%) subjects. Seizure free status was achieved by 3 (7.5%) subjects aged 4 to &lt;7 years and 14 (13.0%) subjects aged 7 to &lt;12 years.

For the SGTC subset of the POS cohort, the same trend as for the POS is observed.

Overall, the clinical effect as regards to the POS or SGTCS seems comparable to that observed in adults. When considering the guideline on clinical investigation of medicinal products in the treatment of epileptic disorders (CHMP/EWP/566/98 Rev.2/Corr), the effect of perampanel on partial seizures, with or without secondary generalization, is extrapolated from adults to children &gt; 4 years of age, after an agreement regarding the weight-based dose has been established.

## 3.3. Uncertainties and limitations about favourable effects

For the POS cohort and SGTC subset of the POS cohort,

The observed favourable effects are weakened by methodological limitations (open-labelled, no placebo group) which per se do not allow to draw any robust conclusion. Therefore, the clinical efficacy results remain only descriptive hence no formal statistics were performed.

<div style=\"page-break-after: always\"></div>

## For the PGTC cohort,

The median percent change in seizure frequency per 28 days as compared to baseline for the PGTC cohort was overall -69.2% (total; n=22), -56.5% (age 4 to &lt;7 years; n=3) and -81.9% (age 7 to &lt;12 years; n=19). There were 14 (63.6%) subjects with a responder rate of 50% or greater of whom 2 (66.7%) subjects aged 4 to &lt;7 years, and 12 (63.2%) subjects aged 7 to &lt;12 years. These results should however be considered very cautiously because of the small number of patients, all the more in the 4 to 7 age cohort (n = 3 patients, 2 IGE and 1 non-IGE) for which no conclusion could be drawn.

The overall seizure free status was achieved in 12 (54.5%) subjects. Seizure free status was achieved by 2 (66.70%) subjects aged 4 to &lt;7 years and 10 (52.6%) subjects aged 7 to &lt;12 years.

Although  the  clinical  efficacy  through  descriptive  data  from  study  311  is  overall  observed  among idiopathic generalized epilepsy (IGE) or non-IGE subjects in both age cohorts (4 to &lt;7 years and 7 to&lt;12 years), the clinical relevance in the PGTC cohort is disputable and does not allow to yield any conclusion in the 4 to &lt;7 years group considering the small number of subjects.

## PK/PD assessment:

As a result of the assessment of the submitted studies, the true PK/PD relationship in children was not established, since PK/PD data from both adult/adolescent and the paediatric population were pooled. In addition the MAH initially claimed that a weight-based dose regimen in the paediatric population (4 to &lt; 12years) was still not required because the weight had no effect on clearance. This was not endorsed. In fact, results from one simulation study clearly showed that with a fixed dose regimen, exposure tended to increase more than adult exposure, because age (and weight) decrease suggested that a weightbased dosing regimen should be studied.

The  uncertainties  regarding  the  dose  in  the  various  age  groups  were  further  solved  through  the determination of a weight-based dose for three weight categories : &lt;20kg, 20 to &lt; 30 kg and &gt; 30 kg.

According to the scientific advice 2017, the following concerns were issued.

- -Regarding  safety,  this  aspect  should  specifically  be  assessed  in  children  as  it  cannot  be extrapolated  from  the  safety  observed  in  adults;  as  PGTCS  appears  within  more  complex syndromes associating different seizure types, the effect of perampanel on these other seizure types should be assessed within the safety assessment, at least to rule out a detrimental effect (or quantify it to integrate it into the overall benefit/risk assessment). The effect of perampanel on neuropsychological aspects in a developing brain and on growth should also be specifically assessed in the paediatric population.

The clinical efficacy data from the study 232 in patients aged 2 to 12 years were overall similar to those collected in study 311. However, the number of patients was very small and therefore the results of this study only brought few information regarding the safety profile. In addition, from a pharmacokinetic aspect,  PK  data  from  Study  232  were  interpreted  with  caution  before  the  critical  issues  with  the developed bioanalytical method were solved.

## 3.4. Unfavourable effects

No new adverse event was reported in the submitted studies. However, there were some uncertainties regarding the submitted safety data and also the lack of long-term data which are of major importance, especially in the paediatric population.

Indeed, according to the guideline, regarding the assessment of safety, a minimum of 100 children treated by the study drug should be followed for at least one year. Moreover short term and long-term studies  should  be  designed  to  detect  possible  impact  on  brain  development,  learning,  intelligence, growth, endocrine functions and puberty.

Firstly,  the  submitted  studies  were  not  designed  to  collect  enough  long-term  safety  information; secondly,  there  were  some  uncertainties  that  needed  clarifications  regarding  the  safety  profile  of

<div style=\"page-break-after: always\"></div>

perampanel. Although the level of recruitment in paediatric studies is a known issue, the data safety collection was a major point, in particular regarding the long-term aspects (neurodevelopment, motor development,  cognition,  behaviour,  growth,  endocrine  functions  and  puberty).  These  aspects  were lacking and the MAH was requested to further provide data related to puberty / sexual maturation and skeletal development, which could not be evaluated in a sufficient number of children. The applicant was therefore requested to continue to monitor the effects in the ongoing paediatric study (Studies 236) and in the future PSUR.

## 3.5. Uncertainties and limitations about unfavourable effects

In PGTCS, the safety profile of perampanel in children aged 2 years and &lt;7 years could not be assessed properly due to the low number of patients studied.

The data presented by the MAH responded to the concerns about the potential effect of perampanel in children under 12 years of age regarding impact on brain development, learning, intelligence, and growth and endocrine function, with the exception of puberty / sexual maturation and skeletal development, which could not be evaluated in a sufficient number of children. Consequently, the MAH was requested to  continue  to  monitor  the  puberty  /  sexual  maturation  and  skeletal  development  in  the  ongoing paediatric study (Studies 236) and in the future PSUR.

The relevant statements have been added in the SmPC regarding the higher incidence of some AE and some precautions were amended or added.

## 3.6. Benefit-risk assessment and discussion

## 3.6.1. Importance of favourable and unfavourable effects

For  the  treatment  of  partial  onset  seizure  (POS)  and  secondary  generalized  tonic-clonic  seizures (SGTCS), the clinical efficacy observed through descriptive data from study 311 is overall reassuring. The efficacy results could be considered clinically meaningful for both age cohorts (4 to &lt;7 years and 7 to&lt;12 years).

When considering the guideline on clinical investigation of medicinal products in the treatment of epileptic disorders (CHMP/EWP/566/98 Rev.2/Corr), the effect of perampanel on partial seizures, with or without secondary generalization, could be extrapolated from adults to children &gt; 4 years of age, provided the dose is established. Based on that statement, the efficacy between adults and children &gt; 4 years of age in the treatment of POS and SGTCS seems comparable and acceptable from a clinical point of view. It  could be considered that the number of subjects is large enough to consider that these observed clinical results are sufficient for an established weight-based dose based on PK/PD extrapolation from adults  to  the  target  population.  However,  the  favourable  effect  for  this  cohort  is  weakened  by methodological limitations (open-labelled, no placebo group) which per se do  not  allow to draw any robust conclusion. Therefore, the clinical efficacy results remain only descriptive and no formal statistics were performed.

For the treatment of primary generalized tonic-clonic seizures (PGTCS) , although the clinical efficacy observed  through  descriptive  data  from  study  311  is  overall  in  favour  of  perampanel,  the  clinical relevance in the PGTC cohort is disputable, all the more in the paediatrics &lt;7 years of age and does not allow to yield any conclusion on the efficacy of perampanel in PGTCS considering the small number of subjects. The occurrence of other types of seizures such as absences and myoclonic seizures, were not completely described and reassuring and a warning is added in section 4.4 of the SmPC accordingly.

For the non-IGE subjects (n=3 overall in study 311), the very small number of patients do not allow to draw any conclusion.

<div style=\"page-break-after: always\"></div>

The  safety  profile  of  perampanel  in  children  aged  2  years  and  &lt;4  years  cannot  be  considered  as sufficiently established, due to the very low number of patients, and the fact that extrapolation from 2 years was not considered acceptable.

According to the draft guideline of clinical investigation of medicinal products in the treatment of epilepsy disorders, it is stated: 'Generally, from the safety point of view, preferably 100 children should be treated by the study drug and followed for at least one year. Moreover, short term and long-term studies should be  designed  to  detect  possible  impact  in  the  neurodevelopment,  motor  development,  cognition, behaviour, growth, endocrine functions and puberty... Some of these studies may require continuation in the post marketing period [see Guideline on clinical investigation of medicinal products in children (CPMP/EWP/462/95)].  Prospective  disease-based  registries  (per  paediatric  epilepsy  syndromes  or symptoms) may be helpful and are encouraged'.

After assessment of the submitted data, some safety aspects were considered reassuring while other need further safety data. Consequently, the MAH was requested to continue to monitor the puberty / sexual maturation and skeletal development in the ongoing paediatric study (Studies 236) and in the future PSUR.

To conclude, based on the submitted clinical data, the extension of indication of perampanel for the treatment of partial onset seizure (POS), with or without secondary generalized tonic-clonic seizures (SGTCS) in children from 4 years old and older was endorsed and depends on the weight-based dosing regimen.

The  extension  of  indication  of  perampanel  for  primary  generalized  tonic-clonic  seizures  (PGTCS)  in idiopathic generalized epilepsy (IGE) in children from 7 years of age and older is also endorsed and also depends on the same weight-based dosing regimen as for POS.

## 3.6.2. Balance of benefits and risks

Perampanel tablets (2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg) are approved in the European Union (EU) for the adjunctive treatment of partial-onset seizures (POS) with or without SG seizures in adult and adolescent patients with epilepsy aged 12 years and older (23 Jul 2012); and as adjunctive therapy for the treatment of PGTCS in adult and adolescent patients aged 12 years and older with IGE (22 Jun 2015).

A 0.5 mg/mL oral suspension was also approved in the EU for the same indications (19 Sep 2016).

In the United States of America (USA), perampanel tablets (2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg) and perampanel oral suspension 0.5 mg/mL are approved for monotherapy of POS with or without SG seizures in adult and adolescent patients, and as adjunctive therapy in the treatment of PGTCS in patients  with  epilepsy  12  years  of  age  and  older.  In  September  2018,  the  US  Food  and  Drug Administration  (FDA)  approved  extension  of  the  indication  of  perampanel  for  monotherapy  and adjunctive use in pediatric  patients  4  years  and  older  for  the  treatment of  POS  with  or  without  SG seizures. The approval includes both tablet and oral suspension formulations.

For the current submission, the MAH proposed to widen the approved indications to children aged 2 years and older through extrapolation of adult and adolescent efficacy and pediatric pharmacokinetic (PK)  data  derived  from  the  open-label  Phase  3  study  311  in  subjects  aged  4  to  &lt;12  years  with inadequately controlled POS or PGTC seizures and from the Phase 2 study 232, which analyzed PK data from subjects aged 2 to &lt;12 years with a diagnosis of epilepsy with any type of seizure according to the International League Against Epilepsy's (ILAE) Classification of Epileptic Seizures.

In paediatric patients aged 2 to &lt;4 years of age, no indication is approvable since the extrapolation from PK/PD is not acceptable in this age group. Moreover, the efficacy data are too sparse and the safety data are lacking.

Based on the assessment of the available clinical data, the extension of indication of perampanel for the treatment of partial onset seizure (POS), with or without secondary generalized tonic-clonic seizures

<div style=\"page-break-after: always\"></div>

(SGTCS) is acceptable in children (from 4 to &lt; 12 years of age) as the administered dose is adjusted according to a body-weight basis as detailed in the proposed SmPC.

For  primary  generalized  tonic-clonic  seizures  (PGTCS)  in  idiopathic  generalized  epilepsy  (IGE)  in paediatrics &lt; 7 years of age, the studied group is too small to estimate the actual efficacy. Moreover, the  safety  profile  in  this  small  group  could  not  be  extrapolated  in  this  condition.  The  extension  of indication  of  perampanel  for  the  treatment  of  primary  generalized  tonic-clonic  seizures  (PGTCS)  in idiopathic generalized epilepsy (IGE) is acceptable in children (from 7 to &lt; 12 years of age) as the administered dose is also adjusted according to a body-weight basis as detailed in the proposed SmPC (same dose of for POS).

Some safety aspects were considered reassuring while other need further safety data. Consequently, the MAH was requested to continue to monitor the puberty / sexual maturation and skeletal development in the ongoing paediatric study (Studies 236) and in the future PSUR (attention deficit/hyperactivity disorder, learning disability, cognitive disorder, disturbance in attention, precocious puberty). Relevant statements  have  been  added  in  the  SmPC  regarding  the  higher  incidence  of  some  AE  and  some precautions were amended or added.

## 3.7. Conclusions

The overall B/R of Fycompa in paediatric patients from 4 to 11 years of age for the adjunctive treatment of partial-onset seizures with or without secondary generalisation and from 7 to 11 years of age for the adjunctive treatment of primary generalised tonic-clonic seizures with idiopathic generalised epilepsy is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, IIIA and IIIB   |

Extension of Indication to include the paediatric patients from 4 to 11 years of age for the adjunctive treatment of partial-onset seizures with or without secondary generalisation and from 7 to 11 years of age for the adjunctive treatment of primary generalised tonic-clonic seizures with idiopathic generalised epilepsy for Fycompa.

As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 4.5 has also been submitted.

<div style=\"page-break-after: always\"></div>

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I and IIIB and to the Risk Management Plan are recommended.

## Paediatric data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0217/2019 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Fycompa-H-C-002434-II-0047'